

British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009

W S Lim, S V Baudouin, R C George, A T Hill, C Jamieson, I Le Jeune, J T Macfarlane, R C Read, H J Roberts, M L Levy, M Wani, M A Woodhead, Pneumonia Guidelines Committee of the BTS Standards of Care Committee

► Full search strategies for each database are published online only at <http://thorax.bmj.com/content/vol64/issueSupplIII>

Correspondence to:
Dr W S Lim, Respiratory
Medicine, Nottingham University
Hospitals, David Evans Building,
Hucknall Road, Nottingham NG5
1PB, UK; weishen.lim@nuh.nhs.uk

Received 11 June 2009
Accepted 6 July 2009

SYNOPSIS OF RECOMMENDATIONS

A summary of the initial management of patients admitted to hospital with suspected community acquired pneumonia (CAP) is presented in fig 8. Tables 4 and 5, respectively, summarise (1) the relevant microbiological investigations and (2) empirical antibiotic choices recommended in patients with CAP.

Investigations (Section 5)

When should a chest radiograph be performed in the community?

1. It is not necessary to perform a chest radiograph in patients with *suspected* CAP unless:
 - The diagnosis is in doubt and a chest radiograph will help in a differential diagnosis and management of the acute illness. [D]
 - Progress following treatment for *suspected* CAP is not satisfactory at review. [D]
 - The patient is considered at risk of underlying lung pathology such as lung cancer. [D]

When should a chest radiograph be performed in hospital?

2. All patients admitted to hospital with *suspected* CAP should have a chest radiograph performed as soon as possible to confirm or refute the diagnosis. [D] The objective of any service should be for the chest radiograph to be performed in time for antibiotics to be administered within 4 h of presentation to hospital should the diagnosis of CAP be confirmed.

When should the chest radiograph be repeated during recovery?

3. The chest radiograph need not be repeated prior to hospital discharge in those who have made a satisfactory clinical recovery from CAP. [D]
4. A chest radiograph should be arranged after about 6 weeks for all those patients who have persistence of symptoms or physical signs or who are at higher risk of underlying malignancy (especially smokers and those aged >50 years) whether or not they have been admitted to hospital. [D]
5. Further investigations which may include bronchoscopy should be considered in patients with persisting signs, symptoms and radiological abnormalities at around 6 weeks after completing treatment. [D]

6. It is the responsibility of the hospital team to arrange the follow-up plan with the patient and the general practitioner for those patients admitted to hospital. [D]

What general investigations should be done in the community?

7. General investigations are not necessary for the majority of patients with CAP who are managed in the community. [C] Pulse oximeters allow for simple assessment of oxygenation. General practitioners, particularly those working in out-of-hours and emergency assessment centres, should consider their use. [D]
8. Pulse oximetry should be available in all locations where emergency oxygen is used. [D]

What general investigations should be done in a patient admitted to hospital?

9. All patients should have the following tests performed on admission:
 - Oxygenation saturations and, where necessary, arterial blood gases in accordance with the BTS guideline for emergency oxygen use in adult patients. [B+]
 - Chest radiograph to allow accurate diagnosis. [B+]
 - Urea and electrolytes to inform severity assessment. [B+]
 - C-reactive protein to aid diagnosis and as a baseline measure. [B+]
 - Full blood count. [B–]
 - Liver function tests. [D]

Why are microbiological investigations performed?

10. Microbiological tests should be performed on all patients with moderate and high severity CAP, the extent of investigation in these patients being guided by severity. [D]
11. For patients with low severity CAP the extent of microbiological investigations should be guided by clinical factors (age, comorbid illness, severity indicators), epidemiological factors and prior antibiotic therapy. [A–]
12. Where there is clear microbiological evidence of a specific pathogen, empirical antibiotics should be changed to the appropriate

pathogen-focused agent unless there are legitimate concerns about dual pathogen infection. [D]

What microbiological investigations should be performed in the community?

13. For patients managed in the community, microbiological investigations are not recommended routinely. [D]
14. Examination of sputum should be considered for patients who do not respond to empirical antibiotic therapy. [D]
15. Examination of sputum for *Mycobacterium tuberculosis* should be considered for patients with a persistent productive cough, especially if malaise, weight loss or night sweats, or risk factors for tuberculosis (eg, ethnic origin, social deprivation, elderly) are present. [D]
16. Urine antigen investigations, PCR of upper (eg, nose and throat swabs) or lower (eg, sputum) respiratory tract samples or serological investigations may be considered during outbreaks (eg, Legionnaires' disease) or epidemic mycoplasma years, or when there is a particular clinical or epidemiological reason. [D]

What microbiological investigations should be performed in hospital?

Blood cultures

17. Blood cultures are recommended for all patients with moderate and high severity CAP, preferably before antibiotic therapy is commenced. [D]
18. If a diagnosis of CAP has been definitely confirmed and a patient has low severity pneumonia with no comorbid disease, blood cultures may be omitted. [A-]

Sputum cultures

19. Sputum samples should be sent for culture and sensitivity tests from patients with CAP of moderate severity who are able to expectorate purulent samples and have not received prior antibiotic therapy. Specimens should be transported rapidly to the laboratory. [A-]
20. Culture of sputum or other lower respiratory tract samples should also be performed for all patients with high severity CAP or those who fail to improve. [A-]
21. Sputum cultures for *Legionella* spp should always be attempted for patients who are legionella urine antigen positive in order to provide isolates for epidemiological typing and comparison with isolates from putative environmental sources. [D]

Sputum Gram stain

22. Clinicians should establish with local laboratories the availability or otherwise of sputum Gram stain. Where this is available, laboratories should offer a reliable Gram stain for patients with high severity CAP or complications as occasionally this can give an immediate indicator of the likely pathogen. Routine performance or reporting of sputum Gram stain on all patients is unnecessary but can aid the laboratory interpretations of culture results. [B-]
23. Samples from patients already in receipt of antimicrobials are rarely helpful in establishing a diagnosis. [B-]
24. Laboratories performing sputum Gram stains should adhere to strict and locally agreed criteria for interpretation and reporting of results. [B+]

Other tests for *Streptococcus pneumoniae*

25. Pneumococcal urine antigen tests should be performed for all patients with moderate or high severity CAP. [A-]
26. A rapid testing and reporting service for pneumococcal urine antigen should be available to all hospitals admitting patients with CAP. [B+]

Tests for *Legionnaires' disease*

27. Investigations for legionella pneumonia are recommended for all patients with high severity CAP, for other patients with specific risk factors and for all patients with CAP during outbreaks. [D]
28. Legionella urine antigen tests should be performed for all patients with high severity CAP. [B+]
29. A rapid testing and reporting service for legionella urine antigen should be available to all hospitals admitting patients with CAP. [B+]
30. As the culture of legionella is very important for clinical reasons and source identification, specimens of respiratory secretions, including sputum, should be sent from patients with high severity CAP or where Legionnaires' disease is suspected on epidemiological or clinical grounds. [D] The clinician should specifically request legionella culture on laboratory request forms.
31. Legionella cultures should be routinely performed on invasive respiratory samples (eg, obtained by bronchoscopy) from patients with CAP. [D]
32. For all patients who are legionella urine antigen positive, clinicians should send respiratory specimens such as sputum and request legionella culture [D]. This is to aid outbreak and source investigation with the aim of preventing further cases.

Tests for *Mycoplasma pneumoniae*

33. Where available, PCR of respiratory tract samples such as sputum should be the method of choice for the diagnosis of mycoplasma pneumonia. [D]
34. In the absence of a sputum or lower respiratory tract sample, and where mycoplasma pneumonia is suspected on clinical and epidemiological grounds, a throat swab for *Mycoplasma pneumoniae* PCR is recommended. [D]
35. Serology with the complement fixation test and a range of other assays is widely available, although considerable caution is required in interpretation of results. [C]

Tests for *Chlamydia pneumoniae*

36. *Chlamydia pneumoniae* antigen and/or PCR detection tests should be available for invasive respiratory samples from patients with high severity CAP or where there is a strong suspicion of psittacosis. [D]
37. The complement fixation test remains the most suitable and practical serological assay for routine diagnosis of respiratory *Chlamydia pneumoniae* infections. [B-] There is no currently available serological test that can reliably detect acute infection due to *C pneumoniae*.

PCR and serological tests for other respiratory pathogens

38. Where PCR for respiratory viruses and atypical pathogens is readily available or obtainable locally, this is preferred to serological investigations. [D]
39. Where available, paired serology tests can be considered for patients with high severity CAP where no particular

microbiological diagnosis has been made by other means (eg, culture, urine antigen, PCR) and who fail to improve, and/or where there are particular epidemiological risk factors. [D] The date of onset of symptoms should be clearly indicated on all serological request forms. [D]

40. Serological tests may be extended to all patients admitted to hospital with CAP during outbreaks and when needed for the purposes of surveillance. The criteria for performing serology tests in these circumstances should be agreed locally between clinicians, laboratories and public health. [D]

Severity assessment (Section 6)

What severity assessment strategy is recommended?

41. Clinical judgement is essential in disease severity assessment. [D]
42. The stability of any comorbid illness and a patient's social circumstances should be considered when assessing disease severity. [D]

Severity assessment of CAP in patients seen in the community

43. For all patients, clinical judgement supported by the CRB65 score should be applied when deciding whether to treat at home or refer to hospital. [D]
44. Patients who have a CRB65 score of 0 are at low risk of death and do not normally require hospitalisation for clinical reasons. [B+]
45. Patients who have a CRB65 score of 1 or 2 are at increased risk of death, particularly with a score of 2, and hospital referral and assessment should be considered. [B+]
46. Patients who have a CRB65 score of 3 or more are at high risk of death and require urgent hospital admission. [B+]
47. When deciding on home treatment, the patient's social circumstances and wishes must be taken into account in all instances. [D]

Severity assessment of CAP in patients seen in hospital

48. For all patients, the CURB65 score should be interpreted in conjunction with clinical judgement. [D]
49. Patients who have a CURB65 score of 3 or more are at high risk of death. These patients should be reviewed by a senior physician at the earliest opportunity to refine disease severity assessment and should usually be managed as having high severity pneumonia. Patients with CURB65 scores of 4 and 5 should be assessed with specific consideration to the need for transfer to a critical care unit (high dependency unit or intensive care unit). [B+]
50. Patients who have a CURB65 score of 2 are at moderate risk of death. They should be considered for short-stay inpatient treatment or hospital-supervised outpatient treatment. [B+]
51. Patients who have a CURB65 score of 0 or 1 are at low risk of death. These patients may be suitable for treatment at home. [B+]
52. When deciding on home treatment, the patient's social circumstances and wishes must be taken into account in all instances. [D]

Reviewing severity status after initial assessment

53. Regular assessment of disease severity is recommended for *all* patients following hospital admission. The "post take" round by a senior doctor and the medical team provides one early opportunity for this review. [D]

54. All patients deemed at high risk of death on admission to hospital should be reviewed *medically* at least 12-hourly until shown to be improving. [D]

General management (Section 7)

General management strategy for patients treated in the community

55. Patients with suspected CAP should be advised to rest, to drink plenty of fluids and not to smoke. [D]
56. Pleuritic pain should be relieved using simple analgesia such as paracetamol. [D]
57. The need for hospital referral should be assessed using the criteria recommended in section 6. [C]
58. Pulse oximetry, with appropriate training, should be available to general practitioners and others responsible for the assessment of patients in the out-of-hours setting for the assessment of severity and oxygen requirement in patients with CAP and other acute respiratory illnesses. [D]

Review policy for patients managed in the community

59. Review of patients in the community with CAP is recommended after 48 h or earlier if clinically indicated. Disease severity assessment should form part of the clinical review. [D]
60. Those who fail to improve after 48 h of treatment should be considered for hospital admission or chest radiography. [D]

General management strategy for patients treated in hospital

61. All patients should receive appropriate oxygen therapy with monitoring of oxygen saturations and inspired oxygen concentration with the aim to maintain arterial oxygen tension (PaO₂) at ≥8 kPa and oxygen saturation (SpO₂) 94–98%. High concentrations of oxygen can safely be given in patients who are not at risk of hypercapnic respiratory failure. [D]
62. Oxygen therapy in patients at risk of hypercapnic respiratory failure complicated by ventilatory failure should be guided by repeated arterial blood gas measurements. [C]
63. Patients should be assessed for volume depletion and may require intravenous fluids. [C]
64. Prophylaxis of venous thromboembolism with low molecular weight heparins should be considered for all patients who are not fully mobile. [A+]
65. Nutritional support should be given in prolonged illness. [C]
66. Medical condition permitting, patients admitted to hospital with uncomplicated CAP should sit out of bed for at least 20 min within the first 24 h and mobility should be increased each subsequent day of hospitalisation. [A–]
67. Patients admitted with uncomplicated pneumonia should not be treated with traditional airway clearance techniques routinely. [B+]
68. Patients should be offered advice regarding expectoration if there is sputum present. [D]
69. Airway clearance techniques should be considered if the patient has sputum and difficulty with expectoration or in the event of a pre-existing lung condition. [D]

Monitoring in hospital

70. Temperature, respiratory rate, pulse, blood pressure, mental status, oxygen saturation and inspired oxygen

concentration should be monitored and recorded initially at least twice daily and more frequently in those with severe pneumonia or requiring regular oxygen therapy. [C]

71. C-reactive protein should be remeasured and a chest radiograph repeated in patients who are not progressing satisfactorily after 3 days of treatment. [B+]
72. Patients should be reviewed within 24 h of planned discharge home, and those suitable for discharge should not have more than one of the following characteristics present (unless they represent the usual baseline status for that patient): temperature $>37.8^{\circ}\text{C}$, heart rate $>100/\text{min}$, respiratory rate $>24/\text{min}$, systolic blood pressure $<90\text{ mm Hg}$, oxygen saturation $<90\%$, inability to maintain oral intake and abnormal mental status. [B+]

Critical care management of CAP

73. Patients with CAP admitted to ICUs should be managed by specialists with appropriate training in intensive care working in close collaboration with specialists in respiratory medicine. [D]
74. Neither non-invasive ventilation (NIV) nor continuous positive airways pressure (CPAP) support is routinely indicated in the management of patients with respiratory failure due to CAP. [A-]
75. If a trial of non-invasive support is considered indicated in CAP, it must only be conducted in a critical care area where immediate expertise is available to enable a rapid transition to invasive ventilation. [D]
76. Steroids are not recommended in the routine treatment of high severity CAP. [A+]
77. Granulocyte colony stimulating factor is not routinely recommended as an adjunct to antibiotics. [A+]

Follow-up arrangements

78. Clinical review should be arranged for all patients at around 6 weeks, either with their general practitioner or in a hospital clinic. [D]
79. At discharge or at follow-up, patients should be offered access to information about CAP such as a patient information leaflet. [D]
80. It is the responsibility of the hospital team to arrange the follow-up plan with the patient and the general practitioner. [D]

Antibiotic management (Section 8)

Empirical antibiotic choice for adults treated in the community

81. For patients treated in the community, amoxicillin remains the preferred agent at a dose of 500 mg three times daily. [A+]
82. Either doxycycline [D] or clarithromycin [A-] are appropriate as an alternative choice, and for those patients who are hypersensitive to penicillins.
83. Those with features of moderate or high severity infection should be admitted urgently to hospital. [C]

Should general practitioners administer antibiotics prior to hospital transfer?

84. For those patients referred to hospital with suspected CAP and where the illness is considered to be life-threatening, general practitioners should administer antibiotics in the community. [D] Penicillin G 1.2 g intravenously or amoxicillin 1 g orally are the preferred agents.

85. For those patients referred to hospital with suspected high severity CAP and where there are likely to be delays of over 6 h in the patient being admitted and treated in hospital, general practitioners should consider administering antibiotics in the community. [D]

When should the first dose of antibiotics be given to patients admitted to hospital?

86. A diagnosis of CAP should be confirmed by chest radiography before the commencement of antibiotics in the majority of patients. Selected patients with life-threatening disease should be treated based on a *presumptive clinical diagnosis* of CAP. In such instances, an immediate chest radiograph to confirm the diagnosis or to indicate an alternative diagnosis is indicated. [D]
87. All patients should receive antibiotics as soon as the diagnosis of CAP is confirmed. [D] This should be before they leave the initial assessment area (emergency department or acute medical unit). The objective for any service should be to confirm a diagnosis of pneumonia with chest radiography and initiate antibiotic therapy for the majority of patients with CAP within 4 h of presentation to hospital. [B-]

Empirical antibiotic choice for adults hospitalised with low severity CAP

88. Most patients with low severity CAP can be adequately treated with oral antibiotics. [C]
89. Oral therapy with amoxicillin is preferred for patients with low severity CAP who require hospital admission for other reasons such as unstable comorbid illnesses or social needs. [D]
90. When oral therapy is contraindicated, recommended parenteral choices include intravenous amoxicillin or benzylpenicillin, or clarithromycin. [D]

Empirical antibiotic choice for adults hospitalised with moderate severity CAP

91. Most patients with moderate severity CAP can be adequately treated with oral antibiotics. [C]
92. Oral therapy with amoxicillin and a macrolide is preferred for patients with moderate severity CAP who require hospital admission. [D]
 - Monotherapy with a macrolide may be suitable for patients who have failed to respond to an *adequate* course of amoxicillin before admission. Deciding on the adequacy of prior therapy is difficult and is a matter of individual clinical judgement. It is therefore recommended that combination antibiotic therapy is the preferred choice in this situation and that the decision to adopt monotherapy is reviewed on the "post take" round within the first 24 h of admission. [D]
93. When oral therapy is contraindicated, the preferred parenteral choices include intravenous amoxicillin or benzylpenicillin, together with clarithromycin. [D]
94. For those intolerant of penicillins or macrolides, oral doxycycline is the main alternative agent. Oral levofloxacin and oral moxifloxacin are other alternative choices. [D]
95. When oral therapy is contraindicated in those intolerant of penicillins, recommended parenteral choices include levofloxacin monotherapy or a second-generation (eg, cefuroxime) or third-generation (eg, cefotaxime or ceftriaxone) cephalosporin together with clarithromycin. [D]

Empirical antibiotic choice for adults hospitalised with high severity CAP

96. Patients with high severity pneumonia should be treated immediately after diagnosis with parenteral antibiotics. [B-]
97. An intravenous combination of a broad-spectrum β -lactamase stable antibiotic such as co-amoxiclav together with a macrolide such as clarithromycin is preferred. [C]
98. In patients allergic to penicillin, a second-generation (eg, cefuroxime) or third-generation (eg, cefotaxime or ceftriaxone) cephalosporin can be used instead of co-amoxiclav, together with clarithromycin. [C]

When should the intravenous or the oral route be chosen?

99. The oral route is recommended in those with low and moderate severity CAP admitted to hospital provided there are no contraindications to oral therapy. [B+]

When should the intravenous route be changed to oral?

100. Patients treated initially with parenteral antibiotics should be transferred to an oral regimen as soon as clinical improvement occurs and the temperature has been normal for 24 h, providing there is no contraindication to the oral route. Pointers to clinical improvement are given in box 4. [B+]
101. The choice of route of administration should be reviewed initially on the "post take" round and then daily. [D]
102. Ward pharmacists could play an important role in facilitating this review by highlighting prescription charts where parenteral antibiotic therapy continues. [D]

Which oral antibiotics are recommended on completion of intravenous therapy?

103. The antibiotic choices for the switch from intravenous to oral are straightforward where there are effective and equivalent oral and parenteral formulations. [C]
104. In the case of parenteral cephalosporins, the oral switch to co-amoxiclav 625 mg three times daily is recommended rather than to oral cephalosporins. [D]
105. For those treated with benzylpenicillin + levofloxacin, oral levofloxacin with or without oral amoxicillin 500 mg–1.0 g three times daily is recommended. [D]

How long should antibiotics be given for?

106. For patients managed in the community and for most patients admitted to hospital with low or moderate severity and uncomplicated pneumonia, 7 days of appropriate antibiotics is recommended. [C]
107. For those with high severity microbiologically-undefined pneumonia, 7–10 days of treatment is proposed. This may need to be extended to 14 or 21 days according to clinical judgement; for example, where *Staphylococcus aureus* or Gram-negative enteric bacilli pneumonia is suspected or confirmed. [C]

Failure of initial empirical therapy

108. When a change in empirical antibiotic therapy is considered necessary, a macrolide could be substituted for or added to the treatment for those with low severity pneumonia treated with amoxicillin monotherapy in the community or in hospital. [D]
109. For those with moderate severity pneumonia in hospital on combination therapy, changing to doxycycline or a

fluoroquinolone with effective pneumococcal cover are alternative options. [D]

110. Adding a fluoroquinolone is an option for those with high severity pneumonia not responding to a β -lactam/macrolide combination antibiotic regimen. [D]

Avoiding inappropriate antibiotic prescribing

111. The diagnosis of CAP and the decision to start antibiotics should be reviewed by a senior clinician at the earliest opportunity. There should be no barrier to discontinuing antibiotics if they are not indicated. [D]
112. The indication for antibiotics should be clearly documented in the medical notes. [D]
113. The need for intravenous antibiotics should be reviewed daily. [D]
114. De-escalation of therapy, including the switch from intravenous to oral antibiotics, should be considered as soon as is appropriate, taking into account response to treatment and changing illness severity. [D]
115. Strong consideration should be given to narrowing the spectrum of antibiotic therapy when specific pathogens are identified or when the patient's condition improves. [D]
116. Where appropriate, stop dates should be specified for antibiotic prescriptions. [D]

Optimum antibiotic choices when specific pathogens have been identified

117. If a specific pathogen has been identified, the antibiotic recommendations are as summarised in table 6. [C]

Specific issues regarding the management of Legionnaires' disease

118. As soon as a diagnosis of legionella pneumonia has been made, the clinician should liaise with the clinical microbiologist to confirm that the local Health Protection Unit has been informed. The Health Protection Unit is responsible for promptly investigating the potential sources of infection. [D]
119. The clinician should assist, where appropriate, in the gathering of clinical and epidemiological information from the patient and their relatives to aid the source investigation. [D]
120. Sputum or respiratory secretions should be sent off specifically for legionella culture in proven cases, even after appropriate antibiotics have started. [D]
121. For low and moderate severity community acquired legionella pneumonia, an oral fluoroquinolone is recommended. In the unusual case when this is not possible due to patient intolerance, a macrolide is an alternative. [D] Antibiotics are not required for the non-pneumonic self-limiting form of legionellosis—pontiac fever. [D]
122. For the management of high severity or life-threatening legionella pneumonia, a fluoroquinolone is recommended. For the first few days this can be combined with a macrolide (azithromycin is an option in countries where it is used for pneumonia) or rifampicin as an alternative. [D] Clinicians should be alert to the potential small risk of cardiac electrophysiological abnormalities with quinolone-macrolide combinations.
123. Duration of therapy should be as for microbiologically-undefined CAP (for those with low to moderate severity pneumonia, 7 days treatment is proposed; for those with high severity pneumonia, 7–10 days treatment is

proposed—this may need to be extended to 14 or 21 days) and should be guided by clinical judgement. [D]

Specific issues regarding Panton-Valentine Leukocidin-producing *Staphylococcus aureus* (PVL-SA)

124. PVL-SA infection is a rare cause of high severity pneumonia and can be associated with rapid lung cavitation and multiorgan failure. Such patients should be considered for critical care admission. [D]
125. If PVL-SA necrotising pneumonia is strongly suspected or confirmed, clinicians should liaise urgently with the microbiology department in relation to further antibiotic management and consider referral to the respiratory medicine department for clinical management advice. [D]
126. Current recommendations for the antibiotic management of strongly suspected necrotising pneumonia include the addition of a combination of intravenous linezolid 600 mg twice daily, intravenous clindamycin 1.2 g four times a day and intravenous rifampicin 600 mg twice daily to the initial empirical antibiotic regimen. As soon as PVL-SA infection is either confirmed or excluded, antibiotic therapy should be narrowed accordingly. [D]

Complications and failure to improve (Section 9)

Failure to improve in hospital

127. For patients who fail to improve as expected, there should be a careful review by an experienced clinician of the clinical history, examination, prescription chart and results of all available investigation results. [D]
128. Further investigations including a repeat chest radiograph, C-reactive protein and white cell count and further specimens for microbiological testing should be considered in the light of any new information after the clinical review. [D]
129. Referral to a respiratory physician should be considered. [D]

Common complications of CAP

130. Early thoracocentesis is indicated for all patients with a parapneumonic effusion. [D]
131. Those found to have an empyema or clear pleural fluid with pH <7.2 should have early and effective pleural fluid drainage. [C]
132. The British Thoracic Society guidelines for the management of pleural infection should be followed. [D]
133. Less usual respiratory pathogens including anaerobes, *S aureus*, Gram-negative enteric bacilli and *S milleri* should be considered in the presence of lung abscess. [D]
134. Prolonged antibiotic therapy of up to 6 weeks depending on clinical response and occasionally surgical drainage should be considered. [D]

Prevention and vaccination (Section 10)

Influenza and pneumococcal vaccination

135. Department of Health guidelines in relation to influenza and pneumococcal immunisation of at-risk individuals should be followed. [C]
136. All patients aged >65 years or at risk of invasive pneumococcal disease who are admitted with CAP and who have not previously received pneumococcal vaccine should receive 23-valent pneumococcal polysaccharide

vaccine (23-PPV) at convalescence in line with the Department of Health guidelines. [C]

Smoking cessation

137. Smoking cessation advice should be offered to all patients with CAP who are current smokers according to smoking cessation guidelines issued by the Health Education Authority. [B+]

SECTION 1 INTRODUCTION

1.1 Scope of these guidelines

- ▶ These guidelines refer to the management of adults with community acquired pneumonia (CAP) of all ages in the community or in hospital. They have been developed to apply to the UK healthcare system and population. They might equally be applicable to any other countries which operate similar healthcare services (figs 1 and 2).
- ▶ They are NOT aimed at patients with known predisposing conditions such as cancer or immunosuppression admitted with pneumonia to specialist units such as oncology, haematology, palliative care, infectious diseases units or AIDS units.
- ▶ They do NOT apply to the much larger group of adults with non-pneumonic lower respiratory tract infection, including illnesses labelled as acute bronchitis, acute exacerbations of chronic obstructive pulmonary disease or “chest infections”.

1.2 Introduction

The British Thoracic Society (BTS) guidelines for the management of Community Acquired Pneumonia (CAP) in Adults were published in December 2001¹ and superseded guidelines published in 1993. A web-based update of the 2001 guidelines was published in 2004.² The 2004 guidelines assessed relevant evidence published up to August 2003.

This update represents a further assessment of published or available evidence from August 2003 to August 2008. An identical search strategy, assessment of relevance and appraisal of articles and grading system was used (see Section 1.8 and Appendices 1–4).

- ▶ This document incorporates material from the 2001 and 2004 guidelines and supersedes the previous guideline documents.

1.3 Definitions


1.3.1 Defining community acquired pneumonia (CAP)

The diagnosis in hospital will be made with the benefit of a chest radiograph. In the community, the recognition and definition of CAP by general practitioners in the UK, without the benefit of investigations or radiology, poses greater challenges and the diagnosis will often be based only on clinical features.

1.3.1.1 Defining CAP in a community setting

The clinical definition of CAP that has been used in community studies has varied widely but has generally included a complex of symptoms and signs both from the respiratory tract and regarding the general health of the patient. Features such as fever (>38°C), pleural pain, dyspnoea and tachypnoea and signs on physical examination of the chest (particularly when new and localising) seem most useful when compared with the gold standard of radiological diagnosis of CAP.^{3 [1]} See Section 5.1 for a fuller discussion pertaining to the clinical diagnosis of CAP managed in the community.

Figure 1 Synopsis of the management of adult patients seen in the community with suspected community acquired pneumonia, with cross reference to relevant sections in the document text.



For the purposes of these guidelines, CAP in the community has been defined as:

- ▶ Symptoms of an acute lower respiratory tract illness (cough and at least one other lower respiratory tract symptom).
- ▶ New focal chest signs on examination.
- ▶ At least one systemic feature (either a symptom complex of sweating, fevers, shivers, aches and pains and/or temperature of 38°C or more).
- ▶ No other explanation for the illness, which is treated as CAP with antibiotics.

1.3.1.2 Definition of CAP in patients admitted to hospital (when a chest radiograph is available)


Studies of CAP from different countries have used very different definitions and inclusion criteria;³⁻⁵ most have required a

combination of symptoms, signs and radiological features. The BTS study of CAP used a definition which included: an acute illness with radiographic shadowing which was at least segmental or present in more than one lobe and was not known to be previously present or due to other causes.⁶ Like most studies, cases were excluded if pneumonia occurred distal to a known carcinoma or foreign body.

For the purposes of these guidelines, CAP in hospital has been defined as:

- ▶ Symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which there is no other explanation (eg, not pulmonary oedema or infarction).
- ▶ The illness is the primary reason for hospital admission and is managed as pneumonia.

Figure 2 Synopsis of the management of adult patients seen in hospital with suspected community acquired pneumonia, with cross reference to relevant sections in the document text.



1.3.2 Defining the terms “atypical pneumonia” and “atypical pathogens”

The term “atypical pneumonia” has outgrown its historical usefulness and we do not recommend its continued use as it implies (incorrectly) a distinctive clinical pattern (see Section 4.2).

For the purposes of these guidelines, the term “atypical pathogens” is used to define infections caused by:

- ▶ *Mycoplasma pneumoniae*;
- ▶ *Chlamydophila pneumoniae*;
- ▶ *Chlamydophila psittaci*; and
- ▶ *Coxiella burnetii*.

These pathogens are characterised by being difficult to diagnose early in the illness and are sensitive to antibiotics other than β -lactams such as macrolides, tetracyclines or fluoroquinolones which are concentrated intracellularly, which is the usual site of replication of these pathogens. As such, we conclude that the term “atypical pathogens” is still useful to clinicians in guiding discussion about aetiology and management of CAP.

Legionella spp, although sharing some of these characteristics, are not considered to be an “atypical pathogen” for the purpose of this document as there are different species and these can be acquired both in the community and hospital environment.

1.3.3 Defining the term “elderly”

There is no agreed age cut-off to define the term “elderly”. When referring to published research, wherever possible we define the age limits used in the relevant studies.

1.4 What is the target end user audience?

We want these guidelines to be of value to:

- ▶ Hospital-based medical and other staff involved with managing adult patients with CAP.
- ▶ General practitioners.
- ▶ Those teaching about the subject at both undergraduate and postgraduate level.

The guidelines have been developed to apply to the UK healthcare system and population, but they might also be of value to other countries which operate similar healthcare

services, with appropriate modification to take into account differences in licensing and availability of antimicrobial agents.

1.5 What patient populations are we including and excluding?

These guidelines address the management of unselected adults with CAP who are managed by their general practitioner or admitted to hospital as an emergency.

Although there are similarities in the principles of management between pneumonic lower respiratory tract infection (ie, CAP) and non-pneumonic lower respiratory tract infection, there are differences in the aetiology, severity assessment, management and outcome. Recommendations for the antibiotic management of acute exacerbations of chronic obstructive pulmonary disease (COPD) are included in the guideline on the management of COPD published by the National Institute of Health and Clinical Excellence (NICE).⁷

We do not consider the management of pneumonia in:

- ▶ Patients where the pneumonia is an expected terminal event or who are known to have lung cancer, pulmonary tuberculosis or cystic fibrosis or primary immune deficiency or secondary immune deficiency related to HIV infection, or drug or systemic disease-induced immunosuppression. We do include patients receiving oral corticosteroid therapy as this is a not uncommon situation for patients admitted on medical take.
- ▶ Patients who have been in hospital within the previous 10 days and may have hospital acquired pneumonia. Patients admitted from healthcare facilities such as nursing homes and residential homes will be commented on separately.
- ▶ Children with CAP (please refer to the BTS guidelines for the management of CAP in childhood⁸).

1.6 What changes have happened in the area of CAP since the 2004 guidelines?

- ▶ Concerns regarding health care-associated infections (HCAIs), particularly methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile* infection, have grown in recent years. These HCAIs are associated with volume of antibiotic use. Antibiotic stewardship should now be an essential responsibility for all clinicians. Measures to avoid and reduce inappropriate antibiotic use are therefore at the forefront of management strategies for all infective episodes.⁹
- ▶ Fluoroquinolone antibiotics with enhanced activity against Gram-positive organisms (the so-called “respiratory quinolones” such as levofloxacin and moxifloxacin) have been widely available for some years now. Their activity against most major respiratory pathogens led initially to widespread use of these antibiotics for respiratory tract infections, including CAP. However, more recently these antibiotics have been associated with both methicillin-resistant *S aureus* (MRSA) and *C difficile* infections.^{10 11} This has promoted increasing pressure to limit the use of these antibiotics in favour of other classes of antibiotics where appropriate.⁹
- ▶ Antimicrobial resistance in *Streptococcus pneumoniae* was noted to rise in the late 1990s. Fortunately, a reversal of this trend has been observed in the last 5 years, with rates of penicillin-resistant *S pneumoniae* in the UK remaining below 4% (see Section 8.4).
- ▶ Pneumonia admissions to hospital rose by 34% between 1997–8 and 2004–5.¹² This was matched by an increase in admissions to intensive care units for CAP¹³ (see Section 2.1).

- ▶ The processes for managing acutely ill medical patients admitted to hospital have undergone important changes. The specialty of acute medicine has developed substantially and, in many hospitals, teams run by acute medicine physicians are already taking responsibility for the early stages of acutely ill medical patients. This shift, together with the demands on junior doctors’ hours arising from the European Working Time Directive, mean that patient care increasingly involves different teams of doctors. Effective handover between teams, careful patient review and coherent clinical guidelines are key aspects of patient management in this context.¹⁴
- ▶ Timeliness of treatment has enlarged as a priority in clinical care processes. This is perhaps most evident in the “4-hour admission to treatment” target applied to emergency departments across the UK.¹⁵ Increased attention to speed to treatment as a measure of performance may have the inadvertent effect of increasing the inappropriate or excessive use of antibiotics in patients with suspected but unconfirmed CAP, thus exacerbating any existing problems with HCAIs (see Section 8.9).
- ▶ Newer microbiological tests for the detection of infection by respiratory pathogens such as urine antigen tests are becoming increasingly available routinely, while previously established tests such as complement fixation tests are gradually being phased out.

1.7 Guidelines Committee membership

The Guidelines Committee was established in January 2008 with representatives from a range of professional groups including the Royal College of General Practitioners, Royal College of Physicians, British Geriatric Society, British Infection Society, British Society for Antimicrobial Chemotherapy, General Practice Airways Group, Health Protection Agency and the Society for Acute Medicine (see Section 11). Three members in the current committee also served on the 2001 and 2004 Guidelines Committee.

The Guidelines Committee agreed the remit of the guidelines. The Centre for Reviews and Dissemination and Centre for Health Economics at the University of York was commissioned by the BTS to undertake literature searches on behalf of the Guidelines Committee.

1.8 How the evidence was assimilated into the guidelines

1.8.1 Literature searches

Systematic electronic database searches were conducted in order to identify potentially relevant studies for inclusion in the CAP guidelines. For each topic area the following databases were searched: Ovid MEDLINE (including MEDLINE In Process), Ovid EMBASE, Ovid CINAHL and the Cochrane Library (including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Cochrane Central Register of Controlled Trials, the Health Technology Assessment database and the NHS Economic Evaluation Database).

The searches were first run in December 2007 and were updated in August 2008. Searches included a combination of indexing terms and free text terms, and were limited to English language publications only. Full search strategies for each database are available in the web-based supplement.

1.8.2 Appraisal of the literature

One individual (HR) read the title and abstract of each article retrieved by the literature searches and decided whether the

paper was definitely relevant, possibly relevant or not relevant to the project. For each unique paper in the first and second category, the full paper was ordered and allocated to the relevant section(s).

The initial searches (2003–7) identified 7449 reference abstracts, of which 1603 were definitely or possibly relevant after the first screen. These were divided into groups as follows: aspiration/institutional pneumonia (141); *C difficile* infection related (66); pneumonia on critical care (161); aetiology (154); antibiotic therapy (420); clinical features (46); community investigations and management (68); complications and failure to improve (37); general investigations and management (288); incidence and epidemiology (55); microbiology investigations (86); prevention (232); radiology (15); severity assessment (134).

The second search (2007–8) identified 1143 reference abstracts, of which only 177 were definitely or possibly relevant. These were divided into the same groups: aspiration/institutional pneumonia (11); *C difficile* infection related (5); pneumonia on critical care (10); aetiology (22); antibiotic therapy (36); clinical features (0); community investigations and management (3); complications and failure to improve;¹⁶ general investigations and management (20); incidence and epidemiology (8); microbiology investigations (10); prevention (9); radiology (2); severity assessment (26).

A total of 547 papers were retrieved and circulated for critical appraisal. The leads for each section independently judged the clinical relevance and scientific rigour of each paper assigned to them using generic study appraisal checklists (see Appendices 1 and 2) adapted from published checklists.^{17–20} The reliability of the evidence in each study was graded from Ia to IVb using a generic list of evidence levels (see Appendix 3) developed from existing insights and checklists.^{21–22} Disagreements were resolved by discussion with the section partner (see Section 11.2). Where relevant, individual references used in this document are followed by an indication of the evidence level in square brackets.

Section leads individually assessed the literature selected and wrote a short document describing study findings and related recommendations. These documents were discussed by the whole committee.

1.8.3 Drafting of the guidelines

The Guidelines Committee corresponded by email on a regular basis throughout the duration of the guideline development. Meetings of the full group were held in February 2008, July 2008 and November 2008. Each section lead edited the corresponding section in the 2001 guidelines document, incorporating all relevant literature and recommendations from the 2004 update and the current update. In December 2008 the guidelines were discussed at an open plenary session at the BTS Winter Conference. A revised draft guidelines document was circulated to professional bodies for endorsement in January 2009 and to the BTS Standards of Care Committee in March 2009.

1.9 Grading of recommendations

Recommendations were graded from A+ to D (table 1) as indicated by the strength of the evidence as listed in the table in Appendix 4.

1.10 Plans for updating these guidelines

Following the BTS protocol for guidelines revisions, the Committee will meet on an annual basis and review new published evidence obtained from a structured literature search,

Table 1 Brief description of the generic levels of evidence and guideline statement grades used

Evidence level	Definition	Guideline statement grade
Ia	A good recent systematic review of studies designed to answer the question of interest	A+
Ib	One or more rigorous studies designed to answer the question, but not formally combined	A–
II	One or more prospective clinical studies which illuminate, but do not rigorously answer, the question	B+
III	One or more retrospective clinical studies which illuminate, but do not rigorously answer, the question	B–
IVa	Formal combination of expert views	C
IVb	Other information	D

A fuller description is given in Section 1 and Appendices 1–4.

comment on any newly licensed and relevant antibiotics and issue guideline updates or revisions as necessary. Important changes will be posted on the BTS website (www.brit-thoracic.org.uk). The membership of the Guideline Committee will change over time on a rolling programme dictated by the BTS Standards of Care Committee policy for the Guideline Committee membership.

1.11 Implementation of the guidelines

We expect that these guidelines will act as a framework for local development or modification of protocols after discussion with local clinicians and management. The subsequent dissemination, implementation and evaluation of these guidelines should be undertaken by the hospital Quality and Clinical Effectiveness Group in conjunction with relevant committees such as those responsible for therapeutics, antibiotic prescribing or protocol development. Countries with similar health service systems will also find the framework of value, adapting the guidelines to take into account any relevant national differences in disease presentation and the availability of investigations and antimicrobial agents.

1.12 Auditing CAP management

The management of CAP is a sufficiently common and important issue to warrant the development of audit measures of the process of care and outcome to evaluate the quality of care for CAP, using guidelines as a standard of management.

An audit tool has been developed and is available through the BTS website (www.brit-thoracic.org.uk).

SECTION 2 INCIDENCE, MORTALITY AND ECONOMIC CONSEQUENCES

2.1 How common is adult CAP in the community and in hospital?

Prospective population studies from the UK,^{23 [11]} Finland^{24 [1b]} and North America^{25 [1b]} have reported an annual incidence of CAP diagnosed in the community of between 5 and 11 per thousand adult population. Pneumonia, diagnosed clinically by general practitioners, accounts for only 5%^{23 [1b]} to 12%^{26 [1b]} of all cases of adult lower respiratory tract infection treated with antibiotics by general practitioners in the community in the UK.

The incidence varies markedly with age, being much higher in the very young and the elderly. In a Finnish study the annual incidence in the 16–59 age group was 6 per 1000 population, for those aged ≥60 years and 34 per 1000 population for those aged ≥75 years.^{24 [1b]} A similar pattern was reported from Seattle, USA.^{25 [1b]}

Population-based studies of the incidence of CAP requiring hospitalisation have reported overall incidences of 1.1 per 1000 adult population per annum in Canada,^{27 [Ib]} 2.6 per 1000 in Spain,^{6 [III]} 2.7 per 1000 population in Ohio, USA^{6 [Ib]} and 4 per 1000 population in Pennsylvanian hospitals, USA.^{28 [III]} Increasing age was associated with an increasing incidence of admission to hospital with CAP in Canada; from 1.29 per 1000 persons aged 18–39 years, to 1.91 per 1000 persons aged 40–54 years, to 13.21 per 1000 persons aged 55 years or above.^{29 [III]} A study of Hospital Episode Statistics for England between 1997 and 2005 showed a rise in hospital admissions for pneumonia over time. The age-standardised incidence of hospitalisations with a primary diagnosis of pneumonia increased by 34% between 1997–8 and 2004–5, from 1.48 to 1.98 per 1000 population. This increase was more marked in older adults.^{12 [III]}

The proportion of adults with CAP who require hospital admission in the UK has been reported as between 22%^{23 [Ib]} and 42%.^{30 [III]} This figure varies in other countries, probably dependent on the structure of the primary and secondary healthcare system. In a Finnish prospective longitudinal population study, 42% were admitted to hospital.^{24 [Ib]} A 50% admission rate was reported in one study from Spain, but this only included patients referred by their general practitioner to the hospital emergency service for confirmation of the diagnosis of CAP.^{10 [II]}

In Seattle, USA 15% were hospitalised.^{31 [Ib]} In the Pneumonia Patient Outcomes Research multicentre prospective cohort study of CAP in America, 41% of adults studied were managed initially as outpatients and the remainder were admitted to hospital. Of those initially treated as outpatients, only 7.5% were subsequently admitted, 56% because of the CAP and the rest because of worsening of a comorbid illness.^{32 [Ib]}

The proportion of adults hospitalised with CAP who require management on an intensive care unit (ICU) varies from 1.2% in one Spanish study^{12 [III]} and 5% in the BTS multicentre study^{65 [II]} to 10% in another Spanish study.^{33 [II]} Previously, between 8%^{13 [II]} and 10%^{34 [III]} of medical admissions to an ICU were found to be for severe CAP. An analysis of admissions to ICUs across England, Wales and Northern Ireland between 1995 and 2004 found CAP to be the cause of 5.9% of all ICU admissions. There was an increase in CAP requiring intensive care from 12.8 per unit in 1996 to 29.2 per unit in 2004. This represented an increase of 128% compared with a rise in the total number of admissions to ICUs of only 24%.^{13 [III]}

Summary

- ▶ The annual incidence in the community is 5–11 per 1000 adult population. [Ib]
- ▶ CAP accounts for 5–12% of all cases of adult lower respiratory tract infection managed by general practitioners in the community. [Ib]
- ▶ The incidence varies markedly with age, being much higher in the very young and the elderly. [Ib]
- ▶ Between 22% and 42% of adults with CAP are admitted to hospital. [Ib]
- ▶ The incidence for patients requiring admission to hospital varies with age from 1.29 per 1000 persons aged 18–39 years up to 13.21 per 1000 persons aged ≥55 years. [III]
- ▶ The age-standardised incidence of admission to hospital increased by 34% from 1.48 to 1.98 per 1000 population between 1997–8 and 2004–5 in England.
- ▶ Between 1.2% and 10% of adults admitted to hospital with CAP are managed on an ICU. [II]

2.2 What is the mortality of CAP?

The reported mortality of adults with CAP managed in the community is low and less than 1%.^{15 23 32 [II] [Ib] [Ib]} Deaths in the community due to CAP are rare in the UK. In one study only seven cases were identified by coroners' post mortems over 1 year in Nottingham, a large urban city of three quarters of a million, giving an incidence of 1 per 100 000.^{23 [III]}

The reported mortality of adults hospitalised with CAP has varied widely. The BTS multicentre study reported a mortality of 5.7%,^{6 [III]} but did not study patients over the age of 74 years. Other UK studies have reported mortalities of 8%,^{35 [III]} 12%^{36 [Ib]} and 14%.^{37 [Ib]} Countries with similar healthcare systems have reported hospital mortality rates of 4%,^{24 [Ib]} 7%,^{38 [II]} 8%^{241 [Ib]} and 10%.^{39 [Ib]}

The longer term mortality of CAP is high, reflecting the frailty of many patients who develop CAP in the first instance. In a US study the 90-day all-cause mortality was 8.7% and mortality at 5.9 years was 39.1%. Age, level of education, male sex and nursing home residence were independently associated with long-term mortality.^{40 [II]} Other studies found long-term mortality to be 20.8% at 1 year, 34.1% at a mean of 901 days and 35.8% at 5 years.^{41 [III]}

The mortality of patients with severe CAP requiring admission to an ICU is high. This is likely to be particularly evident in health services such as the National Health Service where ICU beds are at a premium, such that only critically ill patients in need of assisted ventilation can be admitted. ICU-based studies in the UK have reported mortalities of over 50%,^{25 34 42 43 [III] [III] [III] [III]} although a more recent analysis of admissions to ICUs across England, Wales and Northern Ireland between 1995 and 2004 reported a mortality of 34.9% for patients with CAP.^{13 [III]} Nearly all of the patients required assisted ventilation. By contrast, the mortality rate in a large multicentre study of severe CAP in four French ICUs reported a mortality of 35% with a ventilation rate of only 52%.^{25 [Ib]} Similar figures were reported from another ICU-based study in France.^{44 [II]} In a specialist ICU in Spain, a mortality of 22% was reported, rising to 36% in the 61% of patients who required assisted ventilation.^{33 [II]}

Summary

- ▶ The reported mortality of adults with CAP managed in the community in the UK is very low and less than 1%. [Ib]
- ▶ The reported mortality of adults hospitalised with CAP in the UK has varied between 5.7% and 14%. [Ib]
- ▶ The mortality of patients with severe CAP requiring admission to an ICU in the UK is high at over 30%. [III]
- ▶ The long-term mortality of CAP is between 35.8% and 39.1% at 5 years. [II]

2.3 What are the economic consequences of CAP?

A prevalence-based burden of illness study estimated that CAP in the UK incurred a direct healthcare cost of £441 million annually at 1992–3 prices. The average cost for managing pneumonia in the community was estimated at £100 per episode compared with £1700–5100 when the patient required admission to hospital. Hospitalisation accounted for 87% of the total annual cost.^{30 [III]}

A similar exercise conducted in 1997 in the USA calculated that annual costs of CAP amounted to \$8.4 billion, 52% of the costs being for the inpatient care for 1.1 million patients and the remaining costs for the 4.4 million outpatient consultations. The average hospital length of stay varied between 5.8 days for

those under 65 years of age and 7.8 days for older patients.⁴⁵ [III] A prospective study of costs and outcome of CAP from five hospitals in North America concluded that costs of antibiotic therapy varied widely but had no effect on outcome or mortality. Patients treated in the hospitals with the lowest costs did not have worse medical outcomes.⁴⁶ [Ib]

Summary

- ▶ The direct costs associated with CAP are high and mostly associated with inpatient care costs. [III]
- ▶ Substantial costs savings could likely be made by strategies to prevent CAP, to reduce the requirement for hospital admission and to shorten the length of hospital stay. [III]

2.4 What comments can be made about cost effectiveness of different therapies?

We are not able to provide any structured guidance on this subject. Modern guidelines should attempt to provide information, not only on clinical management but also on the assessment of robust published data on cost effectiveness of therapies. However, it was noted that there is a clear deficiency of good quality comparative clinical data which would allow meaningful comparisons of management and antibiotic strategies for CAP, whether assessing for clinical or cost effectiveness outcome.

Summary

- ▶ We have not attempted a systematic appraisal of current pharmaco-economic evidence for CAP and do not give a structured view on cost effectiveness.
- ▶ Cost effectiveness data pertinent to UK practice does not exist at the time of writing and is an area for further research.

SECTION 3 AETIOLOGY AND EPIDEMIOLOGY

3.1 Introduction

No two studies of the aetiology of CAP are the same. Apparent differences in the observed frequency of pathogens, while possibly real, may also be due to a number of other factors including healthcare delivery (distribution of management between primary and secondary care, hospital and ICU admission practices), population factors (such as age mix, the frequency of alcoholism, comorbid diseases, immune suppression and malignancy) and study factors (type and number of samples collected, investigations performed, result interpretation). Frequently, such details are not explicitly stated in the study methodology and, although we have not included studies which do not comply with certain standards, apparently similar studies may hide very different methodology. With the exception of elderly subjects, few adequately powered studies using the same methodology have been used to compare different population groups. Conclusions about observed differences in the following data must therefore be treated with caution.

Many of the statements in the following text arise from a comparison of studies, rather than data from individual studies that have set out to answer that question. For this reason, evidence grades follow statements to justify that conclusion, as well as individual references.

3.2 What are the causes of adult CAP in the UK?

These are set out in table 2, together with details of the relevant references (and grading of evidence from those individual

references), grouped together by where patients have been managed—be it in the community, in hospital or on an ICU. For all these groups, a common range of pathogens is regularly identified as causes of CAP. [Ib] Although a single pathogen is identified in 85% of patients where an aetiology is found, the true frequency of polymicrobial CAP is not known and observed figures are dependent on the intensity of investigation. *S pneumoniae* is the most frequently identified pathogen. [Ib] The relative frequency of pathogens in patients managed in the community and in hospital is probably similar, but the absence of more than one study in the community makes further conclusions uncertain. *Legionella* species and *S aureus* are identified more frequently in patients managed on the ICU. [Ib] The apparent difference in the frequency of *Mycoplasma pneumoniae* may depend on whether or not a study is performed in an epidemic year. [II] Gram-negative enteric bacilli, *Chlamydomphila psittaci* and *Coxiella burnetii* are uncommon causes of CAP. [Ib]

Since 2001 only one additional study of adults admitted to hospital with CAP has been published,⁴⁷ which found a similar distribution of common causative pathogens to that in previous studies.

3.3 What are the causes of adult CAP in similar populations elsewhere in the world?

The results and references of relevant studies from the remainder of Europe, Australia and New Zealand and North America were compared in the earlier BTS guidelines.¹ Other European studies confirm previous knowledge.^{30 31 48} [Ib] [II] For patients managed in the community and in hospital, the frequency of pathogens is broadly similar to that in the UK. [II] This suggests that aspects of these guidelines will be applicable to other countries as well as the UK. The absence of studies using sensitive methods for pneumococcal polysaccharide capsular antigen detection for the identification of *S pneumoniae* may be the explanation for the lower frequency outside the UK. The apparent differences in *M pneumoniae* may relate to the presence or absence of epidemics at the time of the study. *Chlamydomphila pneumoniae* is identified frequently in some European countries, but recent studies in Germany³¹ [Ib] and the Netherlands³¹ [III] found frequencies of only 0.9% and 3%, respectively.

Antibiotic-resistant *S pneumoniae* appears to be no more frequent in severely ill patients admitted to the ICU than in those managed on an ordinary hospital ward in a country where such resistance is common.⁴⁹ [Ib] Studies of patients with severe CAP from Europe suggest a lower frequency of legionella and a higher frequency of Gram-negative enteric bacilli infections compared with the UK. These may be real or methodological. [IVa]

A frequency of 8% for non-pneumophila legionella species was found in one Dutch study.³² [III] A study of hospitalised patients in Spain⁵⁰ [Ib] found a frequency of mixed aetiology of 13%, similar to the average figure of 11% for the UK. Another Spanish study found a frequency of 5.7%.⁵¹ [Ib] A recent publication showed a high frequency of *C burnetii* infection in the Canary Islands.⁵² [Ib]

3.4 How does the aetiology differ in certain geographical areas?

Specific studies suggest a higher frequency of certain pathogens in some geographical areas as described in the 2001 BTS guidelines (table 3).¹ A global study found a frequency of atypical pathogens of 20–28% of cases in different regions of the

Table 2 Studies of community acquired pneumonia (CAP) conducted in the UK

	Where managed		
	Community	Hospital	Intensive care unit
	1 study* (n = 236)	5 studies† (n = 1137)	4 studies‡ (n = 185)
<i>Streptococcus pneumoniae</i>	36.0 (29.9 to 42.1)	39 (36.1 to 41.8)	21.6 (15.9 to 28.3)
<i>Haemophilus influenzae</i>	10.2 (6.3 to 14.0)	5.2 (4.0 to 6.6)	3.8 (1.5 to 7.6)
<i>Legionella</i> spp	0.4 (0.01 to 2.3)	3.6 (2.6 to 4.9)	17.8 (12.6 to 24.1)
<i>Staphylococcus aureus</i>	0.8 (0.1 to 3.0)	1.9 (1.2 to 2.9)	8.7 (5.0 to 13.7)
<i>Moraxella catarrhalis</i>	?	1.9 (0.6 to 4.3)	?
Gram-negative enteric bacilli	1.3 (0.3 to 3.7)	1.0 (0.5 to 1.7)	1.6 (0.3 to 4.7)
<i>Mycoplasma pneumoniae</i>	1.3 (0.3 to 3.7)	10.8 (9.0 to 12.6)	2.7 (0.9 to 6.2)
<i>Chlamydia pneumoniae</i>	? (?)	13.1 (9.1 to 17.2)	? (?)
<i>Chlamydia psittaci</i>	1.3 (0.3 to 3.7)	2.6 (1.7 to 3.6)	2.2 (0.6 to 5.4)
<i>Coxiella burnetii</i>	0 (0 to 1.6)	1.2 (0.7 to 2.1)	0 (0 to 2.0)
All viruses	13.1 (8.8 to 17.4)	12.8 (10.8 to 14.7)	9.7 (5.9 to 14.9)
Influenza A and B	8.1 (4.9 to 12.3)	10.7 (8.9 to 12.5)	5.4 (2.6 to 9.7)
Mixed	11.0 (7.0 to 15.0)	14.2 (12.2 to 16.3)	6.0 (3.0 to 10.4)
Other	1.7 (0.5 to 4.3)	2 (1.3 to 3)	4.9 (2.3 to 9.0)
None	45.3 (39.0 to 51.7)	30.8 (28.1 to 33.5)	32.4 (25.7 to 39.7)

Values are mean (95% CI) percentages.

*Reference 39^[b].

†References 10^[b], 11^[b], 13^[b], 14^[b], 68^[b].

‡References 20^[b], 21^[b], 65^[b], 72^[b].

world.⁵³ [II] A similar figure of 23.5% was found in a multicentre South Asian study.⁵⁴ [Ib]

Studies from Chile⁵⁵ [Ib] and Nicaragua⁵⁶ [Ib] report a similar pathogen spectrum to previous European studies.

Evidence of legionella infection was found in 31.7% of non-consecutive pneumonia cases in Trinidad⁵⁷ [II] and 5.1% of 645 consecutive cases in Brazil.⁵⁸ [Ib] An incidence of 5.2% for *C pneumoniae* was found by the same group,⁵⁸ [II] with a frequency of 8.1% being found in a Canadian study.⁵⁹ [II] In 62% of these cases an additional pathogen was also found.

An outpatient study in Arizona found evidence of coccidioidomycosis in 29% (16–44%) of 55 cases.⁶⁰ [II]

Studies from south and east Asia found high frequencies of *S pneumoniae*,⁶¹ ⁶² [Ib] *C pneumoniae*⁶¹ [Ib] and Gram-negative bacteria⁶¹ ⁶² [Ib] and *Haemophilus influenzae*⁶³ [Ib] in Thailand. In China, *H influenzae* was the predominant pathogen in one study,⁶⁴ [Ib] but *S pneumoniae* and *M pneumoniae* in another.⁶⁵ [Ib] *S pneumoniae* followed by *H influenzae* predominated in Japan,⁶⁶ [II] and *S pneumoniae* followed by *M pneumoniae* in Taiwan.⁶⁷ [Ib]

S pneumoniae and *Klebsiella pneumoniae* were found to be the most frequent causes of CAP in the ICU on an Indian Ocean island.⁶⁸ [Ib]

Table 3 Pathogens which are more common as a cause of community acquired pneumonia in certain geographical regions

Pathogen	Geographical area	References
<i>Legionella</i> spp	Countries bordering the Mediterranean Sea	27 ^[II] , 378 ^[II]
<i>Coxiella burnetii</i>	North-west Spain	389 ^[II]
<i>Coxiella burnetii</i>	Canada	390 ^[II]
<i>Klebsiella pneumoniae</i>	South Africa	391 ^[II] , 392 ^[II]
<i>Burkholderia pseudomallei</i>	South-east Asia and northern Australia	93 ^[II] , 393 ^[II] , 394 ^[II] , 395 ^[II]
Gram-negative enteric bacilli	Italy	379 ^[II]
<i>Mycobacterium tuberculosis</i>	Non-industrialised countries	93 ^[II] , 94 ^[II]

3.5 Is the aetiology different in specific population groups?

Elderly subjects

Three UK studies (two using a definition of “elderly” of >65 years of age but excluding those aged >79 years (quoted in Venkatesan *et al*⁶⁹ [Ib]) and one study using a definition of >75 years³⁷ [Ib]) have reported data on the comparative frequency of pathogens in elderly subjects compared with that in a younger population. The results are combined in fig 3. For most pathogens their frequency is the same in young as in old subjects, but *M pneumoniae* and legionella infection are less frequent in elderly people. [Ib] *M pneumoniae* and other atypical pathogens were found to occur more frequently in patients aged <60 years in one other study.⁷⁰ [Ib] *H influenzae* may also be more commonly identified in elderly patients [II]. Gram-negative enteric bacilli were no more common in elderly patients [III], although this has been reported in at least one other study.⁷¹ [II] No difference in the frequency of pathogens according to age was found in one study of patients with severe CAP.⁷² [III]


One study from Spain compared the aetiology in those aged >79 years and <80 years and confirmed the previous findings of less *M pneumoniae* and legionella infection and more aspiration and unknown aetiology in the elderly patients, but did not confirm a greater frequency of *S pneumoniae* in elderly subjects (fig 4).⁷³ [Ib]

Patients with chronic obstructive pulmonary disease (COPD)

There are no relevant UK studies and no new data. *H influenzae* and *M catarrhalis* may be more frequent. One Danish study directly compared those with and without COPD and found no difference in pathogen frequency; however, numbers were small so real differences may have been missed.⁷⁴ [II] A Spanish study which focused on patients with COPD but with no control group found a pathogen distribution similar to that described in studies of CAP in the general population.⁷⁵ [II] A further Spanish study found *S pneumoniae*, Enterobacteriaceae, *Pseudomonas aeruginosa* and mixed infections to occur more frequently in those with chronic lung disease.⁷⁵ [Ib] In one study COPD was found more frequently in patients with bacteraemic pneumococcal pneumonia than other CAPs.⁷⁶ [Ib]

Figure 3 Difference in causative pathogens between young and elderly patients. Vertical axis shows the difference in frequency between the young and the elderly groups for pooled data from three UK studies (percentages \pm 95% confidence intervals).

Sp, *Streptococcus pneumoniae*; Hi, *Haemophilus influenzae*; Lp, *Legionella* spp; Sa, *Staphylococcus aureus*; Mcat, *Moraxella catarrhalis*; GNEB, Gram-negative enteric bacilli; Mp, *Mycoplasma pneumoniae*; Cp, *Chlamydophila pneumoniae*; Cpsi, *Chlamydophila psittaci*; Cb, *Coxiella burnetii*; allV, viruses; Flu, influenza viruses; oth, other organisms; none, no pathogen identified. Taken from Venkatesan *et al*⁶⁹ and Lim *et al*.³⁷



Patients with diabetes

Diabetes was found to be more frequent in patients with bacteraemic pneumococcal pneumonia than in those with either non-bacteraemic pneumococcal pneumonia or all CAPs in one study.^{76 [1b]} No new data were found.

Nursing home residents

Aspiration,^{76 77 [II] [III]} Gram-negative enteric bacilli^{78 [III]} and anaerobes [IVb] may be more frequent than in matched elderly patients. North American studies, which suggest these differences, may not be relevant to the UK population and healthcare system. Legionella infections and atypical pathogens are uncommon.^{5 79 [II] [III]} The first UK prospective cohort study comparing 40 patients with nursing home acquired pneumonia with 236 adults aged \geq 65 years with CAP^{80 [1b]} found no evidence that the distribution of causative pathogens is different from that in other older adults with CAP. A comparative study from Spain of patients with health care associated pneumonia

(HCAP) which included 25.4% from a nursing home found a higher frequency of aspiration pneumonia, *H influenzae*, Gram-negative bacilli and *S aureus* and a lower frequency of legionella and “no pathogen” in the HCAP group compared with the non-HCAP group.^{81 [1b]}

Alcoholic patients

There are no UK studies. Aspiration,^{72 [II]} pneumococcal infection overall,^{49 [1b]} bacteraemic pneumococcal infection,^{49 76 [1b] [II]} Gram-negative enteric bacilli,^{71 [II]} legionella,^{82 [III]} atypical pathogens,^{49 [1b]} *C pneumoniae*,^{49 [1b]} anaerobes [IVb] and mixed infections^{49 [1b]} may be more frequent. A further study of hospitalised patients in Spain found an association with current or ex alcoholism and *S pneumoniae* infection.^{83 [1b]}

Patients on oral steroids


There are no UK studies and no new data. Infection with *Legionella* species may be more frequent.^{84 [III]}

Figure 4 Comparative frequency of identification of pathogens in elderly and young patients in European studies that have contemporaneously applied the same methodology to both groups.

Results of four studies totalling 2193 patients (566 elderly patients defined as >60, >65 and >79 years).^{69 70 73 502 [II] [III]}

[II] [III] For each organism, the frequency (\pm 95% confidence intervals) in elderly patients is shown in the left bar and in young patients in the right bar.

Sp, *Streptococcus pneumoniae*; Hi, *Haemophilus influenzae*; Lp, *Legionella* spp; Sa, *Staphylococcus aureus*; Mcat, *Moraxella catarrhalis*; GNEB, Gram-negative enteric bacilli; Mp, *Mycoplasma pneumoniae*; Cp, *Chlamydophila pneumoniae*; Cpsi, *Chlamydophila psittaci*; Cb, *Coxiella burnetii*; allV, viruses; Flu, influenza viruses; oth, other organisms; none, no pathogen identified.



Aspiration pneumonia

There are no UK studies. Most studies of CAP exclude such patients. Anaerobic bacteria and Gram-negative enteric bacilli may be more common (see the section above on elderly subjects).^{72 85 [III] [III]}

Congestive cardiac failure

A study from Spain suggested a higher frequency of this condition (31%) in those with viral pneumonia than in those with mixed (8%) or pneumococcal pneumonia (2%).^{86 [Ib]}

3.6 What are the epidemiological patterns of pathogens causing CAP and is this information useful to the clinician?

Streptococcus pneumoniae

S pneumoniae occurs most commonly in the winter [II].^{87 [II]} Outside the UK, epidemics have occurred in overcrowded settings (eg, mens' shelters and prisons) [II].^{87 88 [II] [II]}

Legionella species

Legionella infection was most common between June and October, with a peak in August and September in the UK between 1999 and 2005.^{89 [II]} Fifty percent of UK cases are related to travel,⁸⁹ 93% of these relating to travel abroad.^{89 [II]} Clusters of cases are linked to Mediterranean resorts, especially France, Greece, Turkey and Spain,^{89 [II]} but only 23%^{90 91 [II]} of cases occur in clusters. Epidemics occur related to water-containing systems in buildings.^{92 [II]}

Mycoplasma pneumoniae

Epidemics spanning three winters occur every 4 years in the UK, as shown in fig 5. The apparent decline in reports is probably related to decreased use of complement fixation testing rather than a true decline in frequency.

Chlamydia pneumoniae

Epidemics occur in the community and in closed communities.^{93-95 [II] [II] [II]} Its direct pathogenic role as a cause, as opposed to being associated with CAP, is not clear. The lack of a diagnostic gold standard means the frequency is unknown. Serological and PCR^{96 [Ib]} results are highly variable between assays. Evidence that antibiotic therapy directed against this organism alters the course of the illness is lacking. When identified, other bacterial pathogens (eg, *S pneumoniae*) are often identified in the same host.^{97-99 [II] [II] [II]} Patients may recover when antibiotics to which *C pneumoniae* is not sensitive are given.^{99 [II]}

Chlamydia psittaci

Infection is acquired from birds and animals but human to human spread may occur. [II] Epidemics are reported in relation to infected sources at work (eg, poultry or duck workers). [II] Only 20% of UK cases have a history of bird contact.^{100 [II]}

Coxiella burnetii

Cases are most common in April to June, possibly related to the lambing and calving season. [II] Epidemics occur in relation to animal sources (usually sheep), but a history of occupational exposure is only present in 7.7% (95% CI 6.2% to 9.4%) of cases.^{101 [II]}

Staphylococcus aureus

It is more common in the winter months. Coincident influenza-type symptoms are reported in 39% (95% CI 27% to 53%) of cases.^{6 35 36 102 [II]} Evidence of coincident influenza virus infection is found in 39% (95% CI 17% to 64%) of those admitted to hospital,^{6 35 36 102 [II]} and 50% (95% CI 25% to 75%) of those admitted to an ICU.^{33 34 42 103 [II]}

Multiple case reports^{104-118 [III]} and series of 2-11 patients,^{119-124 [II]} both from the UK and worldwide, describe episodes of CAP caused by *S aureus* (either methicillin-sensitive *S aureus* (MSSA) or MRSA) capable of production of the Panton-Valentine Leucocidin toxin. Severe illness—with high mortality, bilateral lung shadowing and frequent lung cavitation—is common to these reports. No prospective studies have been performed to identify the true frequency of CAP due to this organism, but it appears to be rare at present.

Influenza virus

Annual epidemics of varying size are seen during the winter months.^{125 [II]} Pneumonia complicates 2.9% (95% CI 1.4% to 5.4%) of cases in the community.^{126 [Ib]} The frequency of staphylococcal pneumonia in patients with influenza symptoms is not known. Of adults with CAP admitted to UK hospitals in whom influenza infection is confirmed, 10% (95% CI 4.1% to 19.5%) have coincident *S aureus* infection. [II] Of those admitted to an ICU, the corresponding figure is 67% (95% CI 35% to 90%).^{34 42 43 103 [II]}

Summary

- ▶ The low frequency of legionella, staphylococcal, *C psittaci* and *C burnetii* infection in patients with CAP in both the community and in hospital, together with the likely high frequency of the relevant risk factors (outlined above) in the general population suggests that routine enquiry about such factors is likely to be misleading. [IV]
- ▶ Only in those with severe illness where the frequency of legionella and staphylococcal infection is higher may enquiry about foreign travel and influenza symptoms be of predictive value. [IV]
- ▶ Knowledge of increased mycoplasma activity in the community during an epidemic period may help guide the clinician to the increased likelihood of mycoplasma infection. [IV]

SECTION 4 CLINICAL FEATURES


4.1 Can the aetiology of CAP be predicted from clinical features?

There have been a large number of publications looking at the possibility of predicting the aetiological agent from the clinical features at presentation; however, while certain symptoms and signs are more common with specific pathogens, none allow accurate differentiation.^{127 128 [II]} This led to a suggestion that the term “atypical” pneumonia be abandoned.¹²⁸ As explained in Section 1.3.2, the term “atypical pathogens” remains useful and there is evidence that pleuritic pain is less likely in pneumonia secondary to these agents.¹²⁹

Summary

- ▶ The likely aetiological agent causing CAP cannot be accurately predicted from clinical features. [II]
- ▶ The term “atypical” pneumonia should be abandoned as it incorrectly implies that there is a characteristic clinical presentation for patients with infection caused by “atypical” pathogens. [II]

Figure 5 Laboratory reports to the Health Protection Agency Centre for Infections of infections due to *Mycoplasma pneumoniae* in England and Wales by date of report, 1990–2008 (4-weekly).



4.2 Specific clinical features of particular respiratory pathogens

Clinical features associated with specific pathogens are described below and summarised in box 1.

Streptococcus pneumoniae

One study using discriminant function analysis found pneumococcal aetiology to be more likely in the presence of cardiovascular comorbidity, an acute onset, pleuritic chest pain and less likely if patients had a cough or flu-like symptoms or had received an antibiotic before admission.¹³⁰ [III]

Bacteraemic pneumococcal pneumonia was found to be more likely in those patients who had at least one of the following features: female, history of no cough or a non-productive cough, history of excess alcohol, diabetes mellitus or COPD.⁷⁶ [II]

In high severity CAP where patients were admitted to an ICU, clinical features had little value in predicting the aetiological agent with the exception of those patients with fever (>39°C) or chest pain who were statistically more likely to have pneumococcal pneumonia.⁴⁴ [II]

Legionella pneumophila

A variety of clinical features have been found to be more common in patients with legionella pneumonia, and yet most

Box 1 Some clinical features reported to be more common with specific pathogens (references are given in the text)

- ▶ *Streptococcus pneumoniae*: increasing age, comorbidity, acute onset, high fever and pleuritic chest pain.
- ▶ Bacteraemic *S pneumoniae*: female sex, excess alcohol, diabetes mellitus, chronic obstructive pulmonary disease, dry cough.
- ▶ *Legionella pneumophila*: younger patients, smokers, absence of comorbidity, diarrhoea, neurological symptoms, more severe infection and evidence of multisystem involvement (eg, abnormal liver function tests, elevated serum creatine kinase).
- ▶ *Mycoplasma pneumoniae*: younger patients, prior antibiotics, less multisystem involvement.
- ▶ *Chlamydia pneumoniae*: longer duration of symptoms before hospital admission, headache.
- ▶ *Coxiella burnetii*: males, dry cough, high fever.

agree that it remains impossible to accurately differentiate on clinical grounds.¹³¹ ¹³² Studies have reported *L pneumophila* to be more common in men,¹³³ in young patients with lower rates of comorbid illness,¹³⁴ in smokers¹³⁵ and in those who have already received antibiotic therapy.¹³³ ¹³⁵ Clinical features which might point towards *L pneumophila* as an aetiological agent include encephalopathy and other neurological symptoms, gastrointestinal symptoms, more severe infection, elevated liver enzymes, elevated creatine kinase and relatively less frequent upper respiratory tract symptoms, pleuritic chest pain and purulent sputum.⁸² ¹³³ ¹³⁶

Mycoplasma pneumoniae

One study has compared CAP due to *M pneumoniae* to patients with pneumococcal or legionella pneumonia. It reported that patients with mycoplasma pneumonia were younger, less likely to have multisystem involvement and more likely to have received an antibiotic before admission.²³ By contrast, another report found no distinctive clinical features in patients with confirmed *M pneumoniae* pneumonia.¹³⁷ [II]

Chlamydia pneumoniae

A comparative study of patients with *C pneumoniae* and *S pneumoniae* pneumonia found the former more likely to present with headaches and a longer duration of symptoms before hospital admission.⁹⁵ [II] A study from Israel reported no distinguishing clinical features for chlamydial pneumonia, except that it affected older patients than pneumococcal and mycoplasma infections.⁹⁸ [II] A comparison of *C pneumoniae* and *M pneumoniae* confirmed the age difference between the groups and stated that, although clinical features could not be used to distinguish between the two, cough, hoarseness and rhinitis were all more common in *M pneumoniae* pneumonia.¹³⁸ [III] Where *C pneumoniae* was the only pathogen identified, the illness was generally mild with non-specific symptoms.¹³⁹ [II]

Coxiella burnetii

CAP due to *C burnetii* (Q fever) causes non-specific clinical features.¹⁴⁰ ¹⁴¹ [II] Two reviews of Q fever have reported that infection was more common in younger men and that patients tended to present with dry cough and high fever.¹⁴² ¹⁴³ [III] Epidemiological features are discussed in Section 3.

infection, or *suspected* CAP, is deciding whether to use an antibiotic, which one and how ill the patient is. Labelling the illness as pneumonia is less important.¹⁶⁵

Recommendations

It is not necessary to perform a chest radiograph in patients with *suspected* CAP unless:

- ▶ **The diagnosis is in doubt and a chest radiograph will help in a differential diagnosis and management of the acute illness. [D]**
- ▶ **Progress following treatment for *suspected* CAP is not satisfactory at review. [D]**
- ▶ **The patient is considered at risk of underlying lung pathology such as lung cancer (see Section 5.6). [D]**

5.2 When should a chest radiograph be performed in hospital for patients presenting with suspected CAP?

A chest radiograph is the cornerstone to confirming a diagnosis of CAP. In patients ill enough to require hospital referral for *suspected* CAP, a chest radiograph is essential to establishing the diagnosis of CAP or an alternative diagnosis, and therefore in guiding management decisions.

Antibiotic treatment of patients with *suspected* CAP prior to, or without, confirmation by chest radiography potentially leads to inappropriate and excessive antibiotic use.

The committee felt that the Department of Health's "4 hour from presentation to admission, transfer or discharge" target for patients admitted to emergency departments represented a practice standard that should apply to all patients presenting to hospital (via the emergency department or acute medical unit) with *suspected* CAP.¹⁵

Recommendation

- ▶ **All patients admitted to hospital with *suspected* CAP should have a chest radiograph performed as soon as possible to confirm or refute the diagnosis. [D] The objective of any service should be for the chest radiograph to be performed in time for antibiotics to be administered within 4 h of presentation to hospital should the diagnosis of CAP be confirmed.**

5.3 Are there characteristic features that enable the clinician to predict the likely pathogen from the chest radiograph?

There are no characteristic features on the chest radiograph in CAP that allow confident prediction of the causative organism.^{98 166-168 [III]} The lower lobes are affected most commonly, regardless of aetiology.

Multilobe involvement^{169 [II]} at presentation and pleural effusions were more likely at presentation in bacteraemic pneumococcal pneumonia than in non-bacteraemic pneumococcal pneumonia or legionella pneumonia. Homogenous shadowing was less common in mycoplasma pneumonia than in the other types. Lymphadenopathy was noted in some cases of mycoplasma infections but not in the other types of infection. CAP due to *S aureus* appears to be more likely to present with multilobar shadowing, cavitation, pneumatoceles or spontaneous pneumothorax.^{170 [III]} *K pneumoniae* has been reported to produce chest radiograph changes with a predilection for upper lobes (especially the right).^{171 [II]} A bulging interlobar fissure and abscess formation with cavitation have also been reported, although the former is probably just a reflection of an intense inflammatory reaction that can occur in any severe infection such as pneumonia due to *S aureus*.^{170 [III]}

Summary

- ▶ There are no characteristic features of the chest radiograph in CAP that allows a confident prediction of the likely pathogen. [II]

5.4 What is the role of CT lung scans in CAP?

There are few data on the role of high-resolution CT lung scans in CAP. A small study has reported that high-resolution CT scans may improve the accuracy of diagnosing CAP compared with chest radiography alone.^{172 [III]} Similarly, CT lung scans have improved sensitivity compared with standard chest radiographs in patients with mycoplasma pneumonia.^{173 [III]} CT lung scans may be useful in subjects where the diagnosis is in doubt^{174 [III]} but, in general, there is little role for CT scanning in the usual investigation of CAP.

With regard to aetiology, one study has reported a difference in CT appearances in 18 patients with CAP due to bacterial infections compared with 14 patients with atypical pathogens.^{175 [III]}

Summary

- ▶ CT scanning currently has no routine role in the investigation of CAP. [II]

5.5 How quickly do chest radiographs improve after CAP?

Radiographic changes resolve relatively slowly after CAP and lag behind clinical recovery. In one study, complete resolution of chest radiographic changes occurred at 2 weeks after initial presentation in 51% of cases, in 64% by 4 weeks and 73% at 6 weeks.¹⁷⁶ Clearance rates were slower in elderly patients, those with more than one lobe involved at presentation, smokers and inpatients rather than outpatients. Multivariate analysis showed that only age and multilobe involvement were independently related to rate of clearance. Age was also a major factor influencing rate of radiographic recovery in the BTS multicentre CAP study.^{6 [Ib]} A study of patients over 70 years of age showed 35%, 60% and 84% radiographic resolution at 3, 6 and 12 weeks, respectively.^{177 [III]} C-reactive protein (CRP) levels >200 mg/l were also linked to slower radiographic resolution.^{178 [III]} When chest radiographs of patients with bacteraemic pneumococcal pneumonia were followed, only 13% had cleared at 2 weeks and 41% at 4 weeks.^{179 [III]} Pneumonias caused by atypical pathogens clear more quickly. The clearance rate has been reported to be faster for mycoplasma pneumonia than for legionella or pneumococcal pneumonia, which may take 12 weeks or more.^{166 [III]} In a series of patients with *C burnetii* pneumonia, 81% of the chest radiographs had returned to normal within 4 weeks.^{143 [III]}

Radiographic deterioration after admission to hospital was more common with legionella (65% of cases) and bacteraemic pneumococcal pneumonia (52%) than with non-bacteraemic pneumococcal (26%) or mycoplasma pneumonia (25%).^{166 [III]} Residual pulmonary shadowing was found in over 25% of cases of legionella and bacteraemic pneumococcal cases. Deterioration after admission has also been reported in over half of cases of *S aureus* pneumonia.^{170 [III]} Radiographic deterioration after hospital admission appears to be commoner in older patients (aged ≥65 years).^{151 [III]}

Summary

- ▶ Radiological resolution often lags behind clinical improvement from CAP, particularly following legionella and bacteraemic pneumococcal infection. [III]

- ▶ Pneumonia caused by atypical pathogens clears more quickly than pneumonia caused by bacterial infection. [III]
- ▶ Radiological resolution is slower in elderly patients and where there is multilobar involvement. [Ib]

5.6 When should the chest radiograph be repeated during recovery and what action should be taken if the radiograph has not returned to normal?

Repeat chest radiographs are probably often ordered unnecessarily following CAP.^{180 [IVa]} Although it has become usual practice to repeat the chest radiograph on hospital discharge and again at “routine” hospital clinic follow-up at around 6 weeks later, there is no evidence on which to base a recommendation regarding the value of this practice in patients who have otherwise recovered satisfactorily.

The main concern is whether the CAP was a complication of an underlying condition such as lung cancer. This concern will depend on a variety of factors such as age, smoking status, pre-existing conditions such as COPD and the clinical condition of the patient. In a study of 236 adults presenting to their general practitioner with a clinical diagnosis of CAP, 10 were found to have underlying lung cancer on investigation. There was a high frequency of lung cancer in older smokers (6 of 36 (17%) smokers aged >60 years), suggesting that a chest radiograph was particularly indicated in this group of patients with CAP in the community.^{23 [II]} Studies of CAP in hospital often exclude patients found to have lung cancer, making it difficult to assess how frequently lung cancer presents acutely with CAP. In one study of 162 adults hospitalised with suspected CAP, the diagnosis was accepted in only 127, 10 (6%) of the 162 being found to have cancer.^{36 [III]} Another study found only 13 (1.3%) of 1011 patients hospitalised with CAP to have an underlying lung cancer on investigation.^{181 [III]} Eight of these were detected on the admission chest radiograph and the others were detected because of unsatisfactory clinical recovery. They concluded that a convalescent radiograph was useful in detecting occult lung cancer only if signs or symptoms persisted after a month or so.

The practice of performing bronchoscopy in patients admitted to hospital with CAP prior to hospital discharge has been investigated.^{182 [III]} In patients aged >50 years or who were current or ex-smokers, 14% were found to have an abnormality at bronchoscopy (11% had a bronchial carcinoma diagnosed).

Recommendations

- ▶ **The chest radiograph need not be repeated prior to hospital discharge in those who have made a satisfactory clinical recovery from CAP. [D]**
- ▶ **A chest radiograph should be arranged after about 6 weeks for all those patients who have persistence of symptoms or physical signs or who are at higher risk of underlying malignancy (especially smokers and those aged >50 years) whether or not they have been admitted to hospital. [D]**
- ▶ **Further investigations which may include bronchoscopy should be considered in patients with persisting signs, symptoms and radiological abnormalities at around 6 weeks after completing treatment. [D]**
- ▶ **It is the responsibility of the hospital team to arrange the follow-up plan with the patient and the general practitioner for those patients admitted to hospital (see Section 7.5). [D]**

5.7 What general investigations should be done in a patient with suspected CAP in the community?

General investigations are performed to assess severity (see Section 6), to assess the impact on or to detect the presence of any comorbid disease, to provide some pointer to the particular aetiological agent or group of pathogens, identify complications and to monitor progress (see Section 9).

It may be appropriate to perform investigations in selected patients, especially if there is delayed improvement on review. However, no firm recommendations can be offered. It is a matter of clinical judgement.

Recommendations

- ▶ **General investigations are not necessary for the majority of patients with CAP who are managed in the community. [C] Pulse oximeters allow for simple assessment of oxygenation. General practitioners, particularly those working in out-of-hours and emergency assessment centres, should consider their use (see Section 7.1). [D]**
- ▶ **Pulse oximetry should be available in all locations where emergency oxygen is used. [D]**

5.8 What general investigations should be done in patients admitted to hospital?

Apart from the chest radiograph essential for diagnosis, the only other simple non-microbiological tests that influence immediate management are the urea, which informs severity assessment, and oxygen saturation, which affects supportive management and track and trigger systems in accordance with the BTS guideline for emergency oxygen use in adult patients.¹⁸³

In addition, it is normal practice to take blood for a full blood count, urea and electrolytes, liver function tests and CRP. These often help to identify important underlying or associated pathologies including renal or hepatic disease and haematological or metabolic abnormalities.

A white cell count of $>15 \times 10^9/l$ strongly implicates a bacterial (particularly pneumococcal) aetiology, although lower counts do not exclude a bacterial cause.^{184 [III]} A white cell count of $>20 \times 10^9/l$ or $<4 \times 10^9/l$ is an indicator of severity (see Section 6).

Considering the role of CRP in the diagnosis of CAP, a prospective study performed in Spain reported a 96% specificity for CAP using a threshold CRP level of $>100 \text{ mg/l}$.^{185 [III]} Criticisms of this study are the small number of patients in one group and the fact that patients with infective exacerbations of COPD were excluded. Another study showed that a raised CRP level on admission is a relatively more sensitive marker of pneumonia than an elevated temperature or raised white cell count. All patients with CAP had CRP levels $>50 \text{ mg/l}$ and 75% of patients had levels $>100 \text{ mg/l}$.^{186 [III]} In the same paper it was reported that a CRP level of $>100 \text{ mg/l}$ helped to distinguish CAP from acute exacerbations of COPD. Another group found that only 5% of patients admitted with CAP had CRP levels $<50 \text{ mg/l}$.^{187 [III]} Although not yet widely available, a bedside finger-prick CRP test has been used to predict CAP in 168 patients presenting with acute cough and, at a cut-off of 40 mg/l , was found to have a sensitivity of 70% and a specificity of 90% independent of any clinical characteristics.^{188 [II]} CRP levels are generally higher in patients who have not received antibiotic therapy before admission.^{186 [III]}

With regard to predicting the microbial aetiology of CAP, higher CRP levels have been associated with pneumococcal

pneumonia (especially if complicated by bacteraemia) compared with mycoplasma or viral pneumonias,¹⁸⁹ [III] and in legionella pneumonia compared with all other identified single aetiologies.¹⁹⁰ [III]

Data relating to CRP as a marker of severity and of treatment failure are discussed in Sections 6.2.1 and 7.3, respectively).

There are a number of studies examining the role of other biomarkers in CAP such as procalcitonin, however these assays are not currently widely available.

Summary

- ▶ The published evidence to date suggests that measurement of CRP on admission may be helpful in distinguishing pneumonia from other acute respiratory illnesses. [III]

Recommendations

All patients should have the following tests performed on admission:

- ▶ **Oxygenation saturations and, where necessary, arterial blood gases in accordance with the BTS guideline for emergency oxygen use in adult patients.** [B+]
- ▶ **Chest radiograph to allow accurate diagnosis.** [B+]
- ▶ **Urea and electrolytes to inform severity assessment.** [B+]
- ▶ **CRP to aid diagnosis and as a baseline measure.** [B+]
- ▶ **Full blood count.** [B-]
- ▶ **Liver function tests.** [D]

5.9 Why are microbiological investigations performed in patients with CAP?

Establishing the microbial cause of CAP is useful for several reasons:

- ▶ Identification of pathogens and antibiotic sensitivity patterns permits selection of optimal antibiotic regimens. To date there has been a habit to continue broad-spectrum empirical antibiotics even if a specific pathogen has been identified. However, with the increasing problem of antibiotic resistance and HCAs such as *C difficile* infection, the balance has now swung towards focusing down antibiotic therapy whenever possible.
- ▶ Targeted and narrow-spectrum antibiotic therapy limits drug costs, the threat of antibiotic resistance and adverse drug reactions such as *C difficile*-associated diarrhoea.
- ▶ Specific pathogens have public health or infection control significance, including legionella, psittacosis, *C burnetii*, influenza A and multiresistant organisms. Patients with these infections should be identified quickly so that appropriate treatment and control measures can be implemented.
- ▶ Microbiological investigations allow monitoring of the spectrum of pathogens causing CAP over time. This allows trends regarding aetiology and antibiotic sensitivity to be tracked for public health needs.

Unfortunately, microbiological investigations are insensitive and often do not contribute to initial patient management.¹⁹¹ [III]

In detailed prospective aetiology studies the microbial cause is not found in 25–60% of patients,²³ ¹⁹² [III] [III] and the yield is even lower in routine hospital practice.¹⁹³ ¹⁹⁴ [III] [III] More recent studies including the use of PCR and antigen detection techniques have not generally increased the proportion of patients with a specific aetiological diagnosis.¹⁹⁵ ¹⁹⁶ [III] [III] In contrast, one recent prospective study of 105 adults with CAP¹⁹⁷ [III] comparing a multiplex real-time PCR for a range of “atypical

pathogens” and respiratory viruses with conventional methods reported a microbiological diagnosis in 80 patients (76%) using the real-time PCR compared with 52 patients (49.5%) using conventional methods. However, no urine antigen testing for either legionella or pneumococcal infection was included in the study, and most of the increase in diagnostic yield obtained was due to enhanced detection of rhinoviruses and coronaviruses. Nevertheless, such studies point the way forward for improving aetiological diagnosis in CAP.

Several studies^{198–201} [III] [III] [III] [III] have examined the positivity rate of routine microbiological investigations (blood and sputum cultures) for patients with CAP. These studies provide further evidence that the overall sensitivity of such tests in CAP is low, particularly for patients with low severity CAP and no comorbid disease, and for those who have received antibiotic therapy prior to admission. One study²⁰⁰ demonstrated a direct correlation between the severity of pneumonia (using the Fine Pneumonia Severity Index (PSI)) and blood culture positivity rate, and questioned the value of routine blood cultures for patients in PSI risk classes I–III (ie, low severity). However, another study found poor correlation of blood culture positivity with the PSI among patients hospitalised with CAP.²⁰¹ [III]

Recommendations

- ▶ **Microbiological tests should be performed on all patients with moderate and high severity CAP, the extent of investigation in these patients being guided by severity.** [D]
- ▶ **For patients with low severity CAP the extent of microbiological investigations should be guided by clinical factors (age, comorbid illness, severity indicators), epidemiological factors and prior antibiotic therapy.** [A-]
- ▶ **Where there is clear microbiological evidence of a specific pathogen, empirical antibiotics should be changed to the appropriate pathogen-focused agent unless there are legitimate concerns about dual pathogen infection.** [D]

5.10 What microbiological investigations should be performed in patients with suspected CAP in the community?

Comments about the pros and cons of different microbiological investigations are given below in Section 5.11. Many of these investigations will not be appropriate for patients with CAP managed in the community. Such patients are not usually severely ill, are at low risk of death and delays in transport of specimens to the laboratory reduces the yield of bacterial pathogens (especially *S pneumoniae*) from sputum cultures. Results are often received too late by the general practitioner to be of much practical value in initial management.

Recommendations

- ▶ **For patients managed in the community, microbiological investigations are not recommended routinely.** [D]
- ▶ **Examination of sputum should be considered for patients who do not respond to empirical antibiotic therapy.** [D]
- ▶ **Examination of sputum for *Mycobacterium tuberculosis* should be considered for patients with a persistent productive cough, especially if malaise, weight loss or night sweats, or risk factors for tuberculosis (eg, ethnic origin, social deprivation, elderly) are present.** [D]

Table 4 Recommendations for the microbiological investigation of community acquired pneumonia (CAP)

Pneumonia severity (based on clinical judgement supported by severity scoring tool)	Treatment site	Preferred microbiological tests
Low severity (eg, CURB65 = 0–1 or CRB-65 score = 0, <3% mortality)	Home	None routinely. PCR, urine antigen or serological investigations* may be considered during outbreaks (eg, Legionnaires' disease) or epidemic mycoplasma years, or when there is a particular clinical or epidemiological reason.
Low severity (eg, CURB65 = 0–1, <3% mortality) but admission indicated for reasons other than pneumonia severity (eg, social reasons)	Hospital	None routinely PCR, urine antigen or serological investigations* may be considered during outbreaks (eg, Legionnaires' disease) or epidemic mycoplasma years, or when there is a particular clinical or epidemiological reason.
Moderate severity (eg, CURB65 = 2, 9% mortality)	Hospital	Blood cultures (minimum 20 ml) Sputum for routine culture and sensitivity tests for those who have <i>not</i> received prior antibiotics (\pm Gram stain*) Pneumococcal urine antigen test Pleural fluid, if present, for microscopy, culture and pneumococcal antigen detection PCR or serological investigations* may be considered during mycoplasma years and/or periods of increased respiratory virus activity. Where legionella is suspected [¶] , investigations for legionella pneumonia: (a) urine for legionella antigen (b) sputum or other respiratory sample for legionella culture and direct immunofluorescence (if available). If urine antigen positive, ensure respiratory samples for legionella culture
High severity (eg, CURB65 = 3–5, 15–40% mortality)	Hospital	Blood cultures (minimum 20 ml) Sputum or other respiratory sample [‡] for routine culture and sensitivity tests (\pm Gram stain [†]) Pleural fluid, if present, for microscopy, culture and pneumococcal antigen detection. Pneumococcal urine antigen test Investigations for legionella pneumonia: (a) Urine for legionella antigen (b) Sputum or other respiratory sample [‡] for legionella culture and direct immunofluorescence (if available) Investigations for atypical and viral pathogens:** (a) If available, sputum or other respiratory sample for PCR or direct immunofluorescence (or other antigen detection test) for <i>Mycoplasma pneumoniae</i> , <i>Chlamydia</i> spp, influenza A and B, parainfluenza 1–3, adenovirus, respiratory syncytial virus, <i>Pneumocystis jirovecii</i> (if at risk) (b) Consider initial and follow-up viral and "atypical pathogen" serology [§]

*If PCR for respiratory viruses and atypical pathogens is readily available or obtainable locally, then this would be preferred to serological investigations.

[†]The routine use of sputum Gram stain is discussed in the text.

[‡]Consider obtaining lower respiratory tract samples by more invasive techniques such as bronchoscopy (usually after intubation) or percutaneous fine needle aspiration for those who are skilled in this technique.

[§]The use of paired serology tests for patients with high severity CAP is discussed in the text. If performed, the date of onset of illness should be clearly indicated on the laboratory request form.

[¶]Patients with clinical or epidemiological risk factors (travel, occupation, comorbid disease). Investigations should be considered for all patients with CAP during legionella outbreaks.

**For patients unresponsive to β -lactam antibiotics or those with a strong suspicion of an "atypical" pathogen on clinical, radiographic or epidemiological grounds.

- ▶ **Urine antigen investigations, PCR of upper (eg, nose and throat swabs) or lower (eg, sputum) respiratory tract samples or serological investigations may be considered during outbreaks (eg, Legionnaires' disease) or epidemic mycoplasma years, or when there is a particular clinical or epidemiological reason. [D]**

5.11 What microbiological investigations should be performed in patients admitted to hospital with CAP?

The investigations that are recommended for patients admitted to hospital are summarised in table 4. More extensive microbiological investigations are recommended only for patients with moderate or high severity CAP, unless there are particular clinical or epidemiological features that warrant further microbiological studies. Comments and recommendations regarding specific investigations are given below.

5.11.1 Blood cultures

Microbial causes of CAP that can be associated with bacteraemia include *S pneumoniae*, *H influenzae*, *S aureus* and *K*

pneumoniae. Isolation of these bacteria from blood cultures in patients with CAP is highly specific in determining the microbial aetiology. Bacteraemia is also a marker of illness severity. However, many patients with CAP do not have an associated bacteraemia. Even in pneumococcal pneumonia the sensitivity of blood cultures is at most only 25%,^{94 202 [II] [III]} and is even lower for patients given antibiotic treatment before admission.^{129 [III]} Several predominantly retrospective North American studies and reviews^{203–206 [II] [III] [III] [III]} have questioned the utility of routine blood cultures in patients hospitalised with CAP on grounds of low sensitivity, cost and negligible impact on antimicrobial management. However, despite these limitations, most continue to recommend blood cultures in high severity CAP.

Recommendations

- ▶ **Blood cultures are recommended for all patients with moderate and high severity CAP, preferably before antibiotic therapy is commenced. [D]**

- ▶ **If a diagnosis of CAP has been definitely confirmed and a patient has low severity pneumonia with no comorbid disease, then blood cultures may be omitted.** [A–]

5.11.2 Sputum cultures

Sputum cultures may identify the causative agent in CAP including unexpected or antibiotic-resistant pathogens such as *S aureus* or antimicrobial-resistant pneumococci. Routine sputum cultures are, however, neither very sensitive nor specific²⁰⁷ [Ia] and often do not contribute to initial patient management.²⁰⁸ [II]

Problems include:

- ▶ The inability of patients to produce good specimens.
- ▶ Prior exposure to antibiotics.
- ▶ Delays in transport and processing.
- ▶ Difficulty in interpretation due to contamination of the sample by upper respiratory tract flora, which may include potential pathogens such as *S pneumoniae* and “coliforms” (especially in patients already given antibiotics).

Recommendations

- ▶ **Sputum samples should be sent for culture and sensitivity tests from patients with CAP of moderate severity who are able to expectorate purulent samples and have not received prior antibiotic therapy. Specimens should be transported rapidly to the laboratory.** [A–]
- ▶ **Culture of sputum or other lower respiratory tract samples should also be performed for all patients with high severity CAP or those who fail to improve.** [A–]
- ▶ **Sputum cultures for *Legionella* spp should always be attempted for patients who are legionella urine antigen positive in order to provide isolates for epidemiological typing and comparison with isolates from putative environmental sources.** [D]

5.11.3 Sputum Gram stain

The value of performing a Gram stain on expectorated sputum has been widely debated. A meta-analysis review concluded that the sensitivity and specificity of sputum Gram stain in patients with CAP varied substantially in different settings.²⁰⁹ [Ia] The presence of large numbers of Gram-positive diplococci in purulent samples from patients with CAP can indicate pneumococcal pneumonia.²¹⁰ [III] A study of 1669 consecutive adult patients with CAP found that good quality sputum samples with a predominant bacterial morphotype on Gram stain (ie, the test was useful) were obtained from only 14.4% of patients overall and, while Gram-positive diplococci as the predominant morphotype was highly specific for *S pneumoniae*, no severity subgroup of patients (assessed using the PSI) could be identified in whom the test would be of greater utility.²¹¹ [III] A similar study²¹² [III] of 347 patients with CAP concluded that Gram stain of sputum was useful in guiding microbiological diagnosis in just 23% of patients and unreliable in patients who had received antimicrobial treatment prior to sample collection. There are many factors which need to be borne in mind when considering the reliability and usefulness of Gram stain results. These are summarised below:

Advantages

- ▶ Quick and relatively inexpensive.
- ▶ Can assess quality of samples (cytological content) with rejection of poor quality samples.

- ▶ Can aid the interpretation of culture results and occasionally give an early indication of possible aetiology.

Disadvantages

- ▶ Strict criteria for interpretation require appropriate operator training.
- ▶ Validity of results is directly related to the experience of the interpreter.²¹³ [III]
- ▶ Sputum Gram stain correlates poorly with culture results in conditions other than CAP.²¹⁴ [III] This poses practical difficulties for laboratories that frequently have to interpret results with little or no clinical information.
- ▶ Lack of availability: a recent survey of diagnostic microbiology laboratories in England and Wales²¹⁵ [III] revealed that, of 138 respondents, 53 laboratories (38%) do not provide a sputum Gram stain service at all and, of the remainder, 52 laboratories (38%) do so only on special request. Thus, ready availability of sputum Gram stain cannot be assumed. This lack of availability reflects the opinion of many microbiologists that sputum examination is rarely helpful in the diagnosis of CAP.

Recommendations

- ▶ **Clinicians should establish with local laboratories the availability or otherwise of sputum Gram stain. Where this is available, laboratories should offer a reliable Gram stain for patients with high severity CAP or complications as occasionally this can give an immediate indicator of the likely pathogen. Routine performance or reporting of sputum Gram stain on all patients is unnecessary but can aid the laboratory interpretations of culture results.** [B–]
- ▶ **Samples from patients already in receipt of antimicrobials are rarely helpful in establishing a diagnosis.** [B–]
- ▶ **Laboratories performing sputum Gram stains should adhere to strict and locally agreed criteria for interpretation and reporting of results.** [B+]

5.11.4 Other tests for *Streptococcus pneumoniae*

Pneumococcal antigen detection

Pneumococcal antigens can be detected in various body fluids during active pneumococcal infection, including sputum, pleural fluid, serum and urine. Antigen detection is less affected by prior antibiotic therapy and the detection of antigenaemia has a correlation with clinical severity.²¹⁶ [IVb]

A commercial immunochromatographic strip test (BINAX NOW) for detection of pneumococcal antigen in urine has been introduced in the last few years and been widely taken up. Numerous studies^{217–222} [II] [III] [III] [III] [III] [III] have evaluated positively the clinical and diagnostic utility and generally good sensitivity and specificity of the pneumococcal urine antigen test in the diagnosis of pneumococcal pneumonia in adults. The studies have shown the usefulness of this assay in determining the aetiology of CAP, with significantly greater sensitivity rates than routine blood or sputum cultures. In addition, the test remains positive in 80–90% of patients for up to 7 days after starting antimicrobial treatment,²²³ [III] and may also be applied to other relevant sample types such as pleural fluid.²²⁴ [III]

Pneumococcal PCR

Many polymerase chain reaction (PCR)-based methods for detection of pneumococcal DNA in clinical samples have been published, varying in precise methodology and the specific

pneumococcal DNA target(s) sought. However, relatively few studies report comprehensive clinical—as opposed to analytical sensitivity—evaluations of pneumococcal PCRs in the diagnosis of CAP. One retrospective study^{225 [III]} compared three different PCR methodologies for use on EDTA blood samples from 175 bacteraemic patients collected at hospital admission (95 pneumococcal bacteraemia and 80 with bacteraemia due to other organisms). The best sensitivity obtained was 45% versus the gold standard of a positive blood culture for *S pneumoniae*. The specificity of all three methods was good at 97–100%. The authors concluded that blood PCR offers no advantage over conventional blood culture for pneumococcal diagnosis in bacteraemic patients and is unlikely to be sufficiently sensitive for diagnosis of non-bacteraemic pneumococcal pneumonia. Pneumococcal PCR has also been applied to sputum and other respiratory tract samples. However, obtaining a good quality sputum sample, as described above, remains problematic and, more importantly, PCR is not readily able to distinguish colonisation from infection of the respiratory tract.^{226 [III]} Pneumococcal PCR has little to offer for the diagnosis of CAP at this time, being insufficiently sensitive and specific for routine use.

Recommendations

- ▶ **Pneumococcal urine antigen tests should be performed for all patients with moderate or high severity CAP. [A–]**
- ▶ **A rapid testing and reporting service for pneumococcal urine antigen should be available to all hospitals admitting patients with CAP. [B+]**

5.11.5 Tests for Legionnaires' disease

Legionella pneumonia can be severe and carries a significant mortality. Prompt diagnosis is important both for patient management and for public health investigations. Risk factors for legionella infection include recent travel (within 10 days of onset), certain occupations, recent repair to domestic plumbing systems and immunosuppression.

Urine antigen detection

Detection of *L pneumophila* urinary antigen by enzyme immunoassay (EIA) is established as a highly specific (>95%) and sensitive (~80%) test^{227 [III]} for the detection of infections caused by *L pneumophila* serogroup 1, the commonest cause of sporadic and travel CAP cases in the UK. Rapid results can be obtained at an early stage of the illness, and this is a valuable method in the early diagnosis of legionella infection.^{92 [III]} It is now widely applied in high severity CAP. A recent survey of diagnostic microbiology laboratories in England and Wales^{215 [III]} revealed that, of 138 respondents, 136 laboratories (99%) offered this test for patients with CAP.

One study looked at the value of rapid legionella urine antigen testing in a large outbreak of Legionnaires' disease caused by *L pneumophila* serogroup 1 in Holland.^{228 [III]} This showed a higher test positivity rate for patients with severe legionella infection. The authors also demonstrated that the results of rapid testing could be used to start early legionella appropriate antibiotic management resulting in an improved outcome, as shown by reducing both mortality and the need for intensive care. In another prospective study of sporadic CAP in adults, the early detection of urine legionella antigen positively influenced the management of seven of nine patients in whom it was detected.^{37 [Ib]}

There are several commercial assays available, including a rapid immunochromatographic test. These assays principally detect infection with *L pneumophila* serogroup 1. They do not reliably detect antigen from other serogroups or legionella species which can cause infection in immunocompromised patients who may present with CAP, or recently hospitalised patients. This has particular significance in nosocomial infection. In one study of culture confirmed cases, while the sensitivity of commercially available urine antigen tests was 93.7% for travel-associated cases and 86.5% for community-acquired cases, it was only 45% for nosocomial cases.^{229 [III]}

Legionella direct immunofluorescence tests

L pneumophila can be detected by direct immunofluorescence (DIF) on invasive respiratory samples such as bronchial aspirates. *L pneumophila* specific reagents should be used, and not hyperimmune rabbit antisera which are poorly specific. The value of performing DIF on expectorated sputum samples is less well established. A considerable degree of laboratory expertise is required for processing and interpretation and, in view of the widespread availability of urine antigen tests for legionella diagnosis, the use of DIF has declined in recent years in the UK.

Culture

The culture of legionella from clinical samples (principally respiratory samples, including sputum) is very important and every effort should be made to diagnose by this method. Culture is 100% specific and is the only reliable method of detecting infection with non-pneumophila legionella species. Culture is also valuable for epidemiological investigations, allowing phenotypic and genotypic comparison of clinical and environmental legionella strains.

Problems with culture include: the inability of many patients with legionella pneumonia to produce sputum samples; prior antibiotic therapy; laboratory time and cost in processing samples; and lack of rapid results (legionella cultures need to be incubated for up to 10 days). Few laboratories will set up legionella cultures on respiratory samples unless specifically requested to do so. Culture should always be attempted from urine antigen positive patients and in suspected nosocomial legionella infection.

Serology

The diagnosis by determination of antibody levels was the mainstay of diagnosis of legionella pneumonia in the past. Serological assays previously employed in the UK were highly specific, although false positive results due to a serological cross-reaction may occur in patients with recent *Campylobacter* infection.^{230 [I]} Serological reagents for legionella diagnosis are no longer available from the Health Protection Agency. Their place has been filled by a number of commercially available serological assays of varying sensitivity and specificity. It is currently recommended that, where a diagnosis of legionella infection relies solely on the results of serological testing, the sample should be referred to a reference laboratory for confirmation.

PCR

Detection of legionella DNA by PCR from respiratory samples is still only available as a reference laboratory or research tool, although it is becoming more widely available.

Recommendations

- ▶ **Investigations for legionella pneumonia are recommended for all patients with high severity CAP, for other patients with specific risk factors and for all patients with CAP during outbreaks. [D]**
- ▶ **Legionella urine antigen tests should be performed for all patients with high severity CAP. [B+]**
- ▶ **A rapid testing and reporting service for legionella urine antigen should be available to all hospitals admitting patients with CAP. [B+]**
- ▶ **As the culture of legionella is very important for clinical reasons and source identification, specimens of respiratory secretions, including sputum, should be sent from patients with high severity CAP or where Legionnaires' disease is suspected on epidemiological or clinical grounds. [D] The clinician should specifically request legionella culture on laboratory request forms.**
- ▶ **Legionella cultures should be routinely performed on invasive respiratory samples (eg, obtained by bronchoscopy) from patients with CAP. [D]**
- ▶ **For all patients who are legionella urine antigen positive, clinicians should send respiratory specimens such as sputum and request legionella culture. [D] This is to aid outbreak and source investigation with the aim of preventing further cases.**

5.11.6 Tests for *Mycoplasma pneumoniae*

The mainstay of conventional diagnosis at the present time is by serology, although diagnosis by specific PCR is likely to become increasingly available. Culture of *M pneumoniae* is generally not available in diagnostic laboratories.

The commonest serological assay used historically was the complement fixation test (CFT), but there are various alternative assays such as microparticle agglutination and EIAs. The CFT is still regarded as the “gold standard” to which other assays have been compared, although it does lack sensitivity and specificity. A comparison of various mycoplasma antibody assays (including IgM and CFT tests) concluded that there is no single assay with significantly better sensitivity and specificity than the others.^{231 [III]} Elevated CFT titres are usually detected no earlier than 10–14 days after the onset of mycoplasma infection, but the insidious onset and slow progression of symptoms means that many patients admitted to hospital with mycoplasma CAP have elevated titres on or shortly after admission.

One study^{232 [III]} compared 12 commercially available serodiagnostic assays for *M pneumoniae* with the CFT using serum samples from patients with PCR-confirmed *M pneumoniae* infection and known onset dates. There were wide variations between the tests in sensitivity and specificity, CFT being the most specific (97%) although not especially sensitive (65%). The authors concluded that there are currently few commercial serological assays for the detection of *M pneumoniae* infections with appropriate performances in terms of sensitivity and specificity, and that PCR is likely to become increasingly important in specific diagnosis. In one series of patients with CAP,^{197 [II]} application of PCR to respiratory tract samples doubled the detection rate of *M pneumoniae* infection versus serological testing alone from 5 to 10 of the 105 patients studied. Another study^{233 [III]} described the application of real-time PCR to acute phase serum samples from patients with serologically (CFT) diagnosed mycoplasma pneumonia. Serum samples from 15 of 29 patients (52%) were *M pneumoniae* PCR

positive, suggesting that serum PCR as opposed to respiratory tract sample PCR—with inherent issues of specimen quality—is worthy of further consideration. PCR diagnosis is already available in some centres in the UK, will become increasingly available, and is likely to replace serodiagnosis in the longer term.

Recommendations

- ▶ **Where available, PCR of respiratory tract samples such as sputum should be the method of choice for the diagnosis of mycoplasma pneumonia. [D]**
- ▶ **In the absence of a sputum or lower respiratory tract sample, and where mycoplasma pneumonia is suspected on clinical and epidemiological grounds, a throat swab for *Mycoplasma pneumoniae* PCR is recommended. [D]**
- ▶ **Serology with the complement fixation test and a range of other assays is widely available, although considerable caution is required in interpretation of results. [C]**

5.11.7 Tests for *Chlamydomphila* species

Culture

It is not appropriate for routine diagnostic laboratories to attempt culture of *Chlamydomphila* from respiratory samples from patients with CAP as special laboratory precautions are required. (*C psittaci* is a “category 3 pathogen” indicating a high-risk pathogen that may put laboratory staff at risk of serious illness if infected occupationally.) *C pneumoniae* is very difficult to grow in the laboratory—culture is slow, time-consuming, expensive and insensitive.

Antigen detection

Chlamydomphila antigen can be detected in respiratory samples using DIF with species- and genus-specific monoclonal antibodies.^{234 [III]} Species-specific reagents are not available for *C psittaci*, which is antigenically highly diverse. DIF requires expertise in slide preparation and reading, and is not widely available in diagnostic laboratories. *C pneumoniae* can also be detected by DIF on throat swabs, with a comparable sensitivity to sputum.²³⁵ However, antigen may be detected for several months after “acute” infection, making interpretation difficult.

Chlamydomphila antigen can also be detected in respiratory samples by EIA with comparable sensitivity to PCR,²³⁶ but this approach requires further studies.

Serology

Various serological assays are used in the diagnosis of respiratory *Chlamydomphila* infections. The CFT is available in some diagnostic serology laboratories. Micro-immunofluorescence (MIF) and whole-cell immunofluorescence (WHIF) are specialised reference tests. Several EIAs have been described, and at least one is commercially available in the UK. Each of these assays has advantages and disadvantages, and there are particular problems in the serological diagnosis of *C pneumoniae* infections.

The CFT uses a genus-specific antigen and is relatively sensitive and specific for diagnosing psittacosis. However in adults, most infections with *C pneumoniae* are re-infections and these generate only a weak or absent CFT response.

The MIF and WHIF tests require considerable experience to read and interpret. They can detect a species-specific response, although this may be delayed for 4–6 weeks, especially with *C*

pneumoniae re-infections. They may also miss *C psittaci* infections, depending on the particular serovars included in the test, and there are conflicting reports regarding the accuracy of these tests in reliably distinguishing chlamydial species.^{237 [IVb]}

A commercial EIA has been used with success,^{238 [III]} but has not been shown to be significantly superior to CFT.

Molecular techniques

Amplification of *Chlamydomphila* DNA by PCR using genus- or species-specific primers has been reported from a variety of respiratory samples. These molecular techniques for diagnosis of respiratory *Chlamydomphila* infection are mostly confined to research/reference/specialist laboratories at the present time although, as with all molecular diagnostics, such tests are likely to become increasingly available, often in commercial kit formats.

Recommendations

- ▶ ***Chlamydomphila* antigen and/or PCR detection tests should be available for invasive respiratory samples from patients with high severity CAP or where there is a strong suspicion of psittacosis. [D]**
- ▶ **The complement fixation test remains the most suitable and practical serological assay for routine diagnosis of respiratory *Chlamydomphila* infections. [B–] There is no currently available serological test that can reliably detect acute infection due to *C pneumoniae*.**

5.11.8 PCR and serology for other respiratory pathogens

PCR tests for a range of respiratory viruses and some atypical pathogens are becoming increasingly available through virology departments across the UK. The ready availability and extent of these investigations varies between individual laboratories and departments, although they are expected to increase over the foreseeable future. Where available, PCR tests are an extremely useful addition to the diagnostic armamentarium and have the advantage of being rapid (relevant on occasions for both clinical and infection control purposes) and sensitive, and so are to be preferred over serological tests. Evidence of influenza and/or other respiratory virus infections as a cause of primary viral pneumonia or as a copathogen in bacterial CAP is best sought by PCR of nose and throat swabs submitted in virus transport medium.

At present there are no readily available alternatives to serology for some of the atypical pathogens and, according to clinical and epidemiological parameters, serological investigations may be appropriate.

Respiratory serology usually comprises antibody tests for the atypical pathogens (*M pneumoniae*, *Chlamydomphila* spp, *C burnetii*), influenza A virus, influenza B virus, adenovirus, respiratory syncytial virus and *L pneumophila*. Fewer laboratories rely on CFTs, which are time consuming and inconvenient to perform and have poor sensitivity and specificity.

There is little value in testing single serum samples taken within 7 days of the onset of CAP. Such samples can be stored until the follow-up (convalescent) sample is taken (7–10 days later) and the paired samples tested in parallel.

However, raised antibody titres—particularly to *L pneumophila* or *M pneumoniae*—may be found in some patients on or soon after hospital admission, particularly if the onset of symptoms is more than 7 days prior to admission. It is thus important that the date of onset of symptoms is clearly

indicated on all serological request forms so that serum samples taken more than 1 week into the illness can be tested immediately.

A suggested algorithm for performing serological investigations is shown in fig 6.

Recommendations

- ▶ **Where PCR for respiratory viruses and atypical pathogens is readily available or obtainable locally, this is preferred to serological investigations. [D]**
- ▶ **Where available, paired serology tests can be considered for patients with high severity CAP where no particular microbiological diagnosis has been made by other means (eg, culture, urine antigen, PCR) and who fail to improve, and/or where there are particular epidemiological risk factors. [D] The date of onset of symptoms should be clearly indicated on all serological request forms. [D]**
- ▶ **Serological tests may be extended to all patients admitted to hospital with CAP during outbreaks and when needed for the purposes of surveillance. The criteria for performing serology tests in these circumstances should be agreed locally between clinicians, laboratories and public health. [D]**

SECTION 6 SEVERITY ASSESSMENT

6.1 Why is severity assessment important?

CAP presents to physicians both in primary and secondary care as a wide spectrum of illness from mild and self-limiting to life-threatening and occasionally fatal disease. This breadth of illness severity is reflected in the variable mortality rates reported by studies of CAP in different clinical settings.

The decision regarding the most appropriate site of care, including whether hospitalisation of a patient with CAP is warranted, is the first and single most important decision in the overall management of CAP. It has consequences both on the level of treatment received by the patient as well as the overall costs of treatment.^{30 [III]} This decision is best informed by an accurate assessment of the severity of illness at presentation and the likely prognosis. The recognition of patients at low risk of complications—and therefore suitable for treatment out of hospital—has the potential to reduce inappropriate hospitalisation and consequently inherent morbidity and costs.

When hospital admission is required, further management is also influenced by illness severity. This includes the extent of microbiological investigation, the choice of initial empirical antimicrobial agents, route of administration, duration of treatment and level of nursing and medical care. Early identification of patients at high risk of death allows initiation of appropriate antibiotic therapy and admission to an intensive care setting where assisted ventilation can be readily initiated if necessary.

6.2 What clinical factors and investigations are associated with a poor prognosis on univariate and multivariate analysis?

A large number of studies conducted in hospital and intensive care settings have employed univariate analysis to identify risk factors associated with a poor prognosis. In-hospital mortality has been the most common outcome measure. Some studies have used admission to the ICU as the main outcome measure.^{239 [Ib]} However, differences in ICU admission criteria make it difficult to compare results from these studies. This is




Figure 6 Suggested algorithm for serological testing for patients with high severity community acquired pneumonia (CAP).

reflected in the widely varying rates of admission of patients with CAP to ICU reported, ranging from 1–3% in New Zealand to 5% in the UK, 12–18% in the USA and 35% in Germany.^{5 6 239–242 [Ib] [Ib] [III] [II] [Ib] [III]} In this document we have concentrated only on studies that have used mortality as the main outcome measure.

Univariate studies have suggested that over 40 different parameters are associated with mortality. An independent association of only a few of these risk factors with mortality has been consistently demonstrated by studies employing multivariate analysis. In particular, the following features are associated with an increased risk of mortality: increasing age;^{5 6 129 243–247 [Ib] [Ib] [Ib] [Ia] [Ib] [Ib] [III] [II] [Ib]} the presence of co-existing illnesses;^{5 243–245 247–251 [Ib] [III] [Ib] [Ib] [Ib] [III] [II] [III] [III]} raised respiratory rate;^{5 6 129 241–243 251–254 [Ib] [Ib] [Ib] [Ib] [III] [Ia] [Ib] [Ib] [II] [III]} mental confusion;^{6 129 244 246 253 255 [Ib] [Ib] [III] [III] [II] [Ib]} low blood pressure;^{6 69 127 129 241 243 246 249 251 253 256 257 [Ib] [II] [III] [Ib] [Ib] [Ia] [III] [II]} hypoxaemia;^{33 241 [II] [Ib]} respiratory failure;^{5 33 44 258 [Ib]} high or low white cell count;^{6 243 [Ib]} bilateral or progressive chest radiograph changes;^{5 33 129 187 243 253 256 258 259 [Ib] [II]} and a positive blood culture.^{5 33 36 44 243 250 258 260 [Ib] [II] [II] [Ia] [III] [Ib] [III]}

The lack of pyrexia, which is easily overlooked in clinical practice, has been identified as an important poor prognostic factor in some studies of elderly patients.^{69 129 253 [II] [Ib] [II]} Being previously bed-ridden and having been admitted from a nursing home are other poor prognostic factors that may be inter-related.^{5 129 153 247 [Ib] [Ib] [II] [Ib]}

6.2.1 Biomarkers and inflammatory markers

A number of biomarker tests have been demonstrated on univariate and multivariate analyses to be independent prognostic factors for either 30-day or in-hospital mortality. These include procalcitonin,^{261–265 [II] [III] [Ib] [Ib] [II]} triggering receptor expressed on myeloid cells-1 (TREM-1),^{266 [Ib]} CD14,^{267 [Ib]} pro-adrenomedullin,^{268 [Ib]} CRP,^{257 269 [Ib] [II]} pro-atrial natriuretic peptide,^{270 271 [Ib] [III]} and pro-vasopressin.^{270 [Ib]} Further validation studies are required in most instances. Furthermore, determination of the majority of these biomarkers is not widely or routinely available at present.

Of the commonly available tests, one study has reported an association of a low CRP level of <100 mg/l at the time of hospital admission with reduced risk for 30-day mortality, need for mechanical ventilation and/or inotropic support, and complicated pneumonia.^{257 [Ib]} This observation warrants further evaluation as a number of other studies have not found an association of admission CRP level with prognosis.^{261 264 265 272 [II] [Ib] [II] [Ib]}

The level of D-dimers on admission has also been reported to be an independent prognostic marker.^{273 274 [Ib] [II]} However, the clinical value of D-dimers over and above a clinical predictive model has not been established. Moreover, since D-dimers are mainly used in the diagnostic investigation of patients with suspected venous thromboembolism, introducing D-dimers solely as a prognostic marker in CAP will potentially lead to increased diagnostic uncertainty or confusion which, in turn, may result in delayed diagnosis or inappropriate management.

6.3 What predictive models for assessing severity on or shortly after hospital admission have been tested?

Clinical assessment of disease severity is dependent on the experience of the attending clinician, but such clinical judgement has been shown to result in apparent underestimation of severity.^{241 [Ib]} No single prognostic factor of mortality is adequately specific and sensitive, so various severity scoring systems and predictive models have been developed in an attempt to help the clinician identify patients with pneumonia and a poor prognosis at an early stage.

However, predictive models have recognised limitations. First, no predictive model enables the unequivocal categorisation of patients into definite risk groups, and it is unrealistic to expect this.^{275 276 [IVb] [IVb]} A predictive model is therefore not a substitute for clinical judgement, but should be considered as an adjunct to clinical judgement. Second, the value of severity-based practice guidelines in improving clinical outcomes has not yet been fully established.^{103 277 278 [III] [II] [II]} Data demonstrating that severity-based practice guidelines are useful in increasing the proportion of patients managed as ambulatory outpatients without increasing morbidity or mortality have come from a cluster randomised trial, two large prospective observational studies and before-after implementation studies.^{279–282 [II] [Ib] [II] [III]} Whether these benefits were mainly due to the use of a predictive model and therefore better stratification of patients to different management strategies, or simply due to better implementation of practice guidelines for the management of

absence of coexisting disease and a CRB65 or CURB65 score of 0 identifies patients with a very good prognosis who should be suitable for home treatment. In comparison, young patients with a respiratory rate of >40/min may warrant hospital supervised management despite a CRB65 or CURB65 score of 1. Clinical judgement is especially important in patients at high risk of death (CURB65 scores 3, 4 and 5) in whom decisions regarding intravenous administration of antibiotics or transfer to critical care facilities need to be made.

- ▶ Stability of comorbid illnesses. The CURB65 score is primarily a CAP severity assessment tool. Pneumonia may result in a worsening of comorbid illness that warrants hospital or critical care management irrespective of severity of pneumonia.
- ▶ Social circumstances. The morbidity associated with CAP negatively influences the functional status of patients and therefore the extent that patients may be able to manage at home within a given set of social circumstances. Patient choice should also be considered when determining social circumstances and the feasibility of further management at home.

Recommendations

- ▶ **Clinical judgement is essential in disease severity assessment. [D]**
- ▶ **The stability of any comorbid illness and a patient's social circumstances should be considered when assessing disease severity. [D]**

6.5 Severity assessment of CAP in patients seen in the community

The severity assessment of CAP in patients seen in the community is shown in fig 7.

Recommendations

- ▶ **For all patients, clinical judgement supported by the CRB65 score should be applied when deciding whether to treat at home or refer to hospital. [D]**
- ▶ **Patients who have a CRB65 score of 0 are at low risk of death and do not normally require hospitalisation for clinical reasons. [B+]**
- ▶ **Patients who have a CRB65 score of 1 or 2 are at increased risk of death, particularly with a score of 2,**

Box 2 Abbreviated Mental Test

The Abbreviated Mental Test (each question scores 1 mark, total 10 marks)

- ▶ Age
- ▶ Date of birth
- ▶ Time (to nearest hour)
- ▶ Year
- ▶ Hospital name
- ▶ Recognition of two persons (eg, doctor, nurse)
- ▶ Recall address (eg, 42 West Street)
- ▶ Date of First World War
- ▶ Name of monarchs
- ▶ Count backwards 20 → 1

A score of 8 or less has been used to define mental confusion in the CURB65 severity score.

and hospital referral and assessment should be considered. [B+]

- ▶ **Patients who have a CRB65 score of 3 or more are at high risk of death and require urgent hospital admission. [B+]**
- ▶ **When deciding on home treatment, the patient's social circumstances and wishes must be taken into account in all instances. [D]**

6.6 Severity assessment of CAP in patients seen in hospital

The severity assessment of CAP in patients seen in hospital is shown in fig 8.

Recommendations

- ▶ **For all patients, the CURB65 score should be interpreted in conjunction with clinical judgement. [D]**
- ▶ **Patients who have a CURB65 score of 3 or more are at high risk of death. These patients should be reviewed by a senior physician at the earliest opportunity to refine disease severity assessment and should usually be managed as having high severity pneumonia. Patients with CURB65 scores of 4 and 5 should be assessed with specific consideration to the need for transfer to a critical care unit (high dependency unit or intensive care unit). [B+]**
- ▶ **Patients who have a CURB65 score of 2 are at moderate risk of death. They should be considered for short-stay inpatient treatment or hospital-supervised outpatient treatment. [B+]**
- ▶ **Patients who have a CURB65 score of 0 or 1 are at low risk of death. These patients may be suitable for treatment at home. [B+]**
- ▶ **When deciding on home treatment, the patient's social circumstances and wishes must be taken into account in all instances. [D]**

6.7 Reviewing severity status after initial assessment in hospital

Summary

- ▶ Regular and structured clinical review and reassessment of disease severity facilitates the stepping down and stepping up of antibiotic management. [Ib]

Recommendations

- ▶ **Regular assessment of disease severity is recommended for all patients following hospital admission. The "post take" round by a senior doctor and the medical team provides one early opportunity for this review. [D]**
- ▶ **All patients deemed at high risk of death on admission to hospital should be reviewed *medically* at least 12-hourly until shown to be improving. [D]**

SECTION 7 GENERAL MANAGEMENT IN THE COMMUNITY AND IN HOSPITAL

7.1 What general management strategy should be offered to patients treated in the community?

Patients with CAP may present with fever, cough, sputum production or pleuritic pain and usually have localised signs on chest examination. They should be advised to rest and avoid smoking³⁰⁵ [Iib] and, especially when febrile, be encouraged to drink plenty of fluids. It is important to relieve pleuritic pain using simple analgesia such as paracetamol or non-steroidal




Figure 7 Severity assessment of community acquired pneumonia (CAP) in patients seen in the community (CRB65 severity score plus clinical judgement). DBP, diastolic blood pressure; SBP, systolic blood pressure.

anti-inflammatory drugs. Physiotherapy is of no proven benefit in acute pneumonia.³⁰⁶ [III] Nutritional status appears important both to the outcome and the risk of acquiring pneumonia and, in prolonged illness, nutritional supplements may be helpful. Patients with pneumonia are often catabolic and those aged >55 years who are malnourished appear to be at greater risk of developing pneumonia.^{150 307} [III] [III]

Patients with pneumonia often become hypoxic because pulmonary blood flow takes place through unventilated lung tissue. The clinical signs of hypoxia are non-specific and often difficult to recognise in the early stages. They include altered mental state, dyspnoea and tachypnoea. Respiratory rate should therefore always be assessed. Central cyanosis is unreliable both as a clinical sign and also as an indicator of tissue hypoxia. In contrast, pulse oximetry which measures arterial oxygen saturation (SpO_2) is, in most situations, a simple and reliable method of assessing oxygenation. However, poor peripheral perfusion, jaundice and pigmented skin can produce a falsely low saturation and carboxyhaemoglobin a falsely high saturation. Pulse oximetry is now widely available in North America. A survey of 944 outpatients and 1332 inpatients with evidence of CAP enrolled from five sites in the USA and Canada reported increasing assessment of arterial oxygen saturation with pulse oximetry in up to 58% of outpatients and 85% of inpatients.³⁰⁸

[II] It is recommended that pulse oximetry, with appropriate training, should become more widely available in general

practice for use in the assessment of patients who may have pneumonia and other acute respiratory illnesses. Oxygen saturation below 94% in a patient with CAP is an adverse prognostic feature and also an indication for oxygen therapy,³⁰⁹ [IVb] which will usually require urgent referral to hospital.

Patients who fall outside the low severity criteria for CAP should be assessed for the need for hospital referral (see Section 6). Social factors will also play an important part in the decision to refer a patient to hospital. Patients with moderate or high severity pneumonia should be admitted to hospital and managed, where possible, with input from a physician with an interest in respiratory medicine.

Recommendations

- ▶ Patients with suspected CAP should be advised to rest, to drink plenty of fluids and not to smoke. [D]
- ▶ Pleuritic pain should be relieved using simple analgesia such as paracetamol. [D]
- ▶ The need for hospital referral should be assessed using the criteria recommended in section 6. [C]
- ▶ Pulse oximetry, with appropriate training, should be available to general practitioners and others responsible for the assessment of patients in the out-of-hours setting for the assessment of severity and oxygen requirement in patients with CAP and other acute respiratory illnesses. [D]

7.2 What review policy should be adopted in patients managed in the community?

When to review a patient with CAP in the community will be determined by the initial severity assessment and other factors such as reliable help in the home. Patients assessed as being at low severity should improve on appropriate therapy within 48 h, at which time severity reassessment is recommended. Those who fail to improve within 48 h should be considered for hospital admission. Patients who do not fulfil the criteria for low severity and are being managed at home will require more frequent review.

Recommendations

- ▶ Review of patients in the community with CAP is recommended after 48 h or earlier if clinically indicated. Disease severity assessment should form part of the clinical review. [D]
- ▶ Those who fail to improve after 48 h of treatment should be considered for hospital admission or chest radiography. [D]


7.3 What general management strategy should be offered to patients in hospital?

Initial management

There is some evidence that use of a critical care pathway for patients referred to hospital can reduce the hospital admission of low-risk patients and can also rationalise inpatient management.⁵¹⁰ [Ib]

All patients referred to hospital with CAP should have a chest radiograph (if not already performed in the community) and should have oxygenation assessed by pulse oximetry, preferably while breathing air. Those with $SpO_2 < 94\%$ should have arterial blood gas measurements, as should all patients with features of high severity pneumonia. Knowledge of the inspired oxygen concentration is essential to the interpretation of blood gas

Figure 8 Hospital management of community acquired pneumonia (CAP) in the first 4 h. CXR, chest x ray; DBP, diastolic blood pressure; SBP, systolic blood pressure.



Aim by 4 hours: diagnosis made and management including antibiotics started

measurements and should be clearly recorded with the blood gas result.

Continuous oxygen therapy is usually indicated for those patients with arterial oxygen tension (PaO_2) < 8 kPa.¹⁸³ The aim of oxygen therapy should be to maintain PaO_2 ≥ 8 kPa or SpO_2 94–98% in patients who are *not* at risk of hypercapnic respiratory failure. In nearly all cases of CAP, unless complicated by severe COPD with ventilatory failure, high concentrations of oxygen of 35% or more are indicated and can be safely used.

High concentration oxygen therapy given to patients at risk of hypercapnic respiratory failure, such as patients with moderate or severe COPD, can reduce hypoxic drive and increase ventilation-perfusion mismatching. In such patients, initial treatment should be with low oxygen concentrations (24–28%), guided by arterial blood gas measurements, with the aim of keeping oxygen saturation at 88–92% without causing a fall in arterial pH ($\text{pH} < 7.35$ or $[\text{H}^+] > 45$ nmol/l).¹⁸³ In selected cases, non-invasive ventilation or respiratory stimulants may be of value and transfer to a high dependency unit or ICU area should be considered. If the patient is hypercapnic (PaCO_2

> 6 kPa or 45 mm Hg) and acidotic ($\text{pH} < 7.35$ or $[\text{H}^+] > 45$ nmol/l), ventilatory support should be considered, especially if acidosis has persisted for more than 30 min despite appropriate therapy.

Patients admitted with pneumonia should be assessed for volume depletion and may require intravenous fluids.

The use of unfractionated or low molecular weight heparins for the prevention of venous thromboembolism in patients with respiratory tract infections has been demonstrated in clinical trials.^{311–315 [1a]}

A randomised study ($n = 458$) found early mobilisation (sitting out of bed for at least 20 min within the first 24 h of hospital admission with increasing mobility on subsequent days) decreased length of stay by 1.1 days.^{314 [1b]} Further studies are needed.

Routine airway clearance has not been shown to improve outcome.^{315 [1b]}

While chest physiotherapy is of no proven value in acute pneumonia,^{315 [111]} a single randomised trial using positive expiratory pressure has suggested that “bottle-blowing” into

an underwater seal bottle on 10 occasions daily can shorten hospital stay.³¹⁶ [III]

In cases of severe pneumonia requiring prolonged hospital admission, increased nutritional support (whether enteral, parenteral or via nasogastric feeding) should be arranged.

Recommendations

- ▶ **All patients should receive appropriate oxygen therapy with monitoring of oxygen saturations and inspired oxygen concentration with the aim to maintain PaO₂ at ≥8 kPa and SpO₂ 94–98%. High concentrations of oxygen can safely be given in patients who are not at risk of hypercapnic respiratory failure. [D]**
- ▶ **Oxygen therapy in patients at risk of hypercapnic respiratory failure complicated by ventilatory failure should be guided by repeated arterial blood gas measurements. [C]**
- ▶ **Patients should be assessed for volume depletion and may require intravenous fluids. [C]**
- ▶ **Prophylaxis of venous thromboembolism with low molecular weight heparins should be considered for all patients who are not fully mobile. [A+]**
- ▶ **Nutritional support should be given in prolonged illness. [C]**
- ▶ **Medical condition permitting, patients admitted to hospital with uncomplicated CAP should sit out of bed for at least 20 min within the first 24 h and increase mobility each subsequent day of hospitalisation. [A–]**
- ▶ **Patients admitted with uncomplicated pneumonia should not be treated with traditional airway clearance techniques routinely. [B+]**
- ▶ **Patients should be offered advice regarding expectoration if there is sputum present. [D]**
- ▶ **Airway clearance techniques should be considered if the patient has sputum and difficulty with expectoration or in the event of a pre-existing lung condition. [D]**

Monitoring in hospital

Pulse, blood pressure, respiratory rate, temperature, oxygen saturation (with a recording of the inspired oxygen concentration at the same time) and mental status should be measured initially at least twice daily. Those with high severity pneumonia, requiring continuous oxygen or cardiovascular support, should be monitored more frequently. Vital signs may be captured by an early warning score and can be used to trigger escalation or de-escalation of management.³¹⁷

The acute phase reactant CRP is a sensitive marker of progress in pneumonia.^{187 189} [III] [III] Prospective studies have shown that repeat measurement of CRP at day 3 or 4 is helpful in identifying patients with treatment failure.^{257 318} [Ib] A failure of CRP to fall by 50% is associated with increased 30-day mortality, increased need for mechanical ventilation and/or inotropic support and increased incidence of complicated pneumonia such as empyema (see Section 6.2.1 and Section 9).²⁵⁷ [Ib]

Failure to improve over 4 days is an indication to repeat the chest radiograph.

In discharge planning, a US prospective multicentre observational cohort study of 680 patients admitted to hospital with CAP reported that almost 20% left hospital with one or more unstable factors in the 24 h prior to discharge. These included

temperature >37.8°C, heart rate >100/min, respiratory rate >24/min, systolic blood pressure <90 mm Hg, oxygen saturation <90%, inability to take oral medication or abnormal mental status. Forty-six per cent of those discharged home with two of these unstable factors died or were readmitted within 30 days. In contrast, only 11% of those with no unstable factors died or were readmitted within 30 days.³¹⁹ [III] A similar prospective cohort study in 373 patients found that 22% of patients were discharged with one or more unstable factors, which led to increased mortality (14.6% vs 2.1%) and increased readmission within 60 days.³²⁰ [III]

Recommendations

- ▶ **Temperature, respiratory rate, pulse, blood pressure, mental status, oxygen saturation and inspired oxygen concentration should be monitored and recorded initially at least twice daily and more frequently in those with severe pneumonia or requiring regular oxygen therapy. [C]**
- ▶ **C-reactive protein should be remeasured and a chest radiograph repeated in patients who are not progressing satisfactorily after 3 days of treatment. [B+]**
- ▶ **Patients should be reviewed within 24 h of planned discharge home, and those suitable for discharge should not have more than one of the following characteristics present (unless they represent the usual baseline status for that patient): temperature >37.8°C, heart rate >100/min, respiratory rate >24/min, systolic blood pressure <90 mm Hg, oxygen saturation <90%, inability to maintain oral intake and abnormal mental status. [B+]**

7.4 What advice should be given regarding the critical care management of CAP?

Severity assessment is an important part of hospital management as it can identify those patients at increased risk of death. Patients who fulfil the severity criteria for high severity CAP on admission and who do not respond rapidly should be considered for transfer to a high dependency unit or a critical care unit (see Section 6). Persisting hypoxia with PaO₂ <8 kPa despite maximal oxygen administration, progressive hypercapnia, severe acidosis (pH <7.26), shock, or depressed consciousness are also indications for transfer to critical care for assisted ventilation and cardiovascular support.³²¹ [IVb]

Observational studies indicate that non-invasive ventilation (NIV) is being used to treat respiratory failure in CAP in many critical care units.³²² [III] However, a systematic review in 2003 concluded that there was no clear benefit of NIV in acute respiratory failure in a non-COPD population.³²³ [Ia] A further systematic review published in 2004 drew broadly similar conclusions. This review included all randomised studies of patients with acute hypoxaemic respiratory failure given NIV. This was a very heterogeneous group and included immunosuppressed patients, those following lung resection and cases of post-extubation failure. Pooled data suggested a reduced need for intubation with NIV but no effect on mortality once studies including patients with COPD or pulmonary oedema were excluded.³²⁴ [Ia] The number of patients with CAP included in these studies has been very limited; only one study exclusively focused on CAP and even this trial only recruited 33 patients without COPD.³²⁵ [III]

Continuous positive airways pressure (CPAP) is also used in some cases of pneumonia. However, a randomised controlled trial (RCT) of 123 patients with acute lung injury (61 with

pneumonia) published in 2000 found no reduction in intubation or improved outcome with CPAP.³²⁶ [II] In addition, CPAP appeared to delay intubation in some patients with adverse consequences. In the non-COPD population with CAP, non-invasive modes of respiratory support are unlikely to be successful. This is particularly the case in patients developing other organ failure.

Despite the apparent benefit of activated protein C (APC) in patients with severe sepsis shown in the PROWESS study,³²⁷ [Ia] there is still substantial controversy about clinical efficacy. The importance of this issue to CAP is highlighted in a retrospective subgroup analysis of outcome in the subgroup of patients with CAP in the PROWESS study.³²⁸ [III] More than one-third of patients recruited were diagnosed as having severe CAP, although this did not correspond precisely with the Centre for Disease Control definition. Twenty-eight day mortality was reduced in the treatment group (odds ratio (OR) 0.81, 95% CI 0.67 to 0.93). By day 90, the OR crossed the no-effect line. However, the groups were not well matched for important covariables and the improved outcome was only found after statistical adjustment. There was also some evidence that outcome in the less severe CAP group treated with APC was worse. A recent systematic review of APC in sepsis concluded that there was no definite evidence for efficacy of APC in sepsis, but the risk of bleeding was increased.³²⁹ [Ia] In view of the uncertainty, a further multicentre RCT of APC in severe sepsis is being conducted. APC continues to have a European product licence for the treatment of severe sepsis, including that caused by CAP. No definite treatment recommendation can be given until the results of the new RCT become available.

One RCT and a systematic review on steroids in severe CAP have been published since the last guidelines update. The single RCT enrolled 47 patients to placebo versus 7-day hydrocortisone infusion.³³⁰ [III] The trial was stopped early because of reported efficacy of the steroid treatment. However, the primary end point was gas exchange and mortality was very low in both groups. In addition, patients were not well matched (controls were sicker and the steroid group received more NIV). The systematic review identified three RCTs of steroids in CAP.³³¹ [Ia] All were small underpowered studies (including the above), which were not optimally conducted. The review concluded that there was no evidence for the use of steroids in severe CAP. In addition, a recent multicentre RCT of patients with severe sepsis found no survival benefit with hydrocortisone treatment.³³² [Ib] This was a heterogeneous group, but a significant number had respiratory infections. There is therefore no high-grade evidence for the efficacy of steroids in severe CAP.

Granulocyte colony stimulating factor (G-CSF) has been the subject of a number of clinical trials in severe infection. A recent Cochrane review of 2018 patients with pneumonia revealed that G-CSF, as an adjunct to antibiotics, did not improve 28-day mortality.³³³ [Ia]

Bronchoscopy after intubation may be valuable to remove retained secretions, to obtain further samples for culture and to exclude endobronchial abnormality such as carcinoma. Hospital-acquired ventilator-associated pneumonia can occur in approximately 14% of patients mechanically ventilated for severe CAP and causes increased mortality.³³⁴ [III] Other aspects of ICU management are outside the scope of these guidelines.

Recommendations

- ▶ **Patients with CAP admitted to ICUs should be managed by specialists with appropriate training in**

intensive care working in close collaboration with specialists in respiratory medicine. [D]

- ▶ **Neither non-invasive ventilation (NIV) nor continuous positive airways pressure (CPAP) support is routinely indicated in the management of patients with respiratory failure due to CAP. [A-]**
- ▶ **If a trial of non-invasive support is considered indicated in CAP, it must only be conducted in a critical care area where immediate expertise is available to enable a rapid transition to invasive ventilation. [D]**
- ▶ **Steroids are not recommended in the routine treatment of high severity CAP. [A+]**
- ▶ **Granulocyte colony stimulating factor is not routinely recommended as an adjunct to antibiotics. [A+]**

7.5 What arrangements should be made for follow-up after hospital discharge and by whom?

It is usual practice to arrange "routine" hospital clinic follow-up and repeat the chest radiograph at around 6 weeks after discharge. However, there is no evidence on which to base a recommendation regarding the value of this practice in patients who have otherwise recovered satisfactorily. It is also not known whether there is any value in arranging clinical follow-up in a hospital clinic rather than with the patient's general practitioner. The main concern is whether the CAP was a complication of an underlying condition such as lung cancer (see Section 5.6).

At discharge or at follow-up, patients should be offered access to information about CAP. In one study of 200 patients who had recently recovered from CAP, a patient information leaflet was judged to be very helpful by the majority of patients.³³⁵ [III] A patient information leaflet on CAP is available on request from British Lung Foundation Headquarters (British Lung Foundation, Freeport SW1233, London EC1B 1BR) and British Lung Foundation UK regional offices.

Recommendations

- ▶ **Clinical review should be arranged for all patients at around 6 weeks, either with their general practitioner or in a hospital clinic. [D]**
- ▶ **At discharge or at follow-up, patients should be offered access to information about CAP such as a patient information leaflet. [D]**
- ▶ **It is the responsibility of the hospital team to arrange the follow-up plan with the patient and the general practitioner. [D]**

Recommendations regarding whether or not to repeat the chest radiograph or perform further investigations at follow-up are given in Section 5.6.

SECTION 8 ANTIBIOTIC MANAGEMENT

8.1 Introduction

Antimicrobial chemotherapy is essential to the management of CAP. While mild pneumonia may be self-limiting, the timely use of appropriate antibiotics abbreviates illness, reduces the risk of complications and lowers mortality.

Few pneumonias are defined microbiologically at initial assessment and hence most prescribing is empirical, especially when managed in the community. Among hospitalised patients the aetiology may be determined, thereby permitting modification of the initial empirical regimen. However, in practice this applies to the minority of infections.¹⁹⁴ [III] Clinical, epidemiological

and radiographic information is rarely predictive of the microbial aetiology. An important principle is that pathogens responsible for CAP are diverse and vary in their ability to cause severe disease.^{243 [1b]} The highest mortality rates are associated with pneumococcal infection and with Legionnaires' disease.

Severity assessment and the association of pre-existing comorbid disease is essential in predicting prognosis and, in turn, determines management, choice of antibiotic therapy and its method of administration (see Section 6).

8.2 Antibiotic stewardship and the individual clinician's responsibility to prevent the overuse of antibiotics when managing CAP

The choice of antibiotic regimen has consequences beyond the management of the individual patient. The inappropriate application of CAP guidelines to community acquired lower respiratory tract infections other than pneumonia and hospital acquired pneumonia leads, in turn, to inappropriate and potentially excessive antibiotic use. Too loose an interpretation of "severe pneumonia" also contributes to the overprescribing of macrolides and β -lactams, especially when administered parenterally, in the management of hospitalised patients with CAP.

Overuse of antibiotics in CAP increases the cost of management and, particularly in relation to quinolones and cephalosporins, serves as a driver for health care-associated infections, including MRSA and *C difficile* infection.^{18 336-342 [1b] [II] [IVa] [II] [II] [1b] [1a] [1b]} The avoidance of inappropriate or excessive use of antibiotics is specifically discussed in Section 8.18. Proper patient selection for treatment and the correct use of antimicrobial agents are emphasised in this document.

In particular, these guidelines stress that the use of empirical broad-spectrum antibiotics is *initially* recommended only in patients with high severity CAP. This group of patients comprise approximately one-third of all patients admitted to hospital with confirmed CAP. Regular review and the prompt "de-escalation" to narrow-spectrum antibiotics based on early microbiological investigations are also emphasised.

8.3 Antibiotic resistance of respiratory pathogens

The rate of increase in resistance among respiratory pathogens has tended to level off in recent years.

Antibiotic resistance among *S pneumoniae* is the main concern owing to the dominance of this organism as a cause of CAP and because penicillin and macrolide resistance are frequently linked.^{343 344 [II] [II]} Resistance among pneumococci is the result of alterations in one or more of the penicillin-binding proteins, thus reducing their affinity for penicillin. This in turn leads to a requirement for higher drug concentrations to bring about death of the organism. Of the >90 known pneumococcal serotypes, a small number have been responsible for penicillin resistance worldwide, among which selected clones (eg, 23F, 9V and 6B) have become widely disseminated. However, despite these concerns, the clinical importance of in vitro penicillin resistance among *S pneumoniae* remains uncertain when treating pneumococcal pneumonia.^{345-350 [II] [II] [IVb] [IVa] [II] [II]} This is reflected in the continued ability of current doses of penicillins to inhibit strains of intermediate susceptibility (minimum inhibitory concentration (MIC) of penicillin 0.1–1.0 mg/l), as well as many strains exhibiting higher level resistance (as defined by an MIC >1 mg/l). The British Society of Antimicrobial Chemotherapy (BSAC) surveillance project has reported on pneumococcal susceptibility to various antimicrobials from both blood and respiratory tract

samples in the UK and Ireland 1999/2000 to 2006/7. They report no convincing evidence of an increase in non-susceptibility over time, 94% of bacteraemia isolates and 92% of respiratory isolate being fully susceptible to penicillin and 85% and 88% of blood and respiratory isolates, respectively, susceptible to erythromycin and, by implication, other macrolides.^{351 [II]} With regard to erythromycin, resistance is the result of genetic mutations that either affect the target site (*erm* gene mutations) or result in elimination of the drug by an efflux pump (*mef* gene mutation). The distribution of such strains differs internationally and probably explains variation in the clinical impact of such resistance, since *erm* gene mutations are linked to high level resistance. Tetracyclines are not widely used in the treatment of CAP and resistance among *S pneumoniae* is relatively low. Likewise, reduced susceptibility of *S pneumoniae* to fluoroquinolones is beginning to be reported, but generally remains low in the UK.^{352 [II]} Recent trends in penicillin, erythromycin and tetracycline resistance of around 4000–5000 *S pneumoniae* isolated from blood and cerebrospinal fluid cultures each year in England and Wales and reported routinely to the Health Protection Agency (HPA) are shown in fig 9 (HPA unpublished data).

Beta-lactamase production among *H influenzae* varies geographically but ranges from 2% to 17% in various parts of the UK.^{344 353 [II] [II]} Data from the BSAC surveillance programme in the UK and Ireland 1999/2000 to 2006/7 suggest that β -lactamase production in *H influenzae* has been relatively stable at around 15% over the study period.^{354 [II]} However, this is an uncommon cause of pneumonia and, unless local data suggest otherwise, there is insufficient justification to include a β -lactamase resistant antibiotic regimen in initial empirical therapy of low or moderate severity CAP. *M catarrhalis* is an even rarer cause of CAP, for which the same argument applies.

S aureus is widely resistant to penicillin,^{355 [II]} and an increasing number are now methicillin-resistant (MRSA). When occurring in the community within the UK, this generally reflects hospitalisation within the recent past or residence within a nursing home. Hence, β -lactamase unstable penicillins (penicillin G, aminopenicillins) and, in the case of MRSA, isoxazolyl penicillins (flucloxacillin, cloxacillin) and cephalosporins are inappropriate for such infections.

L pneumophila and *Legionella* spp in general remain susceptible to fluoroquinolones, macrolides and rifampicin, although in vitro low level resistance has been found in some isolates. However, the clinical significance of these observations remains unclear.³⁵⁶

8.4 Newer antibiotics

Since the 2001 guidelines were published, moxifloxacin has been licensed in the UK for the treatment of "non-severe CAP". It is not licensed at this time for "severe CAP", nor is an intravenous preparation available in the UK; hence, we have not assessed studies which have used intravenous moxifloxacin.

There are reported microbiological, pharmacokinetic and pharmacodynamic advantages for moxifloxacin compared with levofloxacin.^{357 358 [II]} Clinical studies have generally shown equivalence with other oral antibiotics used for CAP.^{359-361 [1b] [1b] [1b]} One showed similar outcomes but fewer side effects when compared with oral amoxicillin (1 g tds) and/or clarithromycin.^{362 [1b]} However, mainly in view of the increased risk of adverse hepatic reactions associated with moxifloxacin, the European Medicines Agency recommended in July 2008 that moxifloxacin should only be given in CAP when treatment with other antibiotics cannot be used. Similar advice is given in the British National Formulary (<http://www.bnf.org/bnf/>).³⁶³

4–5 years largely, has a low mortality rate and affects younger persons. A policy for initial empirical therapy that aimed to always cover this pathogen was considered inappropriate.

For these reasons, as well as the issues of current practice, cost, wide experience and drug tolerance, amoxicillin remains the preferred agent. The alternative agents for those intolerant of amoxicillin are doxycycline and the macrolides clarithromycin and erythromycin.^{277 [Ib]} Recommendation of a tetracycline as an alternative therapy has been adopted on the basis of lower resistance rates among pneumococci (fig 9) and activity against atypical pathogens. Reduced gastrointestinal intolerance and an easier dosing schedule are the major reasons for recommending clarithromycin over erythromycin. Concern over the rising frequency of *in vitro* resistance (fig 9) of *S pneumoniae* to macrolides (which is often linked to penicillin resistance) is recognised, yet published clinical evidence for clinical failure of macrolides in the treatment of pneumococcal pneumonia remains limited^{454 [III] 455} and controversial.^{456 457 [IVa] [IVa]}

The macrolides clarithromycin and azithromycin^{458 [IVa]} and the fluoroquinolones^{459 [IVa]} have microbiological strengths *in vitro*, yet in published studies to date have not been shown to be more efficacious than standard therapy in treating patients with low severity CAP. Several meta-analyses (including a Cochrane review) of trials that have compared empirical antibiotic regimens with atypical pathogen coverage with regimens without atypical pathogen coverage in patients with low severity pneumonia have not found any benefit of regimens with atypical pathogen coverage in terms of survival or clinical efficacy.^{460–462}

The association of *H influenzae* and, to a much lesser extent, *M catarrhalis* with acute exacerbations of COPD is recognised.^{463 [II]} However, both remain uncommon causes of CAP. When CAP does arise with these pathogens, an even smaller percentage of such patients will be infected with β -lactamase producing strains. To illustrate the clinical significance of such resistance for managing CAP, it could be estimated that 5% of CAP cases may be caused by *H influenzae*, of which 15% may be β -lactamase producing strains in the UK. Therefore, of 500 patients with CAP, only 4 may be infected with such antibiotic-resistant strains.

A view that specific pathogens are associated with other comorbid diseases (eg, *H influenzae* and COPD) to increase the risk of CAP is not supported by the literature. For these reasons, these guidelines do not offer alternative regimens for patients with or without comorbid illness, while recognising that such diseases can affect the severity of CAP in an individual.

The current concern over the increasing prevalence of pneumococci with reduced susceptibility to penicillin is recognised. However, the incidence of highly resistant strains (MIC ≥ 4 mg/l) remains uncommon in the UK. Furthermore, the rarity of documented clinical failures among penicillin-resistant pneumococcal pneumonia, if treated with adequate doses of penicillin, is the basis for endorsing oral amoxicillin as first-line therapy at a dosage of 500 mg three times daily.

Recommendations

- ▶ **For patients treated in the community, amoxicillin remains the preferred agent at a dose of 500 mg three times daily. [A+]**
- ▶ **Either doxycycline [D] or clarithromycin [A–] are appropriate as an alternative choice, and for those patients who are hypersensitive to penicillins.**

- ▶ **Those with features of moderate or high severity infection should be admitted urgently to hospital. [C]**

8.8 Should general practitioners administer antibiotics prior to hospital transfer in those patients who need admission?

There is no direct evidence upon which to provide clear guidance on this question. There is, however, some circumstantial evidence to suggest that early antibiotics are of benefit in high severity pneumonia.

Delay in prescribing antibiotics for patients in hospital with diagnosed pneumonia is associated with a worse outcome^{464 465 [III] [III]} and, in patients dying from CAP, the majority had not received prior antibiotics even though most had visited a general practitioner in the previous few days. In a national confidential enquiry into CAP deaths in young adults in England and Wales, 20 of the 27 fatal cases investigated had seen their general practitioner for the illness and only 9 had received antibiotics.^{466 [II]} In the multicentre BTS study of CAP in 1982, none of the patients who died from pneumococcal pneumonia had received an antibiotic before admission. The authors concluded that some deaths may have been preventable and recommended that an antibiotic active against *S pneumoniae* should be started as soon as pneumonia is recognised.^{6 [Ib]} In a study from New Zealand, significantly fewer ($p = 0.05$) of those who died had received antibiotics before admission (20%) compared with those who survived (42%).^{467 [Ib]} Currently, less than half of adults admitted to hospital in the UK with high severity CAP have already received antibiotics from their general practitioner.^{42 103 [III] [III]} Many deaths and requirements for assisted ventilation occur in the first few days of admission for high severity CAP.^{6 37 241 [Ib] [Ib] [Ib]} All of these studies provide further support to the suggestion that, in cases of diagnosed pneumonia, antibiotics should be given as early as possible, if necessary before hospital admission.

Delays do occur between general practitioner assessment in the community, arranging admission, confirmation of the diagnosis in hospital and the start of treatment. Probably these are inevitable and will be exacerbated by transport distances and ambulance availability and prioritisation, bed availability and triage in the medical assessment unit or emergency department. Delays between admission and receiving antibiotics of >6 h have been reported for younger adults dying in hospital of CAP (average delay 260 min),^{264 [III]} although this study was conducted before medical assessment units were introduced into most UK hospitals.

From time to time, general practitioners do see patients who are severely ill with what appears to be pneumonia. In such circumstances, treatment should commence as soon as possible, providing it does not delay transfer to hospital. When general practitioners feel treatment in such circumstances is needed, it should aim to cover pneumococcal pneumonia—the commonest cause of high severity CAP—with intravenous penicillin G 1.2 g or oral amoxicillin 1 g orally (or clarithromycin 500 mg in patients with penicillin sensitivity). General practitioners are likely to carry such antibiotics with them as parenteral penicillin is recommended as the immediate treatment for suspected meningococcal infection. Ambulance services should allocate to patients with pneumonia a high priority for transfer to hospital.

Prescribing antibiotics does have an influence on some microbiological investigations.^{6 [Ib]} However, when general practitioners feel a patient is severely ill or circumstances suggest that delays in transfer will slow assessment and treatment in

hospital, concern over the potential effect on subsequent investigations is not a reason to withhold treatment.

Inappropriate antibiotic use is a major concern both in community and hospital settings. The clinical likelihood of CAP therefore needs to be taken into account when considering antibiotic treatment at the time of hospital referral. It is important to state that, as with the whole of this document, these guidelines refer to patients with CAP and not to the much larger group of patients with non-pneumonic lower respiratory tract infection or exacerbations of COPD.

Summary

- ▶ Delays occur in the process of admitting patients to hospital with CAP and them receiving antibiotics. [III]
- ▶ There is direct and indirect evidence that administering antibiotics early is important in the outcome of CAP, particularly when the patient is assessed as being severely ill. [Ib]
- ▶ Less than half of patients admitted with high severity CAP have received antibiotics before admission, even though they may have seen their general practitioner. [III]
- ▶ Most deaths from CAP occur shortly after admission. [Ib]
- ▶ Pre-admission antibiotics can negatively influence the results of subsequent microbiological investigations, [Ib] but this is not seen as a reason for withholding antibiotics if the general practitioner feels they are indicated.

Recommendations

- ▶ **For those patients referred to hospital with suspected CAP and where the illness is considered to be life-threatening, general practitioners should administer antibiotics in the community. [D] Penicillin G 1.2 g intravenously or amoxicillin 1 g orally are the preferred agents.**
- ▶ **For those patients referred to hospital with suspected high severity CAP and where there are likely to be delays of over 6 h in the patient being admitted and treated in hospital, general practitioners should consider administering antibiotics in the community. [D]**

8.9 When should the first dose of antibiotic be given to patients admitted to hospital with CAP?

The prompt administration of antibiotics to patients with proven CAP is good practice, matches patient expectation and is supported by some data demonstrating improved clinical outcomes. One large retrospective study of patients aged 65 years and older admitted with CAP demonstrated a 15% reduction in 30-day mortality for patients treated within 8 h.⁴⁶⁴ [III] A further retrospective study in patients aged 65 years and older admitted with CAP and who had not received antibiotics before admission reported similar results.⁴⁶⁸ [III]

However, the diagnosis of CAP is not always evident on admission to hospital. One study reported that 22% of patients with CAP had atypical presentations which led initially to diagnostic uncertainty.⁴⁶⁹ Concerns have therefore been raised that undue emphasis on early antibiotic administration will lead to an increase in inaccurate diagnoses and consequently an increase in inappropriate antibiotic use. Studies from the USA have shown that, following a recommendation that the time to first antibiotic dose should be less than 4 h for all patients with CAP, there was a 39% reduction in the accuracy of emergency department diagnosis of CAP, an increase (from 20.6% to

28.3%) in the number of patients diagnosed with “CAP” who actually had a normal chest radiograph⁴⁷⁰ and an increase in inappropriate antibiotic use.⁴⁷¹ [III]

We have sought to offer recommendations that encourage *prompt and appropriate* antibiotic treatment of patients with CAP but that avoid forcing clinicians to diagnose and treat pneumonia when there is genuine uncertainty. The pivotal role of the chest radiograph in confirming or refuting a diagnosis of CAP in patients admitted with *suspected* CAP is emphasised in Section 5.2. It is also recognised that, in a minority of patients, atypical presentations of CAP may result in a delay in diagnosis.

Recommendations

- ▶ **A diagnosis of CAP should be confirmed by chest radiography before the commencement of antibiotics in the majority of patients. Selected patients with life-threatening disease should be treated based on a presumptive clinical diagnosis of CAP. In such instances, an immediate chest radiograph to confirm the diagnosis or to indicate an alternative diagnosis is indicated. [D]**
- ▶ **All patients should receive antibiotics as soon as the diagnosis of CAP is confirmed. [D] This should be before they leave the initial assessment area (emergency department or medical assessment unit). The objective for any service should be to confirm a diagnosis of pneumonia with chest radiography and initiate antibiotic therapy for the majority of patients with CAP within 4 h of presentation to hospital. [B–]**

8.10 Empirical antibiotic choice for adults hospitalised with low severity CAP

Approximately 20% of patients with CAP are hospitalised in the UK (see Section 2). The reasons for hospitalisation vary and include severity of the infection, an unsatisfactory response to treatment initiated by the general practitioner, significant comorbid illness and non-clinical reasons such as inappropriate home circumstances suitable for community management.

It is recognised that a significant number of patients with low severity pneumonia who might otherwise be adequately managed in the community are admitted to hospital for non-clinical reasons (advanced age, personal or family preference, inadequate home care or adverse social circumstances). Others will be admitted who have not received antibiotic therapy. They cannot be considered to have failed community treatment and, as such, initial therapy with a single agent is considered appropriate (see table 5). Furthermore, *M pneumoniae* is an important contributor to the overall incidence of atypical pathogens but is an infrequent cause of CAP in elderly patients. This provides a further justification for simple monotherapy in the hospitalised elderly patient with low severity CAP. In all such circumstances, patient management requires careful clinical judgement and regular reviews.

Following initial assessment and empirical therapy, progress should be monitored carefully. The route and choice of antibiotic treatment will require adjustment, either by stepping up and broadening the spectrum of microbiological activity in the light of clinical deterioration or as a result of positive microbiological information, or stepping down with improvement as discussed below. The review of antibiotic therapy forms an obvious and essential part of the regular clinical review of patients with CAP.

Recommendations

- ▶ **Most patients with low severity CAP can be adequately treated with oral antibiotics.** [C]
- ▶ **Oral therapy with amoxicillin is preferred for patients with low severity CAP who require hospital admission for other reasons such as unstable comorbid illnesses or social needs.** [D]
- ▶ **When oral therapy is contraindicated, recommended parenteral choices include intravenous amoxicillin or benzylpenicillin, or clarithromycin.** [D]

8.11 Empirical antibiotic choice for adults hospitalised with moderate severity CAP

The principles of antibiotic selection for moderate severity CAP managed in hospital are similar to those for its management in the community. The current guidelines incorporate a stratified approach based on disease severity (see Section 6). The predominant pathogen will be *S pneumoniae*. However, overall atypical pathogens including *Legionella* spp account for approximately 20% of defined infections. Therefore, in patients who are admitted with moderate severity disease, oral therapy with a combined β -lactam/macrolide regimen is recommended.

When oral therapy is inappropriate, parenteral amoxicillin or penicillin G are offered as alternatives to oral amoxicillin, with clarithromycin given twice a day as the preferred macrolide for parenteral therapy.

For patients intolerant of penicillin and in whom oral therapy is inappropriate, intravenous levofloxacin once daily or a combination of intravenous cephalosporin with intravenous clarithromycin are appropriate alternative choices. Institutions wishing to avoid the use of quinolones and cephalosporins in these patients may wish to consider monotherapy with intravenous clarithromycin, but must weigh the ecological

benefit of this strategy against the risk of undertreating pneumococcal pneumonia (erythromycin resistance of about 9%; see Section 8.3 and fig 9).

Recommendations

- ▶ **Most patients with moderate severity CAP can be adequately treated with oral antibiotics.** [C]
- ▶ **Oral therapy with amoxicillin and a macrolide is preferred for patients with moderate severity CAP who require hospital admission.** [D]
 - **Monotherapy with a macrolide may be suitable for patients who have failed to respond to an adequate course of amoxicillin prior to admission. Deciding on the adequacy of prior therapy is difficult and is a matter of individual clinical judgement. It is therefore recommended that combination antibiotic therapy is the preferred choice in this situation and that the decision to adopt monotherapy is reviewed on the “post take” round within the first 24 h of admission.** [D]
- ▶ **When oral therapy is contraindicated, the preferred parenteral choices include intravenous amoxicillin or benzylpenicillin, together with clarithromycin.** [D]
- ▶ **For those intolerant of penicillins or macrolides, oral doxycycline is the main alternative agent. Oral levofloxacin and oral moxifloxacin are other alternative choices.** [D]
- ▶ **When oral therapy is contraindicated in those intolerant of penicillins, recommended parenteral choices include levofloxacin monotherapy or a second-generation (eg, cefuroxime) or third-generation (eg, cefotaxime or ceftriaxone) cephalosporin together with clarithromycin.** [D]

Table 5 Initial empirical treatment regimens for community acquired pneumonia (CAP) in adults

Pneumonia severity (based on clinical judgement supported by CURB65 severity score)	Treatment site	Preferred treatment	Alternative treatment
Low severity (eg, CURB65 = 0–1 or CRB65 score = 0, <3% mortality)	Home	Amoxicillin 500 mg tds orally	Doxycycline 200 mg loading dose then 100 mg orally or clarithromycin 500 mg bd orally
Low severity (eg, CURB65 = 0–1, <3% mortality) but admission indicated for reasons other than pneumonia severity (eg, social reasons/unstable comorbid illness)	Hospital	Amoxicillin 500 mg tds orally If oral administration not possible: amoxicillin 500 mg tds IV	Doxycycline 200 mg loading dose then 100 mg od orally or clarithromycin 500 mg bd orally
Moderate severity (eg, CURB65 = 2, 9% mortality)	Hospital	Amoxicillin 500 mg–1.0 g tds orally plus clarithromycin 500 mg bd orally If oral administration not possible: amoxicillin 500 mg tds IV or benzylpenicillin 1.2 g qds IV plus clarithromycin 500 mg bd IV	Doxycycline 200 mg loading dose then 100 mg orally or levofloxacin 500 mg od orally or moxifloxacin 400 mg od orally*
High severity (eg, CURB65 = 3–5, 15–40% mortality)	Hospital (consider critical care review)	Antibiotics given as soon as possible Co-amoxiclav 1.2 g tds IV plus clarithromycin 500 mg bd IV (If legionella strongly suspected, consider adding levofloxacin†)	Benzylpenicillin 1.2 g qds IV plus either levofloxacin 500 mg bd IV or ciprofloxacin 400 mg bd IV OR Cefuroxime 1.5 g tds IV or cefotaxime 1 g tds IV or ceftriaxone 2 g od IV, plus clarithromycin 500 mg bd IV (If legionella strongly suspected, consider adding levofloxacin†)

bd, twice daily; IV, intravenous; od, once daily; qds, four times daily; tds, three times daily.

*Following reports of an increased risk of adverse hepatic reactions associated with oral moxifloxacin, in October 2008 the European Medicines Agency (EMA) recommended that moxifloxacin “should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection”.

†Caution – risk of QT prolongation with macrolide-quinolone combination.

8.12 Empirical antibiotic choice for adults hospitalised with high severity CAP

Mortality is greatly increased in those with high severity pneumonia (see Section 6). The illness may progress before microbiological information is available.

Preferred and alternative initial treatment regimens are summarised in table 5 and mostly include combination therapy with broad-spectrum β -lactams and a macrolide. While *S pneumoniae* remains the predominant pathogen, *S aureus* and Gram-negative enteric bacilli—although uncommon—carry a high mortality,^{243 [1a]} hence the recommendation for broad-spectrum β -lactam regimens in those with high severity CAP. Patients hospitalised with CAP caused by *Legionella* spp are more likely to have high severity pneumonia.^{219 [1a]} For these reasons, the initial empirical antibiotic regimen should also always capture this pathogen within its spectrum of activity.⁴⁷² Specific antibiotic recommendations for treating confirmed legionella infection are provided in Section 8.20. The near universal availability of *L pneumophila* urine antigen testing means that a rapid diagnosis of *L pneumophila* serogroup 1 infection can often be made early in the course of the admission. However, the urine antigen test may be negative on admission and is also insufficiently sensitive to exclude Legionnaires' disease, so empirical therapy for Legionnaires' disease should not be discontinued based solely on a negative antigen test.

Parenteral administration of antibiotic is recommended in those with high severity CAP regardless of the patient's ability or otherwise to take oral medication. This is to ensure prompt high blood and lung concentrations of antibiotic.

The preferred regimen includes co-amoxiclav. This agent has excellent activity against the pneumococcus, *H influenzae* and *S aureus*, as well as activity against anaerobes. In the current guidelines, cephalosporins and fluoroquinolones are included as alternative but not preferred choices, largely on the basis that their use has been consistently associated with hospital acquired infections, notably *C difficile* associated disease. While co-amoxiclav has also been shown to be associated with *C difficile* infection, the Committee considers co-amoxiclav to be less likely to encourage *C difficile* overgrowth compared with cephalosporins and fluoroquinolones. Furthermore, use of co-amoxiclav enables transition from intravenous to oral therapy without switching class of agent, a property which might help physicians switch early to oral therapy which will also help limit *C difficile* infection.

Efficacy data from prospective controlled clinical trials is not available. However, a retrospective study suggests a reduction in mortality for those treated with a third-generation cephalosporin plus a macrolide,^{473 [III]} although no additional benefit has been noted in another study.^{474 [III]}

Levofloxacin is the only licensed and available intravenous fluoroquinolone in the UK at the time of writing. It is marketed in parenteral and oral formulations; since the latter is 98% bioavailable, this indicates that it can be used in high severity pneumonia provided there are no contraindications to oral administration. While it has modest activity against pneumococci in vitro, the published evidence for efficacy in high severity CAP is reassuring.^{198 244 267 329 350 [Ib] [Ib] [Ib] [Ib] [Ib]} However, until more clinical experience is available, we recommend combining it with another agent active against *S pneumoniae* such as parenteral benzylpenicillin when managing high severity CAP.

A small minority of patients will be allergic to both penicillins and cephalosporins. Antibiotic selection is more difficult in these patients and should be discussed with the local respiratory and microbiology services.

Recommendations

- ▶ **Patients with high severity pneumonia should be treated immediately after diagnosis with parenteral antibiotics. [B–]**
- ▶ **An intravenous combination of a broad-spectrum β -lactamase stable antibiotic such as co-amoxiclav together with a macrolide such as clarithromycin is preferred. [C]**
- ▶ **In patients allergic to penicillin, a second-generation (eg, cefuroxime) or third-generation (eg, cefotaxime or ceftriaxone) cephalosporin can be used instead of co-amoxiclav, together with clarithromycin. [C]**

8.13 When should the intravenous or the oral route be chosen?

Parenteral administration of antibiotics is widely and often unnecessarily used in managing hospitalised patients including those with CAP.^{369 475 [Ib] [IVa]} Approximately 30–50% of patients admitted to hospital will initially require treatment with parenteral antibiotics.^{369 [Ib]} Apart from the discomfort to the patient of inserting intravenous devices, there are significant complications, notably infection. In addition, the total cost of parenteral regimens greatly exceeds orally administered therapy.

Factors determining the route of administration are summarised in box 3. Parenteral antibiotics are clearly indicated for patients unable to swallow, where there is concern about adequate absorption of drug from the gut and in the presence of severe pneumonia. However, many antibiotics are well absorbed following oral administration and achieve their maximum plasma concentration within 1–2 h.

Recommendations

- ▶ **The oral route is recommended in those with low and moderate severity CAP admitted to hospital provided there are no contraindications to oral therapy. [B+]**

8.14 When should the intravenous route be changed to oral?

As stated above, parenteral antibiotic therapy is widely and often unnecessarily used among hospitalised patients with low and moderate severity pneumonia. This in part reflects custom and practice but, in addition, may be driven by too liberal an interpretation of the “criteria” for identifying high severity CAP for which parenteral agents are recommended. The current practice of medicine in emergency medical admissions may also be a factor in the choice of parenteral administration where it provides greater confidence to admitting junior medical staff that the patient is receiving the “best” management. Oral therapy was clearly more widely adopted in the past.⁴⁷⁵ However, published evidence indicating comparable efficacy of parenteral and oral regimens is limited, but has been shown for intravenous cefuroxime and oral levofloxacin.^{371 [Ib]}

The choice and timing of any change to oral therapy will be affected by several factors. These include the absence of any contraindications to oral administration, the availability of any microbiological information regarding aetiology of the infection and clear evidence that the patient is responding to initial therapy.

There can be no rigid recommendation concerning the timing of transfer to oral therapy and further studies of this area are needed.^{438 476 477 [III] [Ia] [II]} Any decision must be individualised on the basis of assessing all factors. Nonetheless, the recommended guideline is that oral therapy be considered in a patient who has shown clear evidence of improvement and whose temperature has resolved for a period of 24 h. The features indicating

response to parenteral therapy are summarised in box 4. This policy will allow a significant proportion of patients with pneumonia to be safely transferred to an oral regimen after a period of initial parenteral therapy.^{279 372 393 438 476 478 [II] [Ib] [Ia] [III] [IVa]}

Recommendations

- ▶ **Patients treated initially with parenteral antibiotics should be transferred to an oral regimen as soon as clinical improvement occurs and the temperature has been normal for 24 h, providing there is no contra-indication to the oral route. Pointers to clinical improvement are given in box 4. [B+]**
- ▶ **The choice of route of administration should be reviewed initially on the “post take” round and then daily. [D]**
- ▶ **Ward pharmacists could play an important role in facilitating this review by highlighting prescription charts where parenteral antibiotic therapy continues. [D]**

8.15 Which oral antibiotics are recommended on completion of intravenous therapy?

The selection of agents for oral administration following initial intravenous therapy is based on antimicrobial spectrum, efficacy, safety and cost considerations. Although it may appear logical to select the oral formulation of a parenteral agent, this is not essential and such oral agents may not meet the criteria for selection. For macrolides, oral clarithromycin is better tolerated than oral erythromycin.^{364 365 [Ib] [Ib]} A clinical judgement can be made whether to change to oral monotherapy in those who have responded favourably to parenteral combination therapy or where there is microbiological documentation of the nature of the infection, in which case the recommendations in table 6 should be adopted.

Recommendations

- ▶ **The antibiotic choices for the switch from intravenous to oral are straightforward where there are effective and equivalent oral and parenteral formulations. [C]**
- ▶ **In the case of parenteral cephalosporins, the oral switch to co-amoxiclav 625 mg three times daily is recommended rather than to oral cephalosporins. [D]**
- ▶ **For those treated with benzylpenicillin + levofloxacin, oral levofloxacin with or without oral amoxicillin 500 mg–1.0 g three times daily is recommended. [D]**

8.16 How long should antibiotics be given for?

The precise duration of antibiotic therapy for the management of microbiologically documented and non-documented CAP is

Box 3 Indications for parenteral and oral antibiotic therapy of adult CAP

Parenteral therapy

- ▶ High severity pneumonia
- ▶ Impaired consciousness
- ▶ Loss of swallowing reflex
- ▶ Functional or anatomical reasons for malabsorption

Oral therapy

- ▶ Community managed
- ▶ Hospital managed, non-severe with no other contraindications

not supported by robust evidence. One RCT of adults with low to moderate severity pneumonia treated with amoxicillin reported similar efficacy with a 3-day intravenous course as with an 8-day (3 days intravenous followed by 5 days oral) course.⁴⁷⁹ The Summary of Product Characteristics (formerly the Drug Data Sheets) for many agents used in the treatment of CAP mention a range of treatment durations which sometimes differ internationally. Intracellular pathogens responsible for pneumonia sometimes respond slowly, and hence a 2-week treatment regimen has been proposed for atypical pathogens.

The aim of antibiotic therapy is to ensure elimination of the target pathogen in the shortest time. In uncomplicated infections this is likely to occur rapidly (within 3 days) with many common respiratory pathogens such as *S pneumoniae*. The resolution of pneumonia involves not only the elimination of the invading pathogen and its products, but also the subsidence of the host inflammatory response which together are responsible for the many clinical and radiographic features of pneumonia.

Until we have more precise methods to reliably identify microbiological and clinical end-points, the duration of therapy will remain subject to clinical judgement. For these reasons, the duration of therapy will vary by individual patient, disease severity and speed of resolution.

Recommendations

- ▶ **For community managed and for most patients admitted to hospital with low or moderate severity and uncomplicated pneumonia, 7 days of appropriate antibiotics is recommended. [C]**
- ▶ **For those with high severity microbiologically-undefined pneumonia, 7–10 days treatment is proposed. This may need to be extended to 14 or 21 days according to clinical judgement; for example, where *S aureus* or Gram-negative enteric bacilli pneumonia is suspected or confirmed. [C]**

8.17 Failure of initial empirical therapy

In those patients who fail to respond to initial empirical therapy, several possibilities need to be considered, the first of which is whether the correct diagnosis has been made. Clinical and radiographic review is recommended for patients managed in the community and in hospital to look for secondary diagnoses or complications of CAP such as pleural effusion/empyema, lung abscess or worsening pneumonic shadowing. This aspect is considered in detail in Section 9.

The initial empirical antibiotic regimen may need to be reassessed. However, compliance with and adequate absorption of an oral regimen should first be considered.

Microbiological data should be reviewed and further specimens examined with a view to excluding less common pathogens such as *S aureus*, atypical pathogens, *Legionella* spp, viruses and *Mycobacteria* spp. It should also be noted that mixed infections can arise in approximately 10% of patients hospitalised with CAP. In the absence of any microbiological indicators of infection, the management of those failing initial empirical therapy will vary according to the severity of illness at reassessment. In patients with low severity pneumonia managed in the community, a macrolide could be substituted for amoxicillin. However, when the patient's condition has deteriorated, admission to hospital should be considered.

In the patient with low or moderate severity pneumonia managed in hospital, the addition of a macrolide is recommended

Box 4 Features indicating response to initial empirical parenteral therapy permitting consideration of oral antibiotic substitution

- ▶ Resolution of fever for >24 h
- ▶ Pulse rate <100 beats/min
- ▶ Resolution of tachypnoea
- ▶ Clinically hydrated and taking oral fluids
- ▶ Resolution of hypotension
- ▶ Absence of hypoxia
- ▶ Improving white cell count
- ▶ Non-bacteraemic infection
- ▶ No microbiological evidence of legionella, staphylococcal or Gram-negative enteric bacilli infection
- ▶ No concerns over gastrointestinal absorption

in those patients initially managed with amoxicillin alone. Changing to doxycycline or a new fluoroquinolone such as levofloxacin are alternatives.

In the patient with high severity pneumonia already receiving a β -lactam/clarithromycin regimen, the addition of levofloxacin should be considered. In addition, urgent referral to a respiratory physician should be made for clinical assessment including the possible need for bronchoscopic sampling.

Recommendations

- ▶ When a change in empirical antibiotic therapy is considered necessary, a macrolide could be substituted for or added to the treatment for those with low severity pneumonia treated with amoxicillin monotherapy in the community or in hospital. [D]
- ▶ For those with moderate severity pneumonia in hospital on combination therapy, changing to doxycycline or a fluoroquinolone with effective pneumococcal cover are alternative options. [D]
- ▶ Adding a fluoroquinolone is an option for those with high severity pneumonia not responding to a β -lactam/macrolide combination antibiotic regimen. [D]

8.18 Antibiotic stewardship and avoiding inappropriate antibiotic prescribing for CAP

Inappropriate antibiotic prescribing is a driver for antibiotic resistance and increases the likelihood of development of *C difficile* infection. Given the frequency of admissions to hospital for suspected CAP and the difficulty in identifying a causative pathogen often leading to initial empirical broad-spectrum antibiotic therapy, it is timely to offer guidance to limit inappropriate prescribing in the context of the management of patients with CAP.

Ensuring an accurate diagnosis of CAP is the most important issue in relation to the avoidance of inappropriate antibiotic prescribing. One study reported that 29% of hospitalised

Table 6 Recommended treatment of microbiologically documented pneumonia and aspiration pneumonia (local specialist advice should also be sought*)

Pathogen	Preferred	Alternative
<i>S pneumoniae</i>	Amoxicillin 500 mg –1.0 g† tds orally or benzylpenicillin 1.2 g qds IV	Clarithromycin 500 mg bd orally or cefuroxime 0.75–1.5 g tds IV or cefotaxime 1–2 g tds IV or ceftriaxone 2 g od IV
<i>M pneumoniae</i> <i>C pneumoniae</i>	Clarithromycin 500 mg bd orally or IV	Doxycycline 200 mg loading dose then 100 mg od orally or fluoroquinolone‡ orally or IV
<i>C psittaci</i> <i>C burnetii</i>	Doxycycline 200 mg loading dose then 100 mg od orally	Clarithromycin 500 mg bd orally or 500 mg bd IV
<i>Legionella</i> spp	Fluoroquinolone orally or IV‡§	Clarithromycin 500 mg bd orally or IV (or, if necessary, azithromycin in countries where this antibiotic is used for managing pneumonia)
<i>H influenzae</i>	Non- β -lactamase-producing: amoxicillin 500 mg tds orally or IV β -lactamase-producing: co-amoxiclav 625 mg tds orally or 1.2 g tds IV	Cefuroxime 750 mg –1.5 g tds IV or cefotaxime 1–2 g tds IV or ceftriaxone 2 g od IV or fluoroquinolone‡ orally or IV
Gram-negative enteric bacilli	Cefuroxime 1.5 g tds or cefotaxime 1–2 g tds IV or ceftriaxone 1–2 g bd IV	Fluoroquinolone‡ IV or imipenem 500 mg qds IV or meropenem 0.5–1.0 g tds IV
<i>P aeruginosa</i>	Ceftazidime 2 g tds IV plus gentamicin or tobramycin (dose monitoring)	Ciprofloxacin 400 mg bd IV or piperacillin 4 g tds IV, plus gentamicin or tobramycin (dose monitoring)
<i>S aureus</i>	Non-MRSA: flucloxacillin 1–2 g qds IV \pm rifampicin 600 mg od or bd orally/IV	MRSA: vancomycin 1 g bd IV (dose monitoring) or linezolid 600 mg bd IV or teicoplanin 400 mg bd IV \pm rifampicin 600 mg od or bd orally/IV
Aspiration pneumonia	Co-amoxiclav 1.2 g tds IV	Seek local microbiology advice

bd, twice daily; IV, intravenous; od, once daily; tds, three times daily.

*Treatment can be modified once the results of sensitivity testing are available.

†A higher dose of 1.0 g tds is recommended for infections documented to be caused by less susceptible strains (minimum inhibitory concentration >1.0 mg/l).

‡Currently UK licensed and available suitable fluoroquinolones include ciprofloxacin, ofloxacin and levofloxacin. Moxifloxacin can be used for patients who cannot be treated or have failed treatment with other antibacterials.

§Specifically for legionella pneumonia, the large majority of published experience regarding the efficacy of fluoroquinolones is only with levofloxacin. For high severity or life-threatening legionella pneumonia, combination therapy including the preferred and an alternative antibiotic can be considered for the first few days (see text for further details). Rifampicin is not recommended on its own but could be considered as the second additional antibiotic.

patients treated for CAP did not have radiographic abnormalities.^{471 [III]}

In patients with CAP, broad-spectrum intravenous antibiotics should only be used following careful consideration, taking into account severity of illness, likely pathogens involved and patient-specific factors such as the ability to tolerate oral medication. Whenever appropriate, narrow-spectrum oral antibiotics should be used preferentially.

Recommendations

- ▶ **The diagnosis of CAP and the decision to start antibiotics should be reviewed by a senior clinician at the earliest opportunity. There should be no barrier to discontinuing antibiotics if they are not indicated. [D]**
- ▶ **The indication for antibiotics should be clearly documented in the medical notes. [D]**
- ▶ **The need for intravenous antibiotics should be reviewed daily. [D]**
- ▶ **De-escalation of therapy, including the switch from intravenous to oral antibiotics, should be considered as soon as is appropriate, taking into account response to treatment and changing illness severity. [D]**
- ▶ **Strong consideration should be given to narrowing the spectrum of antibiotic therapy when specific pathogens are identified or when the patient's condition improves. [D]**
- ▶ **Where appropriate, stop dates should be specified for antibiotic prescriptions. [D]**

(B) SPECIFIC PATHOGEN-DIRECTED ANTIBIOTIC THERAPY

8.19 What are the optimum antibiotic choices when specific pathogens have been identified?

In routine clinical practice, only about one-third to one-quarter of patients with CAP admitted to hospital will be defined microbiologically. Of these, some such as mycoplasma, chlamydia and *C burnetii* infection will be diagnosed late in the illness on the basis of seroconversion, reducing the opportunity for early targeted therapy. Among patients managed in the community, very few will be microbiologically defined.

When a pathogen has been identified, specific therapy as summarised in table 6 is proposed. In transferring patients from empirical to pathogen-targeted therapy, the regimen and route of administration will be determined by the continued need for parenteral therapy and known drug intolerance. Hence, table 6 provides preferred and alternative regimens for intravenous or oral administration. However, it should be remembered that approximately 10% (see Section 3) of infections will be of mixed aetiology, although many such co-pathogens will be viral and hence not influenced by antibiotic choice. These recommendations are again based on a synthesis of information which includes in vitro activity of the drugs, appropriate pharmacokinetics and clinical evidence of efficacy gleaned from a variety of studies. The choice of agent may be modified following the availability of sensitivity testing or following consultation with a specialist in microbiology, infectious disease or respiratory medicine.

Currently, *S pneumoniae* highly resistant to penicillin (MIC ≥ 4 mg/l) is uncommon in the UK. *S aureus* is an uncommon cause of CAP in the UK. Most community isolates are

methicillin-sensitive, although the recent increase in MRSA in hospitalised patients may result in subsequent readmission with an MRSA infection which may include CAP. Options for methicillin-sensitive and methicillin-resistant infections are based on parenteral administration in view of the serious nature of staphylococcal pneumonia.

Recommendations

- ▶ **If a specific pathogen has been identified, the antibiotic recommendations are summarised in table 6 [C].**

8.20 Specific issues regarding the management of Legionnaires' disease

Legionella infection is unique as a cause of CAP owing to the mode of spread and the importance of trying to identify the source to prevent further cases. The infection is acquired by inhaling water mist containing legionella bacteria, which are commonly found in natural and manmade water systems. Common sources include drift from evaporative cooling towers and aerosols generated from showers, aerated hot tubs, humidifiers and potable water. In addition, the propensity to cause severe illness including multiple organ failure and the lack of response to β -lactam antibiotics suggests that specific guidance will be helpful to clinicians managing a case.

Detection of legionella urinary antigen using a rapid technique has revolutionised the early diagnosis of pneumonia caused by *L pneumophila* serogroup 1 which is responsible for over 90% of community cases in the UK and Europe. This is a highly sensitive and specific test, particularly in patients who are unwell enough or who have been ill long enough to require hospital admission (see Section 6). Although urinary antigen detection is now the most valuable and frequently used diagnostic test, sputum culture still has a vital role in diagnosing infection caused by other legionella serogroups and species. It is also invaluable for matching legionella species and strains identified from cases, with those positive water cultures from a potential source. This can help prevent further cases of infection. It is therefore important to send off sputum or respiratory secretions specifically for legionella culture, even in proven cases and after appropriate antibiotics have started (see Section 5.11.5).

Legionnaires' disease is not currently a notifiable disease in the UK, but urgent action to investigate the source of infection is essential. In proven cases of legionella pneumonia, the clinician should liaise with the clinical microbiologist to confirm that the local Health Protection Unit has been informed. The Health Protection Unit should initiate immediate investigations and this will include recording details of recent travel and activities within the 2 weeks before illness onset (the usual incubation period is 2–10 days) from the patient or their relatives to assist epidemiological investigation. Clinicians should help by explaining the need for this to patients and relatives; this is important, especially at a time when the patient may be very unwell and their relatives distressed. The Health Protection Agency (HPA) will also request a clinical information sheet to be completed which provides very valuable (anonymous) clinical and outcome data to update the ongoing national and European data sets which are available from the HPA website (www.hpa.org.uk) or, for Scotland, from Health Protection Scotland (www.hps.scot.nhs.uk) and the European Working Group for Legionella Infections (www.ewgli.org). Further details about the investigation of a potential source of

legionella infection and the management of sporadic cases can be found at the HPA website (www.hpa.org.uk) under the section Infectious Diseases→Infections A-Z→Legionnaires' disease→Guidelines.

There are no robust trials comparing the efficacy of different antibiotics for treating Legionnaires' disease, but in vitro studies and clinical experience in the form of observational case series support the use of quinolones, macrolides, azithromycin and rifampicin, with fluoroquinolones being the most effective agents. By contrast, antibiotics are not required for the non-pneumonic form of legionellosis—pontiac fever—which presents as a self-limiting flu-like illness with an incubation period of only 1–2 days.

A recent paper regarding the antibiotic therapy for Legionnaires' disease⁴⁸⁰ [IVa] reviewed the combined results from three recent observational studies of 458 patients with Legionnaires' disease managed with either a macrolide or a fluoroquinolone (mostly levofloxacin in an initial dose of 500 mg twice daily)^{481–483} [II] [III] and concluded that fluoroquinolones appeared to have significant advantages over macrolides when comparing the end points of defervescence, side effects and hospital stay; however, the mortality rate was similar.

As the evidence base regarding the clinical efficacy of specific antibiotics is weak, consensus is used to make recommendations. Fluoroquinolones are regarded as the antibiotic of choice for proven legionella infection and, in such cases, their use should not be restricted by general ecological concerns over quinolone use.

For low and moderate severity community acquired legionella infection, an oral fluoroquinolone is recommended and should be prescribed unless there is definite patient intolerance which prevents its use. In this unusual circumstance, a macrolide is an alternative. (azithromycin is rarely used in the UK for CAP but is an alternative in countries where it is recommended for CAP).

For the management of high severity or life-threatening legionella pneumonia, a fluoroquinolone should be used wherever possible. There are no robust data on the use of combination antibiotics for high severity legionella pneumonia. However, in most circumstances, patients will already be on empirical combined antibiotic therapy for severe CAP which includes a macrolide (clarithromycin) at the time the diagnosis is made. Thus, with the knowledge of the significant mortality of high severity legionella pneumonia and the possibility of dual infection, continuing combined antibiotic therapy with a macrolide in addition to the fluoroquinolone is recommended during the crucial first few days. Azithromycin (in countries where this antibiotic is used for pneumonia) is an alternative to clarithromycin. However, clinicians should be alert to the potential small risk of cardiac electrophysiological abnormalities including prolongation of the QT interval on the ECG with the recommended combination,⁴⁸⁴ [IVa] particularly if other pro-arrhythmic risk factors are present. Rifampicin has traditionally also been offered as an alternative antibiotic to add as the second antibiotic in combined therapy and we include it as a recommended alternative. However, one small cohort observational study of 32 patients with legionella pneumonia reported that the addition of rifampicin to clarithromycin therapy offered no additional benefit in terms of recovery and that those receiving rifampicin had a longer length of stay in hospital.⁴⁸⁵ [III] With parenteral rifampicin there is also a risk of hyperbilirubinaemia, which usually resolves on stopping the drug.⁴⁸⁶ [III] Further studies are indicated in the optimal treatment of high severity legionella pneumonia.

It has become accepted dogma that prolonged antibiotic therapy of 2–3 weeks is needed for legionella pneumonia to prevent relapses. This is based on a few anecdotal cases reported following the Philadelphia outbreak in 1976, largely involving immunocompromised patients.⁴⁸⁷ [III] However, there is no evidence to support the statement that patients with community acquired legionella pneumonia require longer therapy than other patients with CAP, and the duration of therapy should be guided as usual by clinical judgement.

Recommendations

- ▶ **As soon as a diagnosis of legionella pneumonia has been made, the clinician should liaise with the clinical microbiologist to confirm that the local Health Protection Unit has been informed. The Health Protection Unit is responsible for promptly investigating the potential sources of infection. [D]**
- ▶ **The clinician should assist, where appropriate, in the gathering of clinical and epidemiological information from the patient and their relatives to aid the source investigation. [D]**
- ▶ **Sputum or respiratory secretions should be sent off specifically for legionella culture in proven cases, even after appropriate antibiotics have started. [D]**
- ▶ **For low and moderate severity community acquired legionella pneumonia, an oral fluoroquinolone is recommended. In the unusual case when this is not possible due to patient intolerance, a macrolide is an alternative. [D] Antibiotics are not required for the non-pneumonic self-limiting form of legionellosis—pontiac fever. [D]**
- ▶ **For the management of high severity or life threatening legionella pneumonia, a fluoroquinolone is recommended. For the first few days this can be combined with a macrolide (azithromycin is an option in countries where it is used for pneumonia) or rifampicin as an alternative. [D] Clinicians should be alert to the potential small risk of cardiac electrophysiological abnormalities with quinolone-macrolide combinations.**
- ▶ **Duration of therapy should be as for microbiologically-undefined CAP (for those with low to moderate severity pneumonia, 7 days treatment is proposed; for those with high severity pneumonia, 7–10 days treatment is proposed—this may need to be extended to 14 or 21 days, see Section 8.16) and should be guided by clinical judgement. [D]**

8.21 Specific issues regarding Pantone-Valentine Leukocidin-producing *Staphylococcus aureus*

Necrotising pneumonia caused by a Pantone-Valentine Leukocidin (PVL)-producing strain of *S aureus* (PVL-SA, either MSSA or MRSA) is rare in the UK and Europe. If strongly suspected, blood cultures and respiratory samples should have an urgent Gram stain and be cultured on non-selective media to aid recovery of pathogens. Clinicians strongly suspecting infection due to PVL-SA should liaise with their local microbiology laboratory to ensure sensitivity testing and toxin gene profiling are carried out.

Detailed guidance on the specific management of patients with necrotising pneumonia due to PVL-SA is available from the HPA website (http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1218699411960).

Recommendations

- ▶ **PVL-SA infection is a rare cause of high severity pneumonia and can be associated with rapid lung cavitation and multiorgan failure. Such patients should be considered for critical care admission. [D]**
- ▶ **If PVL-SA necrotising pneumonia is strongly suspected or confirmed, clinicians should liaise urgently with the microbiology department in relation to further antibiotic management and consider referral to the respiratory medicine department for clinical management advice. [D]**
- ▶ **Current recommendations for the antibiotic management of strongly suspected necrotising pneumonia include the addition of a combination of intravenous linezolid 600 mg bd, intravenous clindamycin 1.2 g qds and intravenous rifampicin 600 mg bd to the initial empirical antibiotic regimen. As soon as PVL-SA infection is either confirmed or excluded, antibiotic therapy should be narrowed accordingly. [D]**

SECTION 9 COMPLICATIONS AND FAILURE TO IMPROVE

9.1 What factors and action should be considered in patients who fail to improve in hospital?

For patients in hospital with CAP, the median time to improvement in heart rate and blood pressure is 2 days and in temperature, respiratory rate and oxygen saturation is 3 days. Failure to improve with initial management may occur in 6–24% of patients.^{488–489 [III] [III]}

Independent risk factors for failure to improve that have been identified include multilobar involvement, cavitating pneumonia, presence of a pleural effusion, co-existing liver disease, cancer or neurological disease, aspiration pneumonia, legionella pneumonia, Gram-negative pneumonia, leucopenia, high disease severity on admission and inappropriate antimicrobial therapy.^{488–490 [III] [III] [III]}

Patients who fail to improve have a poorer prognosis. Studies have reported a mean increase in length of hospital stay of 4 days^{489 [III]} and an increase in mortality.^{490 [III]}

Failure to improve should lead to consideration of various possibilities summarised in box 5.

Recommendations

- ▶ **For patients who fail to improve as expected, there should be a careful review by an experienced clinician of the clinical history, examination, prescription chart and results of all available investigation results. [D]**
- ▶ **Further investigations, including a repeat chest radiograph, C-reactive protein and white cell count and further specimens for microbiological testing should be considered in the light of any new information after the clinical review. [D]**
- ▶ **Referral to a respiratory physician should be considered. [D]**

9.2 What are the common complications of CAP?

A brief description of the common complications of CAP is given below. Complications associated with specific infections are summarised in table 7.

9.2.1 Pleural effusion and empyema

Parapneumonic effusions develop in 36–57% of bacterial pneumonias admitted to hospital and can be the cause of persisting pyrexia despite adequate antibiotic treatment.^{491 [III]}

The presence of bilateral pleural effusions in CAP is associated with increased mortality.^{259 [III]} Although most effusions will resolve with antibiotic therapy alone, it is recommended that thoracentesis is performed promptly in patients with parapneumonic effusion admitted to hospital. Those patients shown to have an empyema (defined as the detection of cloudy fluid, pus or organisms on Gram stain or culture^{492 [III]}) or a complicated parapneumonic effusion (defined as clear pleural fluid with a pH <7.2^{493 [III]}) should then have early and effective pleural space drainage. Pleural fluid for pH should be collected anaerobically in a heparinised blood gas syringe and measurement is performed in a blood gas analyser.

The incidence of empyema in patients admitted to hospital with CAP in a Canadian study was 0.7–1.3%. The in-hospital mortality in these patients was 4.2%.^{494 [II]} Other data indicate an increase in the incidence of patients hospitalised with empyema over the last decade.^{495–496 [III] [III]}

Recognition of empyema is important as delayed thoracentesis and chest tube drainage lead to longer and more costly hospitalisation.^{491 [III]} Further details on the management of empyema are available in the BTS guidelines on the management of pleural infection.⁴⁹⁷

Recommendations

- ▶ **Early thoracentesis is indicated for all patients with a parapneumonic effusion. [D]**
- ▶ **Those found to have an empyema or clear pleural fluid with pH <7.2 should have early and effective pleural fluid drainage. [C]**
- ▶ **The BTS guidelines for the management of pleural infection should be followed. [D]**

9.2.2 Lung abscess

Lung abscess is a rare complication of CAP, being seen most commonly in the debilitated or alcoholic patient and following aspiration. Infection with anaerobic bacteria, *S aureus*, Gram-negative enteric bacilli or *S milleri* (in the presence of poor dental hygiene) should be considered. Most patients respond to appropriate antibiotics. A prolonged course of antibiotics may be required, although there is a lack of evidence on which to base firm recommendations regarding the optimum duration of antimicrobial therapy. Early surgical drainage via pneumonotomy may occasionally be needed.

Recommendations

- ▶ **Less usual respiratory pathogens including anaerobes, *S aureus*, Gram-negative enteric bacilli and *S milleri* should be considered in the presence of lung abscess. [D]**
- ▶ **Prolonged antibiotic therapy of up to 6 weeks depending on clinical response and occasionally surgical drainage should be considered. [D]**

9.2.3 Metastatic infection

Patients with septicaemia associated with pneumonia can occasionally develop metastatic infection. Meningitis, peritonitis, endocarditis and septic arthritis have all been reported. Purulent pericarditis can occur, usually in direct relation to an empyema.

Most such complications can be detected by careful history and examination.

Box 5 Reasons for failure to improve as expected

Incorrect diagnosis or complicating condition

- ▶ Common
 - Pulmonary embolism/infarction
 - Pulmonary oedema
 - Bronchial carcinoma
 - Bronchiectasis
 - Slow response in the elderly patient
- ▶ Uncommon
 - Pulmonary eosinophilia/eosinophilic pneumonia
 - Cryptogenic organising pneumonia
 - Pulmonary alveolar haemorrhage
 - Foreign body
 - Congenital pulmonary abnormality (eg, lobar sequestration)

Unexpected pathogen or pathogens not covered by antibiotic choice

- ▶ Pathogens always resistant to common antibiotics (eg, an “atypical pathogen” not responding to penicillin)
- ▶ Pathogens sometimes resistant to commonly used antibiotics (eg, ampicillin-resistant *H influenzae*; penicillin-resistant *S pneumoniae*; mycobacteria)

Antibiotic ineffective or causing allergic reaction

- ▶ Poor absorption of oral antibiotic
- ▶ Inadequate dose
- ▶ Antibiotic hypersensitivity
- ▶ Patient not receiving or taking prescribed antibiotic

Impaired local or systemic defences

- ▶ Local (eg, bronchiectasis, endobronchial obstruction, aspiration)
- ▶ Systemic immune deficiency (eg, HIV infection, hypogammaglobulinaemia, myeloma)

Local or distant complications of CAP

- ▶ Pulmonary
 - Parapneumonic effusion
 - Empyema
 - Lung abscess
 - Adult respiratory distress syndrome
- ▶ Extrapulmonary
 - Phlebitis at intravenous cannula site
 - Metastatic infection
 - Septicaemia
 - End organ sequelae of septicaemia (eg, renal failure)

Overwhelming infection**Improvement expected too soon**

- ▶ For example, in elderly patients

SECTION 10 PREVENTION AND VACCINATION**10.1 Influenza and pneumococcal vaccination**

The prevention of CAP, particularly in those considered at high risk of infection, is an important issue in the overall management of CAP. The Joint Committee on Vaccination and Immunisation is an independent expert advisory committee that advises the Secretaries of State of Health, Scotland, Wales and Northern Ireland on matters relating to communicable

Table 7 Some complications associated with specific infections

Pathogen	Complications
<i>S pneumoniae</i>	Septicaemia, pyopneumothorax, pericarditis/endocarditis, meningitis/brain abscess, peritonitis, arthritis, herpes labialis
<i>M pneumoniae</i>	Meningoencephalitis, aseptic meningitis, Guillain-Barré syndrome, transverse myelitis, cerebellar ataxia, ascending polyneuropathy, pericarditis, myocarditis, diarrhoea, haemolytic anaemia, skin rashes, polyarthropathy, hepatitis, pancreatitis, splenomegaly, acute glomerulonephritis, haemorrhagic myringitis
<i>Legionella</i> spp	Confusion, encephalomyelitis, Guillain-Barré syndrome, cerebellar signs, pericarditis, hyponatraemia, renal failure, rhabdomyolysis and myositis, diarrhoea, polyarthropathy
<i>C burnetii</i>	Jaundice/abnormal liver function, pancreatitis, thrombocytopenia
<i>C burnetii</i>	Optic neuritis, hepatitis, haemolytic anaemia, osteomyelitis, endocarditis with chronic infection
<i>S aureus</i>	Pneumatoceles and/or pneumothorax (especially in children), septicaemia, lung abscess, metastatic infection

disease preventable and potentially preventable through immunisation. A full review and discussion relating to the cost effectiveness of influenza and pneumococcal vaccination, including the role of the newer pneumococcal conjugate vaccines, was deemed to be outside the remit of this document.

Existing Department of Health guidelines are referred to (the Green book; see http://www.dh.gov.uk/en/PublicHealth/HealthProtection/Immunisation/Greenbook/DH_4097254).

Recommendations

- ▶ **Department of Health guidelines in relation to influenza and pneumococcal immunisation of at-risk individuals should be followed. [C]**
- ▶ **All patients aged >65 years or at risk of invasive pneumococcal disease who are admitted with CAP and who have not previously received pneumococcal vaccine should receive 23-valent pneumococcal polysaccharide vaccine (23-PPV) at convalescence in line with the Department of Health guidelines. [C]**

10.2 Smoking cessation

Cigarette smoking, both active and passive, is a recognised independent risk factor for CAP.^{498 499 [1b] [1b]} Dose-response relationships with the current number of cigarettes smoked per day, pack-years of smoking and time since quitting have been demonstrated in relation to invasive pneumococcal disease.^{500 [111]}

Recommendations

- ▶ **Smoking cessation advice should be offered to all patients with CAP who are current smokers according to smoking cessation guidelines issued by the Health Education Authority.^{501 [B+]}**

SECTION 11 COMMITTEE MEMBERSHIP AND ACKNOWLEDGEMENTS**11.1 Membership of the BTS Community Acquired Pneumonia Guidelines Committee and affiliations**

Wei Shen Lim (Chairman), Consultant Respiratory Physician, Nottingham University Hospitals; Simon Baudouin, Senior Lecturer in Critical Care Medicine, Royal Victoria Infirmary and Intensive Care Society; Robert George, Director Respiratory and Systemic Infections Department, Health Protection Agency Centre for Infections, Colindale; Adam Hill, Consultant

Respiratory Physician, Edinburgh Royal Infirmary; Conor Jamieson, Principal Pharmacist – Anti-infectives, Heart of England NHS Trust and British Society of Antimicrobial Chemotherapy; Ivan Le Jeune, Consultant in Acute Medicine, Nottingham University Hospitals and Society for Acute Medicine; John Macfarlane, Professor of Respiratory Medicine, University of Nottingham and Consultant Respiratory Physician, Nottingham University Hospitals; Robert Read, Professor in Infectious Diseases, University of Sheffield and British Infection Society; Helen Roberts, Specialist Registrar in Respiratory Medicine, Mid-Trent rotation, Nottingham University Hospitals; Mark Levy, General Practitioner, Royal College of General Practitioners and General Practice Airways Group (GPIAG); Mushtaq Wani, Health Care of the Elderly Consultant, Swansea NHS Trust and British Geriatrics Society; Mark Woodhead, Consultant Respiratory Physician, Manchester Royal Infirmary.

11.2 Authorship of sections of the guidelines

At least two clinical experts (a lead and a partner) were identified for each of the main topic areas and were responsible for the work of critically appraising the literature and preparing a main draft for the relevant section as described in section 1.8.

Section leads and partners

Incidence and mortality: H Roberts, WS Lim
 Aetiology and epidemiology: M A Woodhead, R George
 Clinical and radiological features: I Le Jeune, M Wani
 General investigations: I Le Jeune, M Wani
 Microbiological investigations: R George, W S Lim
 Severity assessment: W S Lim, H Roberts
 General management in hospital: A Hill, S Baudouin
 Critical care issues: S Baudouin, A Hill
 Antibiotic therapy: R Read, M A Woodhead, R George, J T Macfarlane
 Complications and failure to improve: H Roberts, W S Lim
 Primary care issues: M Levy, J T Macfarlane

11.3 Acknowledgements

The Guidelines Development Committee would like to thank many individuals and societies who have contributed to the development of this guideline. In particular, we thank Karen McClean, Sue Allen, Elizabeth Hendron and Natalie Middlemore for organisational, administrative and library support; Dr Richard Bendall, Dr John Bremner, Dr Graham Douglas, Professor Paul Edelstein, Professor Roger Finch, Rosalind Green, Dr Kieran Hand, Dr Elisabeth Ridgway, Dr Martin Springsklee, Dr Kate Templeton, the Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection, Joint Committee on Vaccination and Immunisation, Scottish Clinical Virology Consultants Group and the UK Clinical Virology Network for constructive advice, comments and contributions received; Lisa Stirk, Information Officer at the Centre for Reviews and Dissemination, University of York for performing the literature searches; and Sally Welham, Deputy Chief Executive, British Thoracic Society for support and advice throughout the guideline development process.

11.4 Declarations of interest

The committee members fulfilled the requirements of the BTS regarding personal declaration of interests. Declaration of interest forms were updated annually by committee members

and the contents submitted to the BTS Standards of Care Committee. These are available for inspection on request from the Chairman of this Committee.

Competing interests: None.

Provenance and peer review: Not commissioned; not externally peer reviewed.

REFERENCES

1. **Macfarlane JT**, Boswell T, Douglas G, *et al*. BTS guidelines on the management of community acquired pneumonia in adults. *Thorax* 2001;**56**(Suppl 4):1–64.
2. **British Thoracic Society Pneumonia Guidelines Committee**. BTS guidelines for the management of community acquired pneumonia in adults – 2004 update. 2004. <http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Pneumonia/Guidelines/MACAPrevisedApr04.pdf> (accessed 15 Dec 2008).
3. **Macfarlane J**. Lower respiratory tract infection and pneumonia in the community. *Semin Respir Infect* 1999;**14**:151–62.
4. **Macfarlane J**. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study. *Semin Respir Infect* 1994;**9**:153–65.
5. **Marrie TJ**, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. *Rev Infect Dis* 1989;**11**:586–99.
6. **British Thoracic Society**. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. *Q J Med* 1987;**62**:195–220.
7. **National Institute for Health and Clinical Excellence (NICE)**. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004;**51**(Suppl 1):1–232.
8. **British Thoracic Society Standards of Care Committee**. Guidelines for the management of community acquired pneumonia in childhood. *Thorax* 2002;**57**(Suppl 1).
9. **Department of Health and Health Protection Agency**. *Clostridium difficile infection. How to deal with the problem*. Best Practice Guideline. 2008.
10. **Owens RC Jr**, Donskey CJ, Gaynes RP, *et al*. Antimicrobial-associated risk factors for Clostridium difficile infection. *Clin Infect Dis* 2008;**46**(Suppl 1):S19–31.
11. **Taccconelli E**, De Angelis G, Cataldo MA, *et al*. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. *J Antimicrob Chemother* 2008;**61**:26–38.
12. **Trotter CL**, Stuart JM, George R, *et al*. Increasing hospital admissions for pneumonia, England. *Emerg Infect Dis* 2008;**14**:727–33.
13. **Woodhead M**, Welch CA, Harrison DA, *et al*. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. *Crit Care* 2006;**10**(Suppl 2):S1.
14. **Royal College of Physicians**. *Acute medical care. The right person, in the right setting – first time*. Report of the Acute Medicine Task Force. London: Royal College of Physicians, 2007.
15. **Department of Health**. *The NHS Plan: a plan for investment, a plan for reform*. London: Department of Health, 2000.
16. **Mandell LA**, Wunderink RG, Anzueto A, *et al*. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;**44**(Suppl 2):S27–72.
17. **Eccles M**, Clapp Z, Grimshaw J, *et al*. North of England evidence based guidelines development project: methods of guideline development. *BMJ* 1996;**312**:760–2.
18. **Sackett DL**. Bias in analytic research. *J Chronic Dis* 1979;**32**:51–63.
19. **Jaeschke R**, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. *JAMA* 1994;**271**:389–91.
20. **Scottish Intercollegiate Guidelines Network**. *Clinical guidelines: criteria for appraisal*. Edinburgh: Royal College of Physicians of Edinburgh, 1995.
21. **Eddy DM**. *A manual for assessing health practices and designing practice policies*. Philadelphia: American College of Physicians, 1992.
22. **Guyatt GH**, Sackett DL, Sinclair JC, *et al*. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. *JAMA* 1995;**274**:1800–4.
23. **Woodhead MA**, Macfarlane JT, McCracken JS, *et al*. Prospective study of the aetiology and outcome of pneumonia in the community. *Lancet* 1987;**1**:671–4.
24. **Jokinen C**, Heiskanen L, Juvonen H, *et al*. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. *Am J Epidemiol* 1993;**137**:977–88.
25. **Foy HM**, Cooney MK, Allan I, *et al*. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. *JAMA* 1979;**241**:253–8.
26. **Macfarlane JT**, Colville A, Guion A, *et al*. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. *Lancet* 1993;**341**:511–4.
27. **Marrie TJ**. Epidemiology of community-acquired pneumonia in the elderly. *Semin Respir Infect* 1990;**5**:260–8.
28. **Lave JR**, Fine MJ, Sankey SS, *et al*. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. *J Gen Intern Med* 1996;**11**:415–21.
29. **Marrie TJ**, Carriere KC, Jin Y, *et al*. Factors associated with death among adults <55 years of age hospitalized for community-acquired pneumonia. *Clin Infect Dis* 2003;**36**:413–21.
30. **Guest JF**, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. *Eur Respir J* 1997;**10**:1530–4.

31. **Foy HM**, Cooney MK, McMahan R, *et al*. Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period. *Am J Epidemiol* 1973;**97**:93–102.
32. **Minogue MF**, Coley CM, Fine MJ, *et al*. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. *Ann Emerg Med* 1998;**31**:376–80.
33. **Torres A**, Serra-Batles J, Ferrer A, *et al*. Severe community-acquired pneumonia. Epidemiology and prognostic factors. *Am Rev Respir Dis* 1991;**144**:312–8.
34. **Woodhead MA**, Macfarlane JT, Rodgers FG, *et al*. Aetiology and outcome of severe community-acquired pneumonia. *J Infect* 1985;**10**:204–10.
35. **White RJ**, Blainey AD, Harrison KJ, *et al*. Causes of pneumonia presenting to a district general hospital. *Thorax* 1981;**36**:566–70.
36. **Macfarlane JT**, Finch RG, Ward MJ, *et al*. Hospital study of adult community-acquired pneumonia. *Lancet* 1982;**2**:255–8.
37. **Lim WS**, Macfarlane JT, Boswell TC, *et al*. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. *Thorax* 2001;**56**:296–301.
38. **Karalus NC**, Cursons RT, Leng RA, *et al*. Community acquired pneumonia: aetiology and prognostic index evaluation. *Thorax* 1991;**46**:413–8.
39. **Lim I**, Shaw DR, Stanley DP, *et al*. A prospective hospital study of the aetiology of community-acquired pneumonia. *Med J Aust* 1989;**151**:87–91.
40. **Mortensen EM**, Kapoor WN, Chang C-CH, *et al*. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. *Clin Infect Dis* 2003;**37**:1617–24.
41. **Yende S**, Angus DC, Ali IS, *et al*. Influence of comorbid conditions on long-term mortality after pneumonia in older people. *J Am Geriatr Soc* 2007;**55**:518–25.
42. **British Thoracic Society Research Committee and Public Health Laboratory Service**. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. *Respir Med* 1992;**86**:7–13.
43. **Alkhayer M**, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. *Respir Med* 1990;**84**:13–6.
44. **Moine P**, Vercken JB, Chevret S, *et al*. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. *Chest* 1994;**105**:1487–95.
45. **Niederman MS**, McCombs JS, Unger AN, *et al*. The cost of treating community-acquired pneumonia. *Clin Ther* 1998;**20**:820–37.
46. **Gilbert K**, Gleason PP, Singer DE, *et al*. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. *Am J Med* 1998;**104**:17–27.
47. **Howard LSGE**, Sillis M, Pasteur MC, *et al*. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. *J Infect* 2005;**50**:107–13.
48. **Lagerstrom F**, Bader M, Foldevi M, *et al*. Microbiological etiology in clinically diagnosed community-acquired pneumonia in primary care in Orebro, Sweden. *Clin Microbiol Infect* 2003;**9**:645–52.
49. **Ruiz M**, Ewig S, Marcos MA, *et al*. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. *Am J Respir Crit Care Med* 1999;**160**:397–405.
50. **de Roux A**, Ewig S, Garcia E, *et al*. Mixed community-acquired pneumonia in hospitalised patients. *Eur Respir J* 2006;**27**:795–800.
51. **Gutierrez F**, Masia M, Rodriguez JC, *et al*. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. *Clin Microbiol Infect* 2005;**11**:788–800.
52. **Fernandez Alvarez R**, Suarez Toste I, Rubinos Cuadrado G, *et al*. Community-acquired pneumonia: aetiological changes in a limited geographic area. An 11-year prospective study. *Eur J Clin Microbiol Infect Dis* 2007;**26**:495–9.
53. **Arnold FW**, Summersgill JT, Lajoie AS, *et al*. A worldwide perspective of atypical pathogens in community-acquired pneumonia. *Am J Respir Crit Care Med* 2007;**175**:1086–93.
54. **Ngeow Y-F**, Suwanjutha S, Chantarojanasri T, *et al*. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. *Int J Infect Dis* 2005;**9**:144–53.
55. **Diaz A**, Barria P, Niederman M, *et al*. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. *Chest* 2007;**131**:779–87.
56. **Matute AJ**, Brouwer WP, Hak E, *et al*. Aetiology and resistance patterns of community-acquired pneumonia in Leon, Nicaragua. *Int J Antimicrob Agents* 2006;**28**:423–7.
57. **Nagalingam NA**, Adesiyun AA, Swanston WH, *et al*. Seroprevalence of Legionella pneumophila in pneumonia patients in four major hospitals in Trinidad and Tobago. *West Indian Med J* 2005;**54**:375–8.
58. **Chedid MBF**, Ilha DdO, Chedid MF, *et al*. Community-acquired pneumonia by Legionella pneumophila serogroups 1–6 in Brazil. *Respir Med* 2005;**99**:966–75.
59. **Marrie TJ**, Peeling RW, Reid T, *et al*. Chlamydia species as a cause of community-acquired pneumonia in Canada. *Eur Respir J* 2003;**21**:779–84.
60. **Valdivia L**, Nix D, Wright M, *et al*. Coccidioidomycosis as a common cause of community-acquired pneumonia [correction appears in *Emerg Infect Dis* 2006;**12**:1307]. *Emerg Infect Dis* 2006;**12**:958–62.
61. **Wattanathum A**, Chaoprasong C, Nuntaphisud P, *et al*. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. *Chest* 2003;**123**:1512–9.
62. **Bansal S**, Kashyap S, Pal LS, *et al*. Clinical and bacteriological profile of community acquired pneumonia in Shimla, Himachal Pradesh. *Indian J Chest Dis Allied Sci* 2004;**46**:17–22.
63. **Reechaipichitkul W**, Lulitanond V, Sawanyawisuth K, *et al*. Etiologies and treatment outcomes for out-patients with community-acquired pneumonia (CAP) at Srinagarind Hospital, Khon Kaen, Thailand. *Southeast Asian J Trop Med Publ Health* 2005;**36**:1261–7.
64. **Yen M-Y**, Hu B-S, Chen Y-S, *et al*. A prospective etiologic study of community-acquired pneumonia in Taiwan. *J Formosan Med Assoc* 2005;**104**:724–30.
65. **Huang HH**, Zhang YY, Xiu QY, *et al*. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. *Eur J Clin Microbiol Infect Dis* 2006;**25**:369–74.
66. **Saito A**, Kohno S, Matsushima T, *et al*. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. *J Infect Chemother* 2006;**12**:63–9.
67. **Lauderdale T-L**, Chang F-Y, Ben R-J, *et al*. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. *Respir Med* 2005;**99**:1079–86.
68. **Paganin F**, Lilienthal F, Bourdin A, *et al*. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. *Eur Respir J* 2004;**24**:779–85.
69. **Venkatesan P**, Gladman J, Macfarlane JT, *et al*. A hospital study of community acquired pneumonia in the elderly. *Thorax* 1990;**45**:254–8.
70. **Ausina V**, Coll P, Sarnate M, *et al*. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. *Eur J Clin Microbiol Infect Dis* 1988;**7**:342–7.
71. **Logroscino CD**, Penza O, Locicero S, *et al*. Community-acquired pneumonia in adults: a multicentric observational AIPO study. *Monaldi Arch Chest Dis* 1999;**54**:11–7.
72. **Leroy O**, Vandenbussche C, Coffinier C, *et al*. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. *Am J Respir Crit Care Med* 1997;**156**:1922–9.
73. **Fernandez-Sabe N**, Carratala J, Roson B, *et al*. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. *Medicine* 2003;**82**:159–69.
74. **Ostergaard L**, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. *Chest* 1993;**104**:1400–7.
75. **Torres A**, Dorca J, Zalacaín R, *et al*. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. *Am J Respir Crit Care Med* 1996;**154**:1456–61.
76. **Marrie TJ**. Bacteraemic pneumococcal pneumonia: a continuously evolving disease. *J Infect* 1992;**24**:247–55.
77. **Marrie TJ**, Durant H, Kwan C. Nursing home-acquired pneumonia. A case-control study. *J Am Geriatr Soc* 1986;**34**:697–702.
78. **Garb JL**, Brown RB, Garb JR, *et al*. Differences in etiology of pneumonias in nursing home and community patients. *JAMA* 1978;**240**:2169–72.
79. **Drinka PJ**, Gauerke C, Voeks S, *et al*. Pneumonia in a nursing home. *J Gen Intern Med* 1994;**9**:650–2.
80. **Lim WS**, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. *Eur Respir J* 2001;**18**:362–8.
81. **Carratala J**, Mykietuk A, Fernandez-Sabe N, *et al*. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. *Arch Intern Med* 2007;**167**:1393–9.
82. **Sopena N**, Sabrià-Leal M, Pedro-Botet ML, *et al*. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. *Chest* 1998;**113**:1195–200.
83. **de Roux A**, Cavalcanti M, Marcos MA, *et al*. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. *Chest* 2006;**129**:1219–25.
84. **Stout JE**, Yu VL. Legionellosis. *N Engl J Med* 1997;**337**:682–7.
85. **Mier L**, Dreyfuss D, Darchy B, *et al*. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. *Intensive Care Med* 1993;**19**:279–84.
86. **de Roux A**, Marcos MA, Garcia E, *et al*. Viral community-acquired pneumonia in nonimmunocompromised adults. *Chest* 2004;**125**:1343–51.
87. **Kim PE**, Musher DM, Glazen WP, *et al*. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. *Clin Infect Dis* 1996;**22**:100–6.
88. **Mercat A**, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. *Chest* 1991;**99**:147–51.
89. **Naik FC**, Ricketts KD, Harrison TG, *et al*. Legionnaires' disease in England and Wales (1995–2005). Health Protection Report 2008. 2008.
90. **Newton LH**, Joseph CA, Hutchinson EJ, *et al*. Legionnaires' disease surveillance: England and Wales, 1995. *Commun Dis Rep CDR Rev* 1996;**6**:R151–5.
91. **Joseph CA**, Harrison TG, Ilijic-Car D, *et al*. Legionnaires' disease in residents of England and Wales: 1998. *Commun Dis Public Health* 1999;**2**:280–4.
92. **Joseph CA**, Harrison TG, Ilijic-Car D, *et al*. Legionnaires' disease in residents of England and Wales: 1996. *Commun Dis Rep CDR Rev* 1997;**7**:R153–9.
93. **Saikkku P**, Wang SP, Kleemola M, *et al*. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. *J Infect Dis* 1985;**151**:832–9.
94. **Kleemola M**, Saikkku P, Visakorpi R, *et al*. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. *J Infect Dis* 1988;**157**:230–6.
95. **Troy CJ**, Peeling RW, Ellis AG, *et al*. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. *JAMA* 1997;**277**:1214–8.
96. **Wellinghausen N**, Straube E, Freidank H, *et al*. Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. *Int J Med Microbiol* 2006;**296**:485–91.

97. **Steinhardt D**, Lode H, Ruckdeschel G, *et al*. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. *Clin Infect Dis* 1996;**22**:958–64.
98. **Lieberman D**, Ben-Yaakov M, Lazarovich Z, *et al*. Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. *Infection* 1996;**24**:109–14.
99. **Kauppinen MT**, Saikku P, Kujala P, *et al*. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. *Thorax* 1996;**51**:185–9.
100. **Wreghitt T**. Chlamydial infection of the respiratory tract. *Commun Dis Rep CDR Rev* 1993;**3**:R119–24.
101. **Pebody RG**, Wall PG, Ryan MJ, *et al*. Epidemiological features of Coxiella burnetii infection in England and Wales: 1984 to 1994. *Commun Dis Rep CDR Rev* 1996;**6**:R128–32.
102. **McNabb WR**, Shanson DC, Williams TD, *et al*. Adult community-acquired pneumonia in central London. *J R Soc Med* 1984;**77**:550–5.
103. **Hirani NA**, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. *Thorax* 1997;**52**:17–21.
104. **Rotas M**, McCalla S, Liu C, *et al*. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. *Obstet Gynecol* 2007;**109**:533–6.
105. **Asnis D**, Haralambou G, Tawiah P, *et al*. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. *Obstet Gynecol* 2007;**110**:188.
106. **Garnier F**, Tristan A, Francois B, *et al*. Pneumonia and new methicillin-resistant Staphylococcus aureus clone. *Emerg Infect Dis* 2006;**12**:498–500.
107. **Nimmo GR**, Playford EG. Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia. *Med J Aust* 2003;**178**:245.
108. **Peleg AY**, Munchhof WJ. Fatal necrotizing pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (MRSA). *Med J Aust* 2004;**181**:228–9.
109. **Risson DC**, O'Connor ED, Guard RW, *et al*. A fatal case of necrotizing pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. *Med J Aust* 2007;**186**:479–80.
110. **Vayalunkal JV**, Whittingham H, Vanderkooi O, *et al*. Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments. *CJEM Can J Emerg Med Care* 2007;**9**:300–3.
111. **Monaco M**, Antonucci R, Palange P, *et al*. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. *Emerg Infect Dis* 2005;**11**:1647–8.
112. **Torelli E**, Molin D, Tano E, *et al*. Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). *Scand J Infect Dis* 2005;**37**:902–4.
113. **Soderquist B**, Berglund C, Stralin K. Community-acquired pneumonia and bacteremia caused by an unusual methicillin-resistant Staphylococcus aureus (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. *Eur J Clin Microbiol Infect Dis* 2006;**25**:604–6.
114. **Magira EE**, Zervakis D, Routsis C, *et al*. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: a lethal cause of pneumonia in an adult immunocompetent patient. *Scand J Infect Dis* 2007;**39**:466–9.
115. **Klein JL**, Petrovic Z, Treacher D, *et al*. Severe community-acquired pneumonia caused by Panton-Valentine leukocidin-positive Staphylococcus aureus: first reported case in the United Kingdom. *Intensive Care Med* 2003;**29**:1399.
116. **Honarpour N**, Mao JT. A Case of fatal community-acquired necrotizing pneumonia caused by panton-valentine leukocidin positive methicillin-sensitive Staphylococcus aureus. *Curr Respir Med Rev* 2007;**3**:49–51.
117. **Beilouny B**, Ciupea A, Eloy C, *et al*. Fatal community-acquired pneumonia due to Staphylococcus aureus carrying Panton-Valentine leukocidin genes after a stay in Africa. *Intensive Care Med* 2008;**34**:388–9.
118. **Baldwin LN**, Lowe AD. Panton-Valentine Leukocidin associated with community acquired methicillin resistant Staphylococcus aureus: a case report and review of interim guidelines. *Anaesthesia* 2008;**63**:764–6.
119. **Francis JS**, Doherty MC, Lopatin U, *et al*. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. *Clin Infect Dis* 2005;**40**:100–7.
120. **Hageman JC**, Uyeke TM, Francis JS, *et al*. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. *Emerg Infect Dis* 2006;**12**:894–9.
121. **Chua AP**, Lee KH. Fatal bacteraemic pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus. *Singapore Med J* 2006;**47**:546–8.
122. **Anon**. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza – Louisiana and Georgia, December 2006–January 2007. *MMWR – Morbidity & Mortality Weekly Report* 2007;**56**:325–9.
123. **Hyvernat H**, Pulcini C, Carles D, *et al*. Fatal Staphylococcus aureus haemorrhagic pneumonia producing Panton-Valentine leukocidin. *Scand J Infect Dis* 2007;**39**:183–5.
124. **Balis E**, Diacaki C, Tselioti P, *et al*. Community-acquired pneumonia and bacteraemia due to methicillin-resistant Staphylococcus aureus carrying Panton-Valentine-leukocidin gene in Greece: two case reports and literature review. *J Chemother* 2007;**19**:703–8.
125. **Hutchinson EJ**, Joseph CA, Zambon M, *et al*. Influenza surveillance in England and Wales: October 1995 to June 1996. *Commun Dis Rep CDR Rev* 1996;**6**:R163–9.
126. **Connolly AM**, Salmon RL, Lervy B, *et al*. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. *BMJ* 1993;**306**:1452–4.
127. **Farr BM**, Kaiser DL, Harrison BD, *et al*. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. *Thorax* 1989;**44**:1031–5.
128. **Fang GD**, Fine M, Orloff J, *et al*. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. *Medicine (Baltimore)* 1990;**69**:307–16.
129. **Riquelme R**, Torres A, El-Ebiary M, *et al*. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. *Am J Respir Crit Care Med* 1996;**154**:1450–5.
130. **Bohte R**, Hermans J, van den Broek PJ. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1996;**15**:201–5.
131. **Helms CM**, Wintermeyer LA, Zeidler RR, *et al*. An outbreak of community-acquired Legionnaires' disease pneumonia. *Am J Public Health* 1984;**74**:835–6.
132. **Granados A**, Podzamczar D, Gudiol F, *et al*. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: similarities and differences on presentation. *Eur Respir J* 1989;**2**:130–4.
133. **Fernandez-Sabe N**, Roson B, Carratala J, *et al*. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. *Clin Infect Dis* 2003;**37**:483–9.
134. **Lieberman D**, Porath A, Schlaeffer F, *et al*. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. *Chest* 1996;**109**:1243–9.
135. **Falcó V**, Fernández de Sevilla T, Alegre J, *et al*. Legionella pneumophila. A cause of severe community-acquired pneumonia. *Chest* 1991;**100**:1007–11.
136. **Helms CM**, Viner JP, Sturm RH, *et al*. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. *Ann Intern Med* 1979;**90**:543–7.
137. **Marrie TJ**. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. *Arch Intern Med* 1993;**153**:488–94.
138. **Puljiz I**, Kuzman I, Dakovic-Rode O, *et al*. Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles. *Epidemiol Infect* 2006;**134**:548–55.
139. **File TM Jr**, Plouffe JF Jr, Breiman RF, *et al*. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. *Clin Infect Dis* 1999;**29**:426–8.
140. **Lieberman D**, Boldur I, Manor E, *et al*. Q-fever pneumonia in the Negev region of Israel: a review of 20 patients hospitalised over a period of one year. *J Infect* 1995;**30**:135–40.
141. **Goyette M**, Bouchard J, Poirier A, *et al*. Importance of Q fever in community acquired pneumonia. *Can J Infect Dis* 1996;**7**:370–3.
142. **Sobradillo V**, Ansola P, Baranda F, *et al*. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. *Eur Respir J* 1989;**2**:263–6.
143. **Caron F**, Meurice JC, Ingrand P, *et al*. Acute Q fever pneumonia: a review of 80 hospitalized patients. *Chest* 1998;**114**:808–13.
144. **Feldman C**, Kallenbach JM, Levy H, *et al*. Comparison of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit. *Respiration* 1991;**58**:265–70.
145. **Rudin ML**, Michael JR, Huxley EJ. Community-acquired acinetobacter pneumonia. *Am J Med* 1979;**67**:39–43.
146. **Henderson A**, Wall D. Streptococcus milleri liver abscess presenting as fulminant pneumonia. *Aust N Z J Surg* 1993;**63**:237–40.
147. **Goolam MA**, Feldman C, Smith C, *et al*. Does primary Streptococcus viridans pneumonia exist? *S Afr Med J* 1992;**82**:432–4.
148. **Marrie TJ**. Pneumonia in the elderly. *Curr Opin Pulm Med* 1996;**2**:192–7.
149. **Metlay JP**, Schulz R, Li YH, *et al*. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. *Arch Intern Med* 1997;**157**:1453–9.
150. **Riquelme R**, Torres A, el-Ebiary M, *et al*. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. *Am J Respir Crit Care Med* 1997;**156**:1908–14.
151. **Marrie TJ**, Haldane EV, Faulkner RS, *et al*. Community-acquired pneumonia requiring hospitalization. Is it different in the elderly? *J Am Geriatr Soc* 1985;**33**:671–80.
152. **Kikuchi R**, Watabe N, Konno T, *et al*. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. *Am J Respir Crit Care Med* 1994;**150**:251–3.
153. **Marrie TJ**, Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. *J Am Geriatr Soc* 1997;**45**:50–5.
154. **Reza Shariatzadeh M**, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. *J Am Geriatr Soc* 2006;**54**:296–302.
155. **Bartlett JG**, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. *Am J Med* 1974;**56**:202–7.
156. **Marik PE**, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. *Chest* 1999;**115**:178–83.
157. **El-Solh AA**, Pietrantonio C, Bhat A, *et al*. Microbiology of severe aspiration pneumonia in institutionalized elderly. *Am J Respir Crit Care Med* 2003;**167**:1650–4.
158. **Ott SR**, Allewelt M, Lorenz J, *et al*. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. *Infection* 2008;**36**:23–30.

159. **Metlay JP**, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. *JAMA* 1997;**278**:1440–5.
160. **Metlay JP**, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. *Ann Intern Med* 2003;**138**:109–18.
161. **Spiteri MA**, Cook DG, Clarke SW. Reliability of eliciting physical signs in examination of the chest. *Lancet* 1988;**1**:873–5.
162. **Melbye H**, Straume B, Aasebø U, et al. The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests. *Scand J Prim Health Care* 1988;**6**:111–7.
163. **Diehr P**, Wood RW, Bushyhead J, et al. Prediction of pneumonia in outpatients with acute cough—a statistical approach. *J Chronic Dis* 1984;**37**:215–25.
164. **O'Brien WT Sr**, Rohweder DA, Lattin GE Jr, et al. Clinical indicators of radiographic findings in patients with suspected community-acquired pneumonia: who needs a chest x-ray? [correction appears in *J Am Coll Radiol* 2006;**3**:A4]. *J Am Coll Radiol* 2006;**3**:703–6.
165. **Macfarlane J**, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. *Thorax* 2001;**56**:109–14.
166. **Macfarlane JT**, Miller AC, Roderick Smith WH, et al. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumoniae, and psittacosis. *Thorax* 1984;**39**:28–33.
167. **Kauppinen MT**, Lähde S, Syrjälä H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcal pneumonia. *Arch Intern Med* 1996;**156**:1851–6.
168. **Gikas A**, Kofteridis D, Bouros D, et al. Q fever pneumonia: appearance on chest radiographs. *Radiology* 1999;**210**:339–43.
169. **Marrie TJ**, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. *Am J Med* 1996;**101**:508–15.
170. **Macfarlane J**, Rose D. Radiographic features of staphylococcal pneumonia in adults and children. *Thorax* 1996;**51**:539–40.
171. **Korvick JA**, Hackett AK, Yu VL, et al. Klebsiella pneumoniae in the modern era: clinicoradiographic correlations. *South Med J* 1991;**84**:200–4.
172. **Syrjälä H**, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. *Clin Infect Dis* 1998;**27**:358–63.
173. **Reitner P**, Müller NL, Heyneman L, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. *AJR Am J Roentgenol* 2000;**174**:37–41.
174. **Beall DP**, Scott WW Jr, Kuhlman JE, et al. Utilization of computed tomography in patients hospitalized with community-acquired pneumonia. *Md Med J* 1998;**47**:182–7.
175. **Tanaka N**, Matsumoto T, Kuramitsu T, et al. High resolution CT findings in community-acquired pneumonia. *J Comput Assist Tomogr* 1996;**20**:600–8.
176. **Mittl RL Jr**, Schwab RJ, Duchin JS, et al. Radiographic resolution of community-acquired pneumonia. *Am J Respir Crit Care Med* 1994;**149**(Pt 1):630–5.
177. **El Solh AA**, Aquilina AT, Gunen H, et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. *J Am Geriatr Soc* 2004;**52**:224–9.
178. **Bruns AHW**, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. *Clin Infect Dis* 2007;**45**:983–91.
179. **Jay SJ**, Johanson WG Jr, Pierce AK. The radiographic resolution of Streptococcus pneumoniae pneumonia. *N Engl J Med* 1975;**293**:798–801.
180. **Granet KM**, Wallach SL, Horvath K, et al. Chest radiographs in patients with community-acquired pneumonia. *N J Med* 1996;**93**:37–41.
181. **Holmberg H**, Kraggsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up. *Scand J Infect Dis* 1993;**25**:93–100.
182. **Gibson SP**, Weir DC, Burge PS. A prospective audit of the value of fibre optic bronchoscopy in adults admitted with community acquired pneumonia. *Respir Med* 1993;**87**:105–9.
183. **British Thoracic Society**. BTS guideline for emergency oxygen use in adult patients. *Thorax* 2008;**63**(Suppl 6):vi1–68.
184. **Holmberg H**, Bodin L, Jönsson I, et al. Rapid aetiological diagnosis of pneumonia based on routine laboratory features. *Scand J Infect Dis* 1990;**22**:537–45.
185. **Castro-Guardiola A**, Armengou-Arxe A, Viejo-Rodriguez A, et al. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. *Eur J Intern Med* 2000;**11**:334–9.
186. **Smith RP**, Lipworth BJ, Cree IA, et al. C-reactive protein. A clinical marker in community-acquired pneumonia. *Chest* 1995;**108**:1288–91.
187. **Hansson LO**, Hedlund JU, Orqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. *Scand J Clin Lab Invest* 1997;**57**:111–8.
188. **Flanders SA**, Stein J, Shochat G, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. *Am J Med* 2004;**116**:529–35.
189. **Orqvist A**, Hedlund J, Vretling B, et al. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. *Scand J Infect Dis* 1995;**27**:457–62.
190. **Garcia Vazquez E**, Martínez JA, Mensa J, et al. C-reactive protein levels in community-acquired pneumonia. *Eur Respir J* 2003;**21**:702–5.
191. **Sanyal S**, Smith PR, Saha AC, et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. *Am J Respir Crit Care Med* 1999;**160**:346–8.
192. **Menéndez R**, Córdoba J, de La Cuadra P, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. *Am J Respir Crit Care Med* 1999;**159**:1868–73.
193. **Ewig S**, Bauer T, Hasper E, et al. Value of routine microbial investigation in community-acquired pneumonia. *Can J Infect Dis* 1996;**63**:169.
194. **Woodhead MA**, Arrowsmith J, Chamberlain-Webber R, et al. The value of routine microbial investigation in community-acquired pneumonia. *Respir Med* 1991;**85**:313–7.
195. **van der Eerden MM**, Vlaspolter F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 2005;**24**:241–9.
196. **Hohenthal U**, Vainionpää R, Meurman O, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. *Scand J Infect Dis* 2008;**40**:131–8.
197. **Templeton KE**, Scheltinga SA, van den Eeden WCJFM, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. *Clin Infect Dis* 2005;**41**:345–51.
198. **Theerthakarai R**, El-Halees W, Ismail M, et al. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. *Chest* 2001;**119**:181–4.
199. **Ewig S**, Schlochtermeier M, Goke N, et al. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. *Chest* 2002;**121**:1486–92.
200. **Waterer GW**, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. *Respir Med* 2001;**95**:78–82.
201. **Campbell SG**, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. *Chest* 2003;**123**:1142–50.
202. **Woodhead M**, Macfarlane J. Local antibiotic guidelines for adult community-acquired pneumonia (CAP): a survey of UK hospital practice in 1999. *J Antimicrob Chemother* 2000;**46**:141–3.
203. **Chambers DC**, Waterer GW. Are blood cultures necessary in community-acquired pneumonia? *Clin Pulmon Med* 2005;**12**:146–52.
204. **Benenson RS**, Kepner AM, Pyle DN 2nd, et al. Selective use of blood cultures in emergency department pneumonia patients. *J Emerg Med* 2007;**33**:1–8.
205. **Ramanujam P**, Rathlev NK. Blood cultures do not change management in hospitalized patients with community-acquired pneumonia. *Acad Emerg Med* 2006;**13**:740–5.
206. **Corbo J**, Friedman B, Bijur P, et al. Limited usefulness of initial blood cultures in community acquired pneumonia. *Emerg Med J* 2004;**21**:446–8.
207. **Bartlett JG**, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. *Clin Infect Dis* 2000;**31**:347–82.
208. **Taylor EL**, Marrie TJ, Fine MJ, et al. Observations from a multicentre study on the use of the sputum specimen in patients hospitalized with community-acquired pneumonia. *Can J Infect Dis* 1999;**10**:39–46.
209. **Reed WW**, Byrd GS, Gates RH Jr, et al. Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis. *West J Med* 1996;**165**:197–204.
210. **Rein MF**, Gwaltney JM Jr, O'Brien WM, et al. Accuracy of Gram's stain in identifying pneumococci in sputum. *JAMA* 1978;**239**:2671–3.
211. **Garcia-Vazquez E**, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. *Arch Intern Med* 2004;**164**:1807–11.
212. **Miyashita N**, Shimizu H, Ouchi K, et al. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. *Med Sci Monit* 2008;**14**:CR171–6.
213. **Fine MJ**, Orloff JJ, Rihs JD, et al. Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. *J Gen Intern Med* 1991;**6**:189–98.
214. **Croce MA**, Fabian TC, Waddle-Smith L, et al. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: a prospective study. *Ann Surg* 1998;**227**:743–55.
215. **Roberts ME**, Macfarlane JT, George RC, et al. Microbiology investigations in community acquired pneumonia—most laboratories in England and Wales do not offer all those recommended in the British Thoracic Society guideline. *J Infect* 2008;**56**:291–4.
216. **Venkatesan P**, Macfarlane JT. Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia. *Thorax* 1992;**47**:329–31.
217. **Murdoch DR**, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. *J Clin Microbiol* 2001;**39**:3495–8.
218. **Andreo F**, Dominguez J, Ruiz J, et al. Impact of rapid urine antigen tests to determine the etiology of community-acquired pneumonia in adults. *Respiratory Medicine* 2006;**100**:884–91.
219. **Briones ML**, Blanquer J, Ferrando D, et al. Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. *Clin Vaccine Immunol* 2006;**13**:1092–7.
220. **Gutierrez F**, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. *Clin Infect Dis* 2003;**36**:286–92.

221. **Kobashi Y**, Yoshida K, Miyashita N, *et al*. Evaluating the use of a Streptococcus pneumoniae urinary antigen detection kit for the management of community-acquired pneumonia in Japan. *Respiration* 2007;**74**:387–93.
222. **Lasocki S**, Scavnic A, Le Turdu F, *et al*. Evaluation of the Binax NOW Streptococcus pneumoniae urinary antigen assay in intensive care patients hospitalized for pneumonia. *Intensive Care Med* 2006;**32**:1766–72.
223. **Smith MD**, Derrington P, Evans R, *et al*. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. *J Clin Microbiol* 2003;**41**:2810–3.
224. **Porcel JM**, Ruiz-Gonzalez A, Falguera M, *et al*. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. *Chest* 2007;**131**:1442–7.
225. **Sheppard CL**, Harrison TG, Kearns AM, *et al*. Diagnosis of invasive pneumococcal infection by PCR amplification of Streptococcus pneumoniae genomic fragments in blood: a multi-centre comparative study. *Commun Dis Public Health* 2003;**6**:221–7.
226. **Murdoch DR**, Anderson TP, Beynon KA, *et al*. Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. *J Clin Microbiol* 2003;**41**:63–6.
227. **Birtles RJ**, Harrison TG, Samuel D, *et al*. Evaluation of urinary antigen ELISA for diagnosing Legionella pneumophila serogroup 1 infection. *J Clin Pathol* 1990;**43**:685–90.
228. **Lettinga KD**, Verbon A, Weverling GJ, *et al*. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. *Emerg Infect Dis* 2002;**8**:1448–54.
229. **Helbig JH**, Uldom So A, Bernander S, *et al*. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial Legionnaires' disease. *J Clin Microbiol* 2003;**41**:838–40.
230. **Boswell TC**, Marshall LE, Kudesia G. False-positive legionella titres in routine clinical serology testing detected by absorption with campylobacter: implications for the serological diagnosis of legionnaires' disease. *J Infect* 1996;**32**:23–6.
231. **Medical Devices Agency**. *Mycoplasma pneumoniae antibody assays*. Medical Devices Agency Evaluation Report MDA/98/62, 1998.
232. **Beersma MF**, Dirven K, van Dam AP, *et al*. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". *J Clin Microbiol* 2005;**43**:2277–85.
233. **Daxboeck F**, Khanakah G, Bauer C, *et al*. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumoniae by PCR [correction appears in *Int J Med Microbiol* 2006;296:55]. *Int J Med Microbiol* 2005;**295**:279–85.
234. **Sillis M**, White P, Caul EO, *et al*. The differentiation of Chlamydia species by antigen detection in sputum specimens from patients with community-acquired acute respiratory infections. *J Infect* 1992;**25**(Suppl 1):77–86.
235. **Garnett P**, Brogan O, Lafong C, *et al*. Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence. *J Clin Pathol* 1998;**51**:309–11.
236. **Boman J**, Allard A, Persson K, *et al*. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. *J Infect Dis* 1997;**175**:1523–6.
237. **Sillis M**, Wreghitt TG, Paul ID, *et al*. Chlamydial respiratory infections. Don't get bogged down by differentiating species. *BMJ* 1993;**307**:62–3.
238. **Kutlin A**, Tsumura N, Emre U, *et al*. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. *Clin Diagn Lab Immunol* 1997;**4**:213–6.
239. **Ewig S**, Ruiz M, Mensa J, *et al*. Severe community-acquired pneumonia. Assessment of severity criteria. *Am J Respir Crit Care Med* 1998;**158**:1102–8.
240. **Meyer RJ**, Town GI, Harrè E, *et al*. An audit of the assessment and management of adults admitted to Christchurch Hospital with community acquired pneumonia. *NZ Med J* 1997;**110**:349–52.
241. **Neill AM**, Martin IR, Weir R, *et al*. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. *Thorax* 1996;**51**:1010–6.
242. **Farr BM**, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. *Ann Intern Med* 1991;**115**:428–36.
243. **Fine MJ**, Smith MA, Carson CA, *et al*. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA* 1996;**275**:134–41.
244. **Fine MJ**, Singer DE, Hanusa BH, *et al*. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. *Am J Med* 1993;**94**:153–9.
245. **Hedlund J**, Kalin M, Ortvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. *Scand J Infect Dis* 1997;**29**:387–92.
246. **Conte HA**, Chen YT, Mehal W, *et al*. A prognostic rule for elderly patients admitted with community-acquired pneumonia. *Am J Med* 1999;**106**:20–8.
247. **Kothe H**, Bauer T, Marre R, *et al*. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. *Eur Respir J* 2008;**32**:139–46.
248. **Fine MJ**, Hanusa BH, Lave JR, *et al*. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. *J Gen Intern Med* 1995;**10**:359–68.
249. **Pachon J**, Prados MD, Capote F, *et al*. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. *Am Rev Respir Dis* 1990;**142**:369–73.
250. **Leroy O**, Santré C, Beuscart C, *et al*. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. *Intensive Care Med* 1995;**21**:24–31.
251. **Fine MJ**, Auble TE, Yealy DM, *et al*. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;**336**:243–50.
252. **Ortvist A**, Hedlund J, Grillner L, *et al*. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. *Eur Respir J* 1990;**3**:1105–13.
253. **Garcia-Ordóñez MA**, Garcia-Jimenez JM, Paez F, *et al*. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 2001;**20**:14–9.
254. **van Eeden SF**, Coetzee AR, Joubert JR. Community-acquired pneumonia—factors influencing intensive care admission. *S Afr Med J* 1988;**73**:77–81.
255. **Lim WS**, van der Eerden MM, Laing R, *et al*. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;**58**:377–82.
256. **Gómez J**, Baños V, Ruiz Gómez J, *et al*. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1996;**15**:556–60.
257. **Chalmers JD**, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. *Am J Med* 2008;**121**:219–25.
258. **Leroy O**, Georges H, Beuscart C, *et al*. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. *Intensive Care Med* 1996;**22**:1307–14.
259. **Hasley PB**, Albaum MN, Li YH, *et al*. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? *Arch Intern Med* 1996;**156**:2206–12.
260. **Feldman C**, Kallenbach JM, Levy H, *et al*. Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a "severity of illness" core. *Intensive Care Med* 1989;**15**:302–7.
261. **Hedlund J**, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. *Infection* 2000;**28**:68–73.
262. **Masia M**, Gutierrez F, Shum C, *et al*. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients' outcome research team pneumonia severity index. *Chest* 2005;**128**:2223–9.
263. **Boussekey N**, Leroy O, Alfandari S, *et al*. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. *Intensive Care Med* 2006;**32**:469–72.
264. **Kruger S**, Ewig S, Marre R, *et al*. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. *Eur Respir J* 2008;**31**:349–55.
265. **Boussekey N**, Leroy O, Georges H, *et al*. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. *Infection* 2005;**33**:257–63.
266. **Tejera A**, Santolaria F, Diez ML, *et al*. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. *Cytokine* 2007;**38**:117–23.
267. **Aalto H**, Takala A, Kautiainen H, *et al*. Monocyte CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection. *Scand J Infect Dis* 2007;**39**:596–603.
268. **Christ-Crain M**, Morgenthaler NG, Stolz D, *et al*. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. *Crit Care* 2006;**10**:R96.
269. **Coelho L**, Povoas P, Almeida E, *et al*. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. *Crit Care* 2007;**11**(28).
270. **Kruger S**, Papassotiropoulos J, Marre R, *et al*. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. *Intensive Care Med* 2007;**33**:2069–78.
271. **Prat C**, Lacombe A, Dominguez J, *et al*. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. *J Infect* 2007;**55**:400–7.
272. **Brunkhorst FM**, Al-Nawas B, Krummenauer F, *et al*. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. *Clin Microbiol Infect* 2002;**8**:93–100.
273. **Shilon Y**, Shitrit AB-G, Rudensky B, *et al*. A rapid quantitative D-dimer assay at admission correlates with the severity of community acquired pneumonia. *Blood Coagul Fibrinolysis* 2003;**14**:745–8.
274. **Querol-Ribelles JM**, Tenias JM, Grau E, *et al*. Plasma D-dimer levels correlate with outcomes in patients with community-acquired pneumonia. *Chest* 2004;**126**:1087–92.
275. **Tapson VF**. Risk factors in community-acquired pneumonia: can they be quantified? *Eur Respir Rev* 1998;**8**:291–4.
276. **Niederman MS**, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds [comment]. *Eur Respir J* 2006;**27**:9–11.
277. **Gleason PP**, Kapoor WN, Stone RA, *et al*. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. *JAMA* 1997;**278**:32–9.
278. **Marras TK**, Chan CK. Use of guidelines in treating community-acquired pneumonia. *Chest* 1998;**113**:1689–94.
279. **Atlas SJ**, Benzer TI, Borowsky LH, *et al*. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. *Arch Intern Med* 1998;**158**:1350–6.
280. **Yealy DM**, Auble TE, Stone RA, *et al*. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. *Ann Intern Med* 2005;**143**:881–94.

281. **Renaud B**, Coma E, Labarere J, *et al*. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. *Clin Infect Dis* 2007;**44**:41–9.
282. **Richeldi L**, De Guglielmo M, Fabbri LM, *et al*. Management of CAP using a validated risk score. *Thorax* 2005;**60**:172–3.
283. **Barlow G**, Nathwani D, Williams F, *et al*. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis. *Thorax* 2007;**62**:67–74.
284. **Tang CM**, Macfarlane JT. Early management of younger adults dying of community acquired pneumonia. *Respir Med* 1993;**87**:289–94.
285. **Gladman J**, Barer D, Venkatesan P, *et al*. Outcome of pneumonia in the elderly: a hospital survey. *Clin Rehab* 1991;**5**:201–5.
286. **Capelastegui A**, Espana PP, Quintana JM, *et al*. Validation of a predictive rule for the management of community-acquired pneumonia. *Eur Respir J* 2006;**27**:151–7.
287. **Myint PK**, Kamath AV, Vowler SL, *et al*. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts. *Age Ageing* 2006;**35**:286–91.
288. **Aujesky D**, Auble TE, Yealy DM, *et al*. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. *Am J Med* 2005;**118**:384–92.
289. **Barlow G**, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. *Thorax* 2007;**62**:253–9.
290. **Spindler C**, Ortvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. *Eur Respir J* 2006;**28**:816–23.
291. **Buising KL**, Thursky KA, Black JF, *et al*. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. *Thorax* 2006;**61**:419–24.
292. **Shindo Y**, Sato S, Maruyama E, *et al*. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. *Respirology* 2008;**13**:731–5.
293. **Loh L-C**. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS “curb” index to assess severity. *Med J Malaysia* 2006;**61**:128–30.
294. **Espana PP**, Capelastegui A, Gorordo I, *et al*. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. *Am J Respir Crit Care Med* 2006;**174**:1249–56.
295. **Ananda-Rajah MR**, Charles PG, Melvani S, *et al*. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. *Scand J Infect Dis* 2008;**40**:293–300.
296. **Bauer TT**, Ewig S, Marre R, *et al*. CRB-65 predicts death from community-acquired pneumonia. *J Intern Med* 2006;**260**:93–101.
297. **Schaaf B**, Kruse J, Rupp J, *et al*. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. *Eur Respir J* 2007;**30**:517–24.
298. **Man SY**, Lee N, Ip M, *et al*. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. *Thorax* 2007;**62**:348–53.
299. **Bont J**, Hak E, Hoes AW, *et al*. A prediction rule for elderly primary-care patients with lower respiratory tract infections. *Eur Respir J* 2007;**29**:969–75.
300. **Myint PK**, Kamath AV, Vowler SL, *et al*. Simple modification of CURB-65 better identifies patients including the elderly with severe CAP. *Thorax* 2007;**62**:1015–6.
301. **Ewig S**, de Roux A, Bauer T, *et al*. Validation of predictive rules and indices of severity for community acquired pneumonia. *Thorax* 2004;**59**:421–7.
302. **Buising KL**, Thursky KA, Black JF, *et al*. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. *Emerg Med Australas* 2007;**19**:418–426.
303. **Charles PG**, Wolfe R, Whitby M, *et al*. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. *Clin Infect Dis* 2008;**47**:375–84.
304. **Leroy O**, Devos P, Guery B, *et al*. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. *Chest* 1999;**116**:157–65.
305. **Farr BM**, Woodhead MA, Macfarlane JT, *et al*. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. *Respir Med* 2000;**94**:422–7.
306. **Tydemann DE**, Chandler AR, Graveling BM, *et al*. An investigation into the effects of exercise tolerance training on patients with chronic airways obstruction. *Physiotherapy* 1984;**70**:261–4.
307. **LaCroix AZ**, Lipson S, Miles TP, *et al*. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. *Public Health Rep* 1989;**104**:350–60.
308. **Levin KP**, Hanusa BH, Rotondi A, *et al*. Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. *J Gen Intern Med* 2001;**16**:590–8.
309. **Fulmer JD**, Snider GL. American College of Chest Physicians/National Heart, Lung, and Blood Institute National Conference on Oxygen Therapy. *Heart Lung* 1984;**13**:550–62.
310. **Marrie TJ**, Lau CY, Wheeler SL, *et al*. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. *JAMA* 2000;**283**:749–55.
311. **Scottish Intercollegiate Guideline Network**. Prophylaxis of venous thromboembolism. 2002. <http://www.sign.ac.uk/guidelines/fulltext/62/index.html>.
312. **Mismetti P**, Laporte-Simitsidis S, Tardy B, *et al*. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. *Thromb Haemost* 2000;**83**:14–9.
313. **NHS Lothian**. *NHS Lothian Antithrombotic Guide*. 2006.
314. **Mundy LM**, Leet TL, Darst K, *et al*. Early mobilization of patients hospitalized with community-acquired pneumonia. *Chest* 2003;**124**:883–9.
315. **Tydemann DE**. An investigation into the effectiveness of physiotherapy in the treatment of patients with community acquired pneumonia. *Physio Pract* 1989;**5**:75–8.
316. **Björkqvist M**, Wiberg B, Bodin L, *et al*. Bottle-blowing in hospital-treated patients with community-acquired pneumonia. *Scand J Infect Dis* 1997;**29**:77–82.
317. **National Institute for Health and Clinical Excellence (NICE)**. *Acutely ill patients in hospital*. Clinical Guideline 50. July 2007.
318. **Menendez R**, Cavalcanti M, Reyes S, *et al*. Markers of treatment failure in hospitalised community acquired pneumonia. *Thorax* 2008;**63**:447–52.
319. **Halm EA**, Fine MJ, Kapoor WN, *et al*. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. *Arch Intern Med* 2002;**162**:1278–84.
320. **Dagan E**, Novack V, Porath A. Adverse outcomes in patients with community acquired pneumonia discharged with clinical instability from Internal Medicine Department. *Scand J Infect Dis* 2006;**38**:860–6.
321. **Bone RC**, Balk RA, Cerra FB, *et al*. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992;**101**:1644–55.
322. **Demoule A**, Girou E, Richard J-C, *et al*. Benefits and risks of success or failure of noninvasive ventilation. *Intensive Care Med* 2006;**32**:1756–65.
323. **Sinuff T**, Cook DJ. Health technology assessment in the ICU: noninvasive positive pressure ventilation for acute respiratory failure. *J Crit Care* 2003;**18**:59–67.
324. **Keenan SP**, Sinuff T, Cook DJ, *et al*. Does noninvasive positive pressure ventilation improve outcome in acute hypoxemic respiratory failure? A systematic review. *Crit Care Med* 2004;**32**:2516–23.
325. **Confalonieri M**, Potena A, Carbone G, *et al*. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. *Am J Respir Crit Care Med* 1999;**160**:1585–91.
326. **Delclaux C**, L’Her E, Alberti C, *et al*. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: a randomized controlled trial. *JAMA* 2000;**284**:2352–60.
327. **Bernard GR**, Vincent JL, Laterre PF, *et al*. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001;**344**:699–709.
328. **Laterre P-F**, Garber G, Levy H, *et al*. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. *Crit Care Med* 2005;**33**:952–61.
329. **Marti-Carvajal A**, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. *Cochrane Database Syst Rev* 2008;(1):CD004388.
330. **Confalonieri M**, Urbino R, Potena A, *et al*. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. *Am J Respir Crit Care Med* 2005;**171**:242–8.
331. **Gorman SK**, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. *Ann Pharmacother* 2007;**41**:1233–7.
332. **Sprung CL**, Annane D, Keh D, *et al*. Hydrocortisone therapy for patients with septic shock. *N Engl J Med* 2008;**358**:111–24.
333. **Cheng AC**, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. *Cochrane Database Syst Rev* 2007;(2):CD004400.
334. **Leroy O**, Guille J, Georges H, *et al*. Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia. *J Crit Care* 1999;**14**:12–9.
335. **Caine M**, Lim WS, Macfarlane JT, *et al*. Keeping patients informed about their illness: community acquired pneumonia. *Thorax* 2000;**55**(Suppl 3):A71.
336. **Impallomeni M**, Galletly NP, Wort SJ, *et al*. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. *BMJ* 1995;**311**:1345–6.
337. **Riley TV**. Clostridium difficile: a pathogen of the nineties. *Eur J Clin Microbiol Infect Dis* 1998;**17**:137–41.
338. **Zadik PM**, Moore AP. Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile. *J Hosp Infect* 1998;**39**:189–93.
339. **MacGowan AP**, Feeney R, Brown I, *et al*. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. *J Antimicrob Chemother* 1997;**39**:537–41.
340. **Settle CD**, Wilcox MH, Fawley WN, *et al*. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. *Aliment Pharmacol Ther* 1998;**12**:1217–23.
341. **Spencer RC**. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. *J Antimicrob Chemother* 1998;**41**(Suppl C):21–7.
342. **Ludlum H**, Brown N, Sule O, *et al*. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. *Age Ageing* 1999;**28**:578–80.
343. **Johnson AP**. Antibiotic resistance among clinically important gram-positive bacteria in the UK. *J Hosp Infect* 1998;**40**:17–26.

344. **Felmingham D**, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens—findings of the Alexander Project 1992–1996. *J Chemother* 1999;**11**(Suppl 1):5–21.
345. **Pallares R**, Linares J, Vadillo M, *et al*. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. *N Engl J Med* 1995;**333**:474–80.
346. **Einarsson S**, Kristjansson M, Kristinsson KG, *et al*. Pneumonia caused by penicillin-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. *Scand J Infect Dis* 1998;**30**:253–6.
347. **Klugman K**, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. *Infect Dis Clin Pract* 1998;**7**:180–4.
348. **Pallares R**, Viladrich PF, Linares J, *et al*. Impact of antibiotic resistance on chemotherapy for pneumococcal infections. *Microb Drug Resist* 1998;**4**:339–47.
349. **Garau J**, Aguilar L, Rodriguez-Creixems M, *et al*. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with beta-lactam monotherapy. *J Chemother* 1999;**11**:266–72.
350. **Ewig S**, Kleinfeld T, Bauer T, *et al*. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. *Eur Respir J* 1999;**14**:370–5.
351. **Farrell DJ**, Felmingham D, Shackcloth J, *et al*. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. *J Antimicrob Chemother* 2008;**62**(Suppl 2):ii87–95.
352. **Chen DK**, McGeer A, de Azavedo JC, *et al*. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. *N Engl J Med* 1999;**341**:233–9.
353. **Powell M**, Yeo SF, Seymour A, *et al*. Antimicrobial resistance in Haemophilus influenzae from England and Scotland in 1991. *J Antimicrob Chemother* 1992;**29**:547–54.
354. **Morrissey I**, Maher K, Williams L, *et al*. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999–2007. *J Antimicrob Chemother* 2008;**62**(Suppl 2):ii97–103.
355. **Andrews J**, Ashby J, Jevons G, *et al*. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. *J Antimicrob Chemother* 2000;**45**:285–93.
356. **Nielsen K**, Bangsberg JM, Hoiby N. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin. *Diagn Microbiol Infect Dis* 2000;**36**:43–8.
357. **Lode H**, Garau J, Grassi C, *et al*. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxicillin-clavulanic acid and erythromycin. *Eur Respir J* 1995;**8**:1999–2007.
358. **Soman A**, Honeybourne D, Andrews J, *et al*. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. *J Antimicrob Chemother* 1999;**44**:835–8.
359. **Hoffken G**, Meyer HP, Winter J, *et al*. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. *Respir Med* 2001;**95**:553–64.
360. **Petitpretz P**, Arvis P, Marell M, *et al*. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. *Chest* 2001;**119**:185–95.
361. **Fogarty C**, Grossman C, Williams J, *et al*. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. *Infect Med* 1999:748–63.
362. **Torres A**, Muir JF, Corris P, *et al*. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. *Eur Respir J* 2003;**21**:135–43.
363. **Anon**. *British National Formulary*. London: BMJ Publishing Group and RPS Publishing, 2008.
364. **Anderson G**, Esmonde TS, Coles S, *et al*. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. *J Antimicrob Chemother* 1991;**27**(Suppl A):117–24.
365. **Chien SM**, Pichotta P, Siepmann N, *et al*. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. *Chest* 1993;**103**:697–701.
366. **Green JA**, Butler T, Todd WM. Randomized double-blind trial of the comparative efficacy and safety of cefpodoxime proxetil and cefaclor in the treatment of acute community-acquired pneumonia. *Curr Ther Res* 1994;**55**:1003–15.
367. **Rizzato G**, Allegra L. Efficacy and tolerability of a teicoplanin-ciprofloxacin combination in severe community-acquired pneumonia. *Clin Drug Invest* 1997;**14**:337–45.
368. **Bohte R**, van't Wout JW, Lobatto S, *et al*. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1995;**14**:182–7.
369. **Chan R**, Hemeryck L, O'Regan M, *et al*. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. *BMJ* 1995;**310**:1360–2.
370. **Plouffe JF**, Herbert MT, File TM Jr, *et al*. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. *Antimicrob Agents Chemother* 1996;**40**:1175–9.
371. **File TM Jr**, Segreti J, Dunbar L, *et al*. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. *Antimicrob Agents Chemother* 1997;**41**:1965–72.
372. **Van den Brande P**, Vondra V, Vogel F, *et al*. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. *Chest* 1997;**112**:406–15.
373. **Vetter N**, Stamler D, O'Neill S, *et al*. Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalized community-acquired pneumonia patients: intravenous followed by oral therapy. *Clin Drug Invest* 1997;**14**:439–49.
374. **O'Doherty B**, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. *Eur J Clin Microbiol Infect Dis* 1998;**17**:828–33.
375. **Carbon C**, Ariza H, Rabie WJ, *et al*. Comparative study of levofloxacin and amoxicillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. *Clin Microbiol Infect* 1999;**5**:724–32.
376. **Rovira E**, Martinez-Moragon E, Belda A, *et al*. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. *Respiration* 1999;**66**:413–8.
377. **Johnson RH**, Levine S, Traub SL. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia. *Infect Dis Clin Pract* 1996;**5**:265–72.
378. **Bartoloni A**, Strohmeier M, Corti G, *et al*. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. *Drugs Exp Clin Res* 1999;**25**:243–52.
379. **Garau J**, Twynholm M, Garcia-Mendez E, *et al*. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. *J Antimicrob Chemother* 2003;**52**:826–36.
380. **Siquier B**, Sanchez-Alvarez J, Garcia-Mendez E, *et al*. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. *J Antimicrob Chemother* 2006;**57**:536–45.
381. **Dunbar LM**. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance. *Am J Med Sci* 2003;**326**:360–8.
382. **Baumgartner JD**, Glauser MP. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia. *Am J Med* 1984;**77**:54–8.
383. **Fredlund H**, Bodin L, Back E, *et al*. Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin. *Scand J Infect Dis* 1987;**19**:459–66.
384. **Zuck P**, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. *J Antimicrob Chemother* 1990;**26**(Suppl E):71–7.
385. **Poirier R**. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. *J Antimicrob Chemother* 1991;**27**(Suppl A):109–16.
386. **Koulla-Shiro S**, Kuaban C, Auckenthaler R, *et al*. Adult response to initial treatment with ampicillin in community acquired pneumonia in Yaounde, Cameroon. *Cent Afr J Med* 1993;**39**:188–92.
387. **Gaillat J**, Bru JP, Sedallian A. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1994;**13**:639–44.
388. **Low DE**, Mandell LA. A prospective open-label multi-centre trial on the use of 1 g, once daily ceftriaxone in lower respiratory tract infections. *Can J Infect Dis* 1994;**5**(Suppl C):3–8C.
389. **Uzun O**, Hayran M, Akova M, *et al*. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report. *J Chemother* 1994;**6**:53–7.
390. **Jang TN**, Liu CY, Wang FD, *et al*. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia. *Zhonghua Yi Xue Za Zhi (Taipei)* 1995;**55**:302–6.
391. **Rizzato G**, Montemurro L, Fraioli P, *et al*. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. *Eur Respir J* 1995;**8**:398–402.
392. **Oh HM**, Ng AW, Lee SK. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. *Singapore Med J* 1996;**37**:255–7.
393. **Siegel RE**, Halpern NA, Almenoff PL, *et al*. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. The optimal duration of therapy. *Chest* 1996;**110**:965–71.
394. **Genne D**, Siegrist HH, Humair L, *et al*. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1997;**16**:783–8.
395. **Ho A**, Leung R, Lai CK, *et al*. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. *Respiration* 1997;**64**:224–8.
396. **Cabellos C**, Ariza J, Barreiro B, *et al*. Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia. *Eur J Clin Microbiol Infect Dis* 1998;**17**:265–8.
397. **Fogarty CM**, Sullivan JG, Chattman MS, *et al*. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. *Infect Dis Clin Pract* 1998;**7**:400–7.
398. **Rhew DC**, Hackner D, Henderson L, *et al*. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. *Chest* 1998;**113**:142–6.

399. **Speich R**, Imhof E, Vogt M, *et al*. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. *Eur J Clin Microbiol Infect Dis* 1998;**17**:313–7.
400. **Shorr AF**, Khashab MM, Xiang JX, *et al*. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine risk class III/IV community-acquired pneumonia patients. *Respir Med* 2006;**100**:2129–36.
401. **File TM Jr**. Community-associated methicillin-resistant *Staphylococcus aureus*: not only a cause of skin infections, also a new cause of pneumonia. *Curr Opin Infect Dis* 2005;**18**:123–4.
402. **Fogarty C**, Siami G, Kohler R, *et al*. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. *Clin Infect Dis* 2004;**38**(Suppl 1):S16–23.
403. **Plouffe JF**, Breiman RF, Fields BS, *et al*. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. *Clin Infect Dis* 2003;**37**:1475–80.
404. **Welte T**, Petermann W, Schurmann D, *et al*. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. *Clin Infect Dis* 2005;**41**:1697–705.
405. **Lode H**, Grossman C, Choudhri S, *et al*. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. *Respir Med* 2003;**97**:1134–42.
406. **Wallace RJ Jr**, Martin RR, Quinones FJ, *et al*. Ceforanide and ceftazolin therapy of pneumonia: comparative clinical trial. *Antimicrob Agents Chemother* 1981;**20**:648–52.
407. **Grieco MM**, Lange M, Daniels JA, *et al*. Single-blind controlled study of ceftizoxime and cefamandole in the treatment of community-acquired pneumonia. *J Antimicrob Chemother* 1982;**10**(Suppl C):223–5.
408. **Wallace RJ Jr**, Niefeld SL, Waters S, *et al*. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. *Antimicrob Agents Chemother* 1982;**21**:231–5.
409. **Keeton GR**, Kehoe B, Phillips SW, *et al*. Ceftazidime and cefamandole in the treatment of pneumonia. *J Antimicrob Chemother* 1983;**12**(Suppl A):27–30.
410. **Geckler RW**, McCormack GD, Goodman JS. Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract. *Rev Infect Dis* 1984;**6**(Suppl 4):S847–52.
411. **Weber DJ**, Calderwood SB, Karchmer AW, *et al*. Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia. *Antimicrob Agents Chemother* 1987;**31**:876–82.
412. **Carbon C**, Leophonte P, Petitpretz P, *et al*. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. *Antimicrob Agents Chemother* 1992;**36**:833–9.
413. **Kissling M**. Cefetamet pivoxil in community-acquired pneumonia: an overview. *Curr Med Res Opin* 1992;**12**:631–9.
414. **Wiesner B**, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. *Arzneimittelforschung* 1993;**43**:1014–7.
415. **Aquino R**, Lansang MA, Salvador A, *et al*. The effectiveness and safety of ceftriaxone to cefetamet pivoxil vs ceftazidime to cefetamet pivoxil vs cefepazone to cefetamet pivoxil in the treatment of community-acquired pneumonia in adult Filipinos. *Phil J Intern Med* 1994;**31**:237–40.
416. **Liippo K**, Tala E, Puolijoki H, *et al*. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. *J Infect* 1994;**28**:131–9.
417. **Williams D**, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1994;**13**:293–8.
418. **De Palma M**, Rocchi D, Canepa G, *et al*. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. *Clin Ther* 1995;**17**:413–24.
419. **Hopkins S**, Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. *Curr Ther Res* 1995;**56**:915–25.
420. **Aubier M**, Lode H, Gialdroni-Grassi G, *et al*. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. *J Antimicrob Chemother* 1996;**37**(Suppl A):73–82.
421. **Hernandez JM**, Sides GD, Conforti PM, *et al*. Clinical efficacy of dirithromycin in patients with bacteremic pneumonia. *Clin Ther* 1996;**18**:1128–38.
422. **Ortvist A**, Valtonen M, Cars O, *et al*. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. *Chest* 1996;**110**:1499–506.
423. **Portier H**, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxicillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. *J Antimicrob Chemother* 1996;**37**(Suppl A):83–91.
424. **Rubinstein E**. Safety profile of sparfloxacin in the treatment of respiratory tract infections. *J Antimicrob Chemother* 1996;**37**(Suppl A):145–60.
425. **Donowitz GR**, Brandon ML, Salisbury JP, *et al*. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. *Clin Ther* 1997;**19**:936–53.
426. **Drehobl M**, Bianchi P, Keyserling CH, *et al*. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. *Antimicrob Agents Chemother* 1997;**41**:1579–83.
427. **Ragnar NS**. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. *J Antimicrob Chemother* 1997;**39**:499–508.
428. **O'Doherty B**, Dutchman DA, Pettit R, *et al*. Randomized, double-blind, comparative study of grepafloxacin and amoxicillin in the treatment of patients with community-acquired pneumonia. *J Antimicrob Chemother* 1997;**40**(Suppl A):73–81.
429. **Aubier M**, Verster R, Regamey C, *et al*. Once-daily sparfloxacin versus high-dose amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. *Clin Infect Dis* 1998;**26**:1312–20.
430. **Salvareza CR**, Mingrone H, Fachinelli H, *et al*. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. *J Antimicrob Chemother* 1998;**41**(Suppl B):75–80.
431. **Tremolieres F**, de Kock F, Pluck N, *et al*. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. *Eur J Clin Microbiol Infect Dis* 1998;**17**:447–53.
432. **Zervos M**, Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group. *Antimicrob Agents Chemother* 1998;**42**:729–33.
433. **Daniel R**. Trovafloxacin vs high dose amoxicillin in the treatment of community-acquired bacterial pneumonia. *Drugs* 1999;**58**(Suppl 2):304–5.
434. **Daniel R**. Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia. *Drugs* 1999;**58**(Suppl 2):320–2.
435. **Grossman RF**, Campbell DA, Landis SJ, *et al*. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. *J Antimicrob Chemother* 1999;**43**:549–54.
436. **Moola S**, Hagberg L, Churchyard GA, *et al*. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. *Chest* 1999;**116**:974–83.
437. **Peterson J**. Oral trovafloxacin vs oral cefuroxime ± erythromycin in community acquired pneumonia. *Drugs* 1999;**58**(Suppl 2):301–3.
438. **Ramirez J**, Unowsky J, Talbot GH, *et al*. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. *Clin Ther* 1999;**21**:103–17.
439. **Leophonte P**, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. *Respir Med* 2004;**98**:708–20.
440. **Tellier G**, Niederman MS, Nusrat R, *et al*. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. *J Antimicrob Chemother* 2004;**54**:515–23.
441. **Drehobl MA**, De Salvo MC, Lewis DE, *et al*. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. *Chest* 2005;**128**:2230–7.
442. **Blaser MJ**, Klaus BD, Jacobson JA, *et al*. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. *Antimicrob Agents Chemother* 1983;**24**:163–7.
443. **Cassell GH**, Drnec J, Waites KB, *et al*. Efficacy of clarithromycin against *Mycoplasma pneumoniae*. *J Antimicrob Chemother* 1991;**27**(Suppl A):47–59.
444. **Morales JO**, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. *Am J Med* 1994;**97**:28–33.
445. **Ramirez JA**. Switch therapy in community-acquired pneumonia. *Diagn Microbiol Infect Dis* 1995;**22**:219–23.
446. **Higuera F**, Hidalgo H, Feris J, *et al*. Comparison of oral cefuroxime axetil and oral amoxicillin/clavulanate in the treatment of community-acquired pneumonia. *J Antimicrob Chemother* 1996;**37**:555–64.
447. **Berman SJ**, Sieger B, Geckler W, *et al*. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. *Curr Ther Res* 1997;**58**:903–16.
448. **Ailani RK**, Agastya G, Mukunda BN, *et al*. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. *Arch Intern Med* 1999;**159**:266–70.
449. **Schonwald S**, Kuzman I, Oreskovic K, *et al*. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome—a randomized study. *Infection* 1999;**27**:198–202.
450. **Sherer Y**, Bakshi E, Rotman P, *et al*. Comparative clinical study of cefonicid, chloramphenicol, and penicillin in community-acquired pneumonia. *Int J Mol Med* 1998;**2**:343–8.
451. **Stocks JM**, Wallace RJ Jr, Griffith DE, *et al*. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. *Am J Med* 1989;**87**(6C):52–6S.
452. **Morandini G**, Perduca M, Zannini G, *et al*. Clinical efficacy of azithromycin in lower respiratory tract infections. *J Chemother* 1993;**5**:32–6.
453. **Finch RG**, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. *Drugs* 1998;**55**:31–45.
454. **Moreno S**, Garcia-Leoni ME, Cercenado E, *et al*. Infections caused by erythromycin-resistant *Streptococcus pneumoniae*: incidence, risk factors, and response to therapy in a prospective study. *Clin Infect Dis* 1995;**20**:1195–200.
455. **Jackson MA**, Burry VF, Olson LC, *et al*. Breakthrough sepsis in macrolide-resistant pneumococcal infection. *Pediatr Infect Dis J* 1996;**15**:1049–51.
456. **Amsden GW**. Pneumococcal macrolide resistance—myth or reality? *J Antimicrob Chemother* 1999;**44**:1–6.

457. **Perez-Trallero E.** Pneumococcal macrolide resistance—not a myth. *J Antimicrob Chemother* 2000;**45**:401–3.
458. **Carbon C,** Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. *J Chemother* 1999;**11**:107–18.
459. **Moss PJ,** Finch RG. The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. *Thorax* 2000;**55**:83–5.
460. **Robenshtok E,** Shefet D, Gaafar-Gvili A, *et al.* Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. *Cochrane Database Systemat Rev* 2008;(1):CD004418.
461. **Shefet D,** Robenshtok E, Paul M, *et al.* Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. *Arch Intern Med* 2005;**165**:1992–2000.
462. **Mills GD,** Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. *BMJ* 2005;**330**:456.
463. **Sportel JH,** Koeter GH, van Altena R, *et al.* Relation between beta-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease (COPD). *Thorax* 1995;**50**:249–53.
464. **Meehan TP,** Fine MJ, Krumholz HM, *et al.* Quality of care, process, and outcomes in elderly patients with pneumonia. *JAMA* 1997;**278**:2080–4.
465. **Houck PM,** Bratzler DW, Nsa W, *et al.* Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. *Arch Intern Med* 2004;**164**:637–44.
466. **Simpson JC,** Macfarlane JT, Watson J, *et al.* A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. *Thorax* 2000;**55**:1040–5.
467. **Marston BJ,** Plouffe JF, File TM Jr, *et al.* Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. *Arch Intern Med* 1997;**157**:1709–18.
468. **Houck PM,** Bratzler DW, Nsa W, *et al.* Antibiotic administration in community-acquired pneumonia. *Chest* 2004;**126**:320–1.
469. **Metersky ML,** Sweeney TA, Getzow MB, *et al.* Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? *Chest* 2006;**130**:16–21.
470. **Welker JA,** Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. *Arch Intern Med* 2008;**168**:351–6.
471. **Kanwar M,** Brar N, Khatib R, *et al.* Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. *Chest* 2007;**131**:1865–9.
472. **Schulin T,** Wennersten CB, Ferraro MJ, *et al.* Susceptibilities of Legionella spp. to newer antimicrobials in vitro. *Antimicrob Agents Chemother* 1998;**42**:1520–3.
473. **Gleason PP,** Meehan TP, Fine JM, *et al.* Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. *Arch Intern Med* 1999;**159**:2562–72.
474. **Burgess DS,** Lewis JS 2nd. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. *Clin Ther* 2000;**22**:872–8.
475. **MacGregor RR,** Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. *Clin Infect Dis* 1997;**24**:457–67.
476. **Mandell LA,** Bergeron MG, Gribble MJ, *et al.* Sequential antibiotic therapy: effective cost management and patient care. *Can J Infect Dis* 1995;**6**:306–15.
477. **Siegel RE,** Alicea M, Lee A, *et al.* Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. *Am J Ther* 1999;**6**:217–22.
478. **Nathwani D.** Sequential switch therapy for lower respiratory tract infections: a European perspective. *Chest* 1998;**113**(3 Suppl):211–8S.
479. **el Moussaoui R,** de Borgia CAJM, van den Broek P, *et al.* Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. *BMJ* 2006;**332**:1355.
480. **Pedro-Botet L,** Yu VL. Legionella: macrolides or quinolones? *Clin Microbiol Infect* 2006;**12**(Suppl 3):25–30.
481. **Sabria M,** Pedro-Botet ML, Gomez J, *et al.* Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. *Chest* 2005;**128**:1401–5.
482. **Blazquez Garrido RM,** Espinosa Parra FJ, Alemany Frances L, *et al.* Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. *Clin Infect Dis* 2005;**40**:800–6.
483. **Mykietiak A,** Carratala J, Fernandez-Sabe N, *et al.* Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. *Clin Infect Dis* 2005;**40**:794–9.
484. **Owens RC Jr,** Nolin TD. Antimicrobial-associated QT interval prolongation: points of interest. *Clin Infect Dis* 2006;**43**:1603–11.
485. **Grau S,** Antonio JM, Ribes E, *et al.* Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. *Int J Antimicrob Agents* 2006;**28**:249–52.
486. **Hubbard RB,** Mathur RM, MacFarlane JT. Severe community-acquired legionella pneumonia: treatment, complications and outcome. *Q J Med* 1993;**86**:327–32.
487. **Kirby J,** Polis G, Romansky MJ. A controlled blind study of pneumococcal pneumonia treated with tetracycline and tetracycline plus 6-methyl prednisolone. *Antibiot Ann* 1959;**7**:175–81.
488. **Roson B,** Carratala J, Fernandez-Sabe N, *et al.* Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. *Arch Intern Med* 2004;**164**:502–8.
489. **Genne D,** Sommer R, Kaiser L, *et al.* Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 2006;**25**:159–66.
490. **Menendez R,** Torres A, Zalacain R, *et al.* Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. *Thorax* 2004;**59**:960–5.
491. **Heffner JE,** McDonald J, Barbieri C, *et al.* Management of parapneumonic effusions. An analysis of physician practice patterns. *Arch Surg* 1995;**130**:433–8.
492. **Light RW.** A new classification of parapneumonic effusions and empyema. *Chest* 1995;**108**:299–301.
493. **Heffner JE,** Brown LK, Barbieri C, *et al.* Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. *Am J Respir Crit Care Med* 1995;**151**:1700–8.
494. **Ahmed RA,** Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. *Am J Med* 2006;**119**:877–83.
495. **Finley C,** Clifton J, Fitzgerald JM, *et al.* Empyema: an increasing concern in Canada. *Can Respir J* 2008;**15**:85–9.
496. **Farjah F,** Symons RG, Krishnadasan B, *et al.* Management of pleural space infections: a population-based analysis. *J Thorac Cardiovasc Surg* 2007;**133**:346–51.
497. **Davies CW,** Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. *Thorax* 2003;**58**(Suppl 2):ii18–28.
498. **Almirall J,** Bolibar I, Serra-Prat M, *et al.* New evidence of risk factors for community-acquired pneumonia: a population-based study. *Eur Respir J* 2008;**31**:1274–84.
499. **Baik I,** Curhan GC, Rimm EB, *et al.* A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. *Arch Intern Med* 2000;**160**:3082–8.
500. **Nuorti JP,** Butler JC, Farley MM, *et al.* Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. *N Engl J Med* 2000;**342**:681–9.
501. **West R,** McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. *Thorax* 2000;**55**:987–99.
502. **Berntsson E,** Blomberg J, Lagergard T, *et al.* Etiology of community-acquired pneumonia in patients requiring hospitalization. *Eur J Clin Microbiol* 1985;**4**:268–72.

APPENDIX 1 CHECKLIST USED BY REVIEWERS FOR APPRAISING STUDIES

Study: _____ Reviewer: _____
Please complete section 1 first. If study OK, complete one of sections 2a–d as appropriate.

1. General: is the study relevant to our question?

- Were the patients studied similar (in age, gender, disease severity ...) to target patients?
- Were the outcome measures of interest to us and our patients?
- Was the clinical setting (primary care, intensive care ...) similar to our setting?
- Was the study carried out in a healthcare system similar to ours?
- Is the study design recognisable and appropriate, with clear methods described?
- Is the study recent enough to take account of any important advances?
- If negative, was this study large enough to provide useful information?

2a. Studies of cause and effect (randomised trial of treatment)

- Was assignment of patients to treatment truly randomised?
- Was the planned therapy concealed from those recruiting patients before enrolment?
- Were all patients who entered the study accounted for?
- Were patients analysed in the groups to which they were initially randomised?
- Were patients and doctors blind to the therapy given?
- Were groups treated the same way, apart from the therapy?
- Were the groups similar at the start of the trial?

2b. Studies of aetiology (case-control study of a harmful agent)

- Were there two groups of cases, similar except for exposure to harmful agent?
- Was occurrence of the outcome measured in the same way for both groups?
- Were enough patients followed up for long enough for the outcome to develop?
- Did exposure clearly precede the outcome?
- Was there a dose-response gradient?
- Was there a re-challenge, or improvement after the drug stopped?
- Does the association make biological sense?

2c. Studies of diagnosis (evaluation of clinical findings or tests)

- Was the finding or result compared with a 24 carat gold standard for diagnosis?
- Was the finding or result determined blind to the gold standard?
- Was the gold standard determined blind to the finding or test result?
- Was the gold standard determined in all cases, not just those with an abnormal result?

2d. Studies of prognosis, prognostic index (cohort studies)

- Was a defined sample of patients assembled at an early stage of the disease?
- Were patients followed up long enough for the outcome to develop?
- Was the outcome clearly defined, objective and assessed blind to exposure in all cases?
- Was the performance of any prognostic index tested on a fresh set of cases?

3. Comments

APPENDIX 2 ADDITIONAL CHECKLIST USED FOR APPRAISING STUDIES TO INFORM PNEUMONIA AETIOLOGY

Absolute requirements:

- ▶ Is this an original report?
- ▶ Were patients with CAP separately identified?
- ▶ Was the study designed to assess CAP aetiology?
- ▶ Was the patient sample representative (eg, sufficient numbers, consecutive cases, exclusions clearly defined)?
- ▶ Was the study of sufficient duration to exclude seasonal bias?

Data qualification:

- ▶ Is the geographical area clear and relevant?
- ▶ Is the patient age group defined?
- ▶ Are microbial investigations clearly defined?
- ▶ Was the investigation biased towards a specific pathogen?
- ▶ Is the setting community, hospital, intensive care or a combination?

Appendix 3 Types of study and levels of evidence used to illuminate specific clinical questions

Type of clinical question	Evidence level	Brief definition	Types of study providing this level of evidence
<i>Treatment</i> Is therapy T effective?	Ia	A good recent systematic review	Systematic review of randomised trials
	Ib	A rigorous study designed to answer the question	A rigorous randomised trial comparing T with best alternative
	II	One or more prospective clinical studies	A cohort study or faulty randomised trial
	III	One or more retrospective clinical studies	A case-control study
	IVa	Formal expert consensus	Delphi study of expert practice
<i>Aetiology or harm</i> Does A cause disease D? Does drug D cause side effect S?	IVb	Other information	Study of pharmacology of T
	Ia	A good recent systematic review	Systematic review of cohort studies
Does A cause disease D? Does drug D cause side effect S?	Ib	A rigorous study designed to answer the question	A large well-designed cohort study
	II	One or more prospective clinical studies	A faulty cohort study
	III	One or more retrospective clinical studies	A case-control study
	IVa	Formal expert consensus	Delphi study of expert opinion
	IVb	Other information	Study of pathophysiology of D
<i>Diagnosis or prognosis</i> Is T an accurate test for diagnosis of D? Is finding F an accurate predictor of event E?	Ia	A good recent systematic review	Systematic review of blind comparisons of T with gold standard
	Ib	A rigorous study designed to answer the question	Blind prospective comparison of T, F or M with gold standard for D or E (eg, response to specific therapy) with multivariate analysis
Does severity measure M accurately predict event E?	II	One or more prospective clinical studies	Analysis of prospective test results in patients enrolled in a randomised clinical trial of therapy for varying stages of D. Prospective validation study with univariate analysis
	III	One or more retrospective clinical studies	Retrospective study of test results or findings in a database of patients with univariate or multivariate analysis
	IVa	Formal expert consensus	Delphi study of expert opinion about T
	IVb	Other information	Study of pathophysiology of D
<i>Public health, health policy</i> Is policy P cost effective in the NHS?	Ia	Economic and policy analysis based on good recent systematic reviews	Economic and policy analysis with modelling and sensitivity analysis using data from systematic reviews of effectiveness and of cost studies in the same routine clinical settings
	Ib	Economic and policy analysis based on a rigorous study designed to answer the question	Economic and policy analysis with modelling and sensitivity analysis using data from a randomised clinical trial of effectiveness and a cost study in the same routine clinical setting
	II	Economic and policy analysis based on one or more prospective clinical studies	Economic and policy analysis with modelling and sensitivity analysis using other prospective data in various settings
	III	Economic and policy analysis based on one or more retrospective clinical studies	Economic and policy analysis with modelling and sensitivity analysis using retrospective data
	IVa	Formal expert consensus	Delphi study of national expert opinion about P
	IVb	Other information	Local opinion about P

Appendix 4 Generic levels of evidence and guideline statement grades, appropriate across all types of clinical questions

Evidence level	Definition	Example of study providing this level of evidence for a therapy question	Guideline statement grade
Ia	A good recent systematic review of studies designed to answer the question of interest	Cochrane systematic review of randomised controlled trials studying the effectiveness of flu vaccines	A+
Ib	One or more rigorous studies designed to answer the question, but not formally combined	Randomised controlled trial of effectiveness of a flu vaccine	A–
II*	One or more prospective clinical studies which illuminate, but do not rigorously answer, the question	Prospective cohort study comparing pneumonia rates in patients who are and are not vaccinated against flu; non-randomised controlled trial	B+
III†	One or more retrospective clinical studies which illuminate but do not rigorously answer the question	Audit or retrospective case control study, comparing flu vaccination history in patients who did and did not present with pneumonia	B–
IVa‡	Formal combination of expert views	Delphi study of UK expert recommendations for flu vaccination	C
IVb	Other information	Expert opinion, informal consensus; in vitro or in vivo studies on related topics	D

*Hard to differentiate Agency for Health Care Policy and Research's "well designed controlled study without randomisation" (level IIa) from "other type of well-designed experimental study" (level IIb).

†Major criterion is retrospective versus prospective data collection, since non-experimental designs are better suited than even randomised clinical trials for answering certain questions.

‡Distinguish formal consensus from informal consensus methods according to the Health Technology Assessment 1998 systematic review.